{
    "data": [
        {
            "id": "4876544",
            "title": "S&P 500 Slips, World Soars: A Massive Market Mood Shift In February",
            "description": "<p data-eci=\"true\"><figure class=\"getty-figure\" data-type=\"getty-image\"><picture> <img src=\"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2187254257/image_2187254257.jpg?io=getty-c-w630\" alt=\"Wall Street New York stock exchange stock market\" data-id=\"2187254257\" data-type=\"getty-image\" width=\"1536\" height=\"1024\" srcset=\"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2187254257/image_2187254257.jpg?io=getty-c-w1536 1536w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2187254257/image_2187254257.jpg?io=getty-c-w1280 1280w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2187254257/image_2187254257.jpg?io=getty-c-w1080 1080w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2187254257/image_2187254257.jpg?io=getty-c-w750 750w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2187254257/image_2187254257.jpg?io=getty-c-w640 640w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2187254257/image_2187254257.jpg?io=getty-c-w480 480w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2187254257/image_2187254257.jpg?io=getty-c-w320 320w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2187254257/image_2187254257.jpg?io=getty-c-w240 240w\" sizes=\"(max-width: 767px) calc(100vw - 36px), (max-width: 1023px) calc(100vw - 132px), (max-width: 1199px) calc(100vw - 666px), (max-width: 1307px) calc(100vw - 708px), 600px\" fetchpriority=\"high\"> </picture><figcaption><p class=\"item-caption\"> </p> <p class=\"item-credits\">alexsl/iStock via Getty Images</p></figcaption></figure></p> <div class=\"inline_ad_placeholder\"></div> <p><span>The S&amp;P 500 Index (SP500, SPY) <a href=\"https://schrts.co/FnFthrpm\" rel=\"nofollow\">struggled</a> in February. Often a tough month, U.S. large caps gave back 1% after a </span><a href=\"https://seekingalpha.com/article/4864570-january-barnburner-gold-soars-and-crashes-stocks-rally-bonds-quiet\" rel=\"noreferrer noopener\"><span>solid beginning to 2026</span></a><span>. But it wasn’t all doom and gloom, particularly for diversified investors. The<span class=\"paywall-full-content\"> S&amp;P MidCap 400 ETF (</span><a href=\"https://seekingalpha.com/symbol/MDY\" title=\"State Street SPDR S&amp;P MidCap 400 ETF Trust\" class=\"paywall-full-content\">MDY</a><span class=\"paywall-full-content\">) jumped 3.5% for its best monthly close, while the Russell 2000 ETF (</span><span class=\"ticker-hover-wrapper paywall-full-content\"><a href=\"https://seekingalpha.com/symbol/IWM\" title=\"iShares Russell 2000 ETF\">IWM</a></span><span class=\"paywall-full-content\">) managed to finish about unchanged in the first quarter’s middle month. </span></span></p> <p class=\"paywall-full-content\"><span>There was </span><a href=\"https://seekingalpha.com/article/4871751-spdw-ex-us-developed-markets-are-hot-and-its-not-about-the-dollar\" rel=\"noreferrer noopener\"><span>major strength internationally</span></a><span>. The Vanguard FTSE All-World Ex-US ETF (<a href=\"https://seekingalpha.com/symbol/VEU\" title=\"Vanguard FTSE All-World ex US Index Fund ETF\">VEU</a>) soared 5%, finishing February with its 14</span><span>th</span><span> consecutive weekly climb on a total return basis. The U.S. dollar Index ETF (<a href=\"https://seekingalpha.com/symbol/UUP\" title=\"Invesco DB US Dollar Index Bullish Fund ETF\">UUP</a>) actually gained 1%, making VEU’s intense relative strength all the more impressive.</span></p> <p class=\"paywall-full-content\"><span>Over in the bond market, the iShares US Aggregate Bond ETF (<a href=\"https://seekingalpha.com/symbol/AGG\" title=\"iShares Core US Aggregate Bond ETF\">AGG</a>) logged a </span><a href=\"https://seekingalpha.com/article/4867474-agg-muted-volatility-and-light-positioning-why-thats-bullish\" rel=\"noreferrer noopener\"><span>nearly 2% total return</span></a><span>, thanks to falling Treasury rates. The benchmark 10-year rate (<a href=\"https://seekingalpha.com/symbol/US10Y\" title=\"United States 10-Year Bond Yield\">US10Y</a>) dipped under 4% for the first time in three months—its lowest weekly settle since September 2024. The 2-year rate is now at its lowest since September 2022. Private credit worries seeped into the U.S. high-yield space, with the HY OAS widening to near 300 basis points.</span></p> <p class=\"paywall-full-content\"><span>Oil (<a href=\"https://seekingalpha.com/symbol/USO\" title=\"United States Oil Fund LP ETF\">USO</a>), meanwhile, ticked toward 7-month highs. WTI scaled $67 per barrel, and Brent hit $72. The spread between US and international oil widened amid concerns that the U.S. would strike Iran.</span></p> <p class=\"paywall-full-content\"><span>We can’t leave out gold (</span>XAUUSD:CUR) and bitcoin (<a href=\"https://seekingalpha.com/symbol/BTC-USD\" title=\"Bitcoin USD\">BTC-USD</a>). The former recovered impressively after a sharp late-January correction. The Gold ETF (<a href=\"https://seekingalpha.com/symbol/GLD\" title=\"SPDR Gold Shares ETF\">GLD</a>) <a href=\"https://seekingalpha.com/article/4866746-kinross-gold-surging-free-cash-flow-with-gold-near-5000-hiking-my-target\" rel=\"noreferrer noopener\">added 8%</a>. <a href=\"https://seekingalpha.com/article/4864811-bitcoins-fall-why-now-is-the-time-for-a-contrarian-long-ibit-play\" rel=\"noreferrer noopener\">Bitcoin</a>, however, fell hard through the first half of February. The iShares Bitcoin ETF (<a href=\"https://seekingalpha.com/symbol/IBIT\" title=\"iShares Bitcoin Trust ETF\">IBIT</a>) tallied yet another down month, taking a 22% February drubbing. The S&amp;P VIX Index (<a href=\"https://seekingalpha.com/symbol/VIX\" title=\"S&amp;P VIX Index\">VIX</a>) hit 22 on the final day of the month, its highest weekly close going back to November 2025.</p> <h2 class=\"paywall-full-content\">Nasdaq 100 and S&amp;P 500 Were Weak, But U.S. SMIDs and Ex-US Positive</h2> <p class=\"paywall-full-content\"><figure class=\"regular-img-figure paywall-full-content\" contenteditable=\"false\"><span><a href=\"https://static.seekingalpha.com/uploads/2026/2/27/36131525-1772222378567275_origin.png\" rel=\"lightbox\" data-width=\"915\" data-height=\"652\" data-og-image-twitter_small_card=\"true\" data-og-image-twitter_large_card=\"true\" data-og-image-twitter_image_post=\"true\" data-og-image-msn=\"true\" data-og-image-facebook=\"true\" data-og-image-google_news=\"true\" data-og-image-google_plus=\"true\" data-og-image-linkedin=\"true\" role=\"button\" aria-label=\"Expand image into lightbox view\"><img src=\"https://static.seekingalpha.com/uploads/2026/2/27/36131525-1772222378567275_origin.png?io=w640\" alt=\"Nasdaq 100 and S&amp;P 500 Were Weak But US SMIDs and Ex-US Positive\" width=\"640\" height=\"456\" contenteditable=\"false\" loading=\"lazy\" srcset=\"https://static.seekingalpha.com/uploads/2026/2/27/36131525-1772222378567275_origin.png?io=w640 640w,https://static.seekingalpha.com/uploads/2026/2/27/36131525-1772222378567275_origin.png?io=w480 480w,https://static.seekingalpha.com/uploads/2026/2/27/36131525-1772222378567275_origin.png?io=w320 320w,https://static.seekingalpha.com/uploads/2026/2/27/36131525-1772222378567275_origin.png?io=w240 240w\" sizes=\"(max-width: 767px) calc(100vw - 36px), (max-width: 1023px) calc(100vw - 180px), 552px\"></a></span><figcaption><p class=\"item-caption\"><span>Koyfin Charts</span></p></figcaption></figure></p> <h2 class=\"paywall-full-content\">Bonds (AGG) Near Record Highs on a Total Return Basis</h2> <p class=\"paywall-full-content\"><figure class=\"regular-img-figure paywall-full-content\" contenteditable=\"false\"><span><a href=\"https://static.seekingalpha.com/uploads/2026/2/27/36131525-17722230650835526_origin.png\" rel=\"lightbox\" data-width=\"1240\" data-height=\"737\" data-og-image-twitter_small_card=\"true\" data-og-image-twitter_large_card=\"true\" data-og-image-twitter_image_post=\"true\" data-og-image-msn=\"true\" data-og-image-facebook=\"true\" data-og-image-google_news=\"true\" data-og-image-google_plus=\"true\" data-og-image-linkedin=\"true\" role=\"button\" aria-label=\"Expand image into lightbox view\"><img src=\"https://static.seekingalpha.com/uploads/2026/2/27/36131525-17722230650835526_origin.png?io=w640\" alt=\"Bonds (&lt;a href='https://seekingalpha.com/symbol/AGG' title='iShares Core US Aggregate Bond ETF'&gt;AGG&lt;/a&gt;) Near Record Highs on a Total Return Basis\" width=\"640\" height=\"380\" contenteditable=\"false\" loading=\"lazy\" srcset=\"https://static.seekingalpha.com/uploads/2026/2/27/36131525-17722230650835526_origin.png?io=w640 640w,https://static.seekingalpha.com/uploads/2026/2/27/36131525-17722230650835526_origin.png?io=w480 480w,https://static.seekingalpha.com/uploads/2026/2/27/36131525-17722230650835526_origin.png?io=w320 320w,https://static.seekingalpha.com/uploads/2026/2/27/36131525-17722230650835526_origin.png?io=w240 240w\" sizes=\"(max-width: 767px) calc(100vw - 36px), (max-width: 1023px) calc(100vw - 180px), 552px\"></a></span><figcaption><p class=\"item-caption\"><span>Stockcharts.com</span></p></figcaption></figure></p> <p class=\"paywall-full-content\"><span>Zooming into the <a href=\"https://app.koyfin.com/share/1e8fb48f61\" rel=\"nofollow\">sector performance view</a>, Utilities (<a href=\"https://seekingalpha.com/symbol/XLU\" title=\"State Street Utilities Select Sector SPDR ETF\">XLU</a>) and Energy (<a href=\"https://seekingalpha.com/symbol/XLE\" title=\"State Street Energy Select Sector SPDR ETF\">XLE</a>) led. Power generation stocks and the oil &amp; gas space gained amid falling interest rates and heightened geopolitical tensions. Materials (<a href=\"https://seekingalpha.com/symbol/XLB\" title=\"State Street Materials Select Sector SPDR ETF\">XLB</a>) and Consumer Staples (<a href=\"https://seekingalpha.com/symbol/XLP\" title=\"State Street Cons Staples Sel Sec SPDR Inc ETF\">XLP</a>) were also up big, despite the negative SPX return. </span></p> <p class=\"paywall-full-content\"><span>So-called “HALO” (heavy-asset, low obsolescence) stocks became the talk of the street. That means blue-chip, cyclicals were in favor, while high-ARR and low-variable expense equities (such as software) were tossed to the curb. Industrials (<a href=\"https://seekingalpha.com/symbol/XLI\" title=\"State Street Industrial Select Sector SPDR ETF\">XLI</a>) and Real Estate posted large alpha, as well.</span></p> <p class=\"paywall-full-content\"><span>All told, just four of the S&amp;P 500 sector ETFs were in the red for February: Communications Services (<a href=\"https://seekingalpha.com/symbol/XLC\" title=\"State Street Com Svc Sel Sec SPDR ETF\">XLC</a>), Information Technology (<a href=\"https://seekingalpha.com/symbol/XLK\" title=\"State Street Technology Select Sector SPDR ETF\">XLK</a>), Consumer Discretionary (<a href=\"https://seekingalpha.com/symbol/XLY\" title=\"State Street Cons Disc Sel Sect SPDR Income ETF\">XLY</a>), and Financials (<a href=\"https://seekingalpha.com/symbol/XLF\" title=\"State Street Financial Sel Sec SPDR ETF\">XLF</a>). </span></p> <p class=\"paywall-full-content\"><span>Indeed, dispersion and diversification were the market’s passwords in February.</span></p> <h2 class=\"paywall-full-content\">7 of 11 Sectors Were Up Materially In February</h2> <p class=\"paywall-full-content\"><figure class=\"regular-img-figure paywall-full-content\" contenteditable=\"false\"><span><a href=\"https://static.seekingalpha.com/uploads/2026/2/27/36131525-17722223783691835_origin.png\" rel=\"lightbox\" data-width=\"922\" data-height=\"510\" data-og-image-twitter_small_card=\"true\" data-og-image-twitter_large_card=\"true\" data-og-image-twitter_image_post=\"true\" data-og-image-msn=\"true\" data-og-image-facebook=\"true\" data-og-image-google_news=\"true\" data-og-image-google_plus=\"true\" data-og-image-linkedin=\"true\" role=\"button\" aria-label=\"Expand image into lightbox view\"><img src=\"https://static.seekingalpha.com/uploads/2026/2/27/36131525-17722223783691835_origin.png?io=w640\" alt=\"7 of 11 Sectors Were Up Materially In February\" width=\"640\" height=\"354\" contenteditable=\"false\" loading=\"lazy\" srcset=\"https://static.seekingalpha.com/uploads/2026/2/27/36131525-17722223783691835_origin.png?io=w640 640w,https://static.seekingalpha.com/uploads/2026/2/27/36131525-17722223783691835_origin.png?io=w480 480w,https://static.seekingalpha.com/uploads/2026/2/27/36131525-17722223783691835_origin.png?io=w320 320w,https://static.seekingalpha.com/uploads/2026/2/27/36131525-17722223783691835_origin.png?io=w240 240w\" sizes=\"(max-width: 767px) calc(100vw - 36px), (max-width: 1023px) calc(100vw - 180px), 552px\"></a></span><figcaption><p class=\"item-caption\"><span>Koyfin Charts</span></p></figcaption></figure></p> <h2 class=\"paywall-full-content\">Mag 7 Deep Red in February, Most Global Stocks Were Up</h2> <p class=\"paywall-full-content\"><figure class=\"regular-img-figure paywall-full-content\" contenteditable=\"false\"><span><a href=\"https://static.seekingalpha.com/uploads/2026/2/27/36131525-1772222380046108_origin.png\" rel=\"lightbox\" data-width=\"922\" data-height=\"540\" data-og-image-twitter_small_card=\"true\" data-og-image-twitter_large_card=\"true\" data-og-image-twitter_image_post=\"true\" data-og-image-msn=\"true\" data-og-image-facebook=\"true\" data-og-image-google_news=\"true\" data-og-image-google_plus=\"true\" data-og-image-linkedin=\"true\" role=\"button\" aria-label=\"Expand image into lightbox view\"><img src=\"https://static.seekingalpha.com/uploads/2026/2/27/36131525-1772222380046108_origin.png?io=w640\" alt=\"Mag 7 Deep Red in February, Most Global Stocks Were Up\" width=\"640\" height=\"375\" contenteditable=\"false\" loading=\"lazy\" srcset=\"https://static.seekingalpha.com/uploads/2026/2/27/36131525-1772222380046108_origin.png?io=w640 640w,https://static.seekingalpha.com/uploads/2026/2/27/36131525-1772222380046108_origin.png?io=w480 480w,https://static.seekingalpha.com/uploads/2026/2/27/36131525-1772222380046108_origin.png?io=w320 320w,https://static.seekingalpha.com/uploads/2026/2/27/36131525-1772222380046108_origin.png?io=w240 240w\" sizes=\"(max-width: 767px) calc(100vw - 36px), (max-width: 1023px) calc(100vw - 180px), 552px\"></a></span><figcaption><p class=\"item-caption\"><span>Finviz</span></p></figcaption></figure></p> <h2 class=\"paywall-full-content\">Silver Shone in February, Natural Gas Down Huge</h2> <p class=\"paywall-full-content\"><figure class=\"regular-img-figure paywall-full-content\" contenteditable=\"false\"><span><a href=\"https://static.seekingalpha.com/uploads/2026/2/27/36131525-17722223787982092_origin.png\" rel=\"lightbox\" data-width=\"928\" data-height=\"894\" data-og-image-twitter_small_card=\"true\" data-og-image-twitter_large_card=\"true\" data-og-image-twitter_image_post=\"true\" data-og-image-msn=\"true\" data-og-image-facebook=\"true\" data-og-image-google_news=\"true\" data-og-image-google_plus=\"true\" data-og-image-linkedin=\"true\" role=\"button\" aria-label=\"Expand image into lightbox view\"><img src=\"https://static.seekingalpha.com/uploads/2026/2/27/36131525-17722223787982092_origin.png?io=w640\" alt=\"Silver Shone in February, Natural Gas Down Huge\" width=\"640\" height=\"617\" contenteditable=\"false\" loading=\"lazy\" srcset=\"https://static.seekingalpha.com/uploads/2026/2/27/36131525-17722223787982092_origin.png?io=w640 640w,https://static.seekingalpha.com/uploads/2026/2/27/36131525-17722223787982092_origin.png?io=w480 480w,https://static.seekingalpha.com/uploads/2026/2/27/36131525-17722223787982092_origin.png?io=w320 320w,https://static.seekingalpha.com/uploads/2026/2/27/36131525-17722223787982092_origin.png?io=w240 240w\" sizes=\"(max-width: 767px) calc(100vw - 36px), (max-width: 1023px) calc(100vw - 180px), 552px\"></a></span><figcaption><p class=\"item-caption\"><span>Finviz</span></p></figcaption></figure></p> <p class=\"paywall-full-content\"><span>Turning to the economy, the </span><a href=\"https://seekingalpha.com/article/4868761-january-jobs-jump-stocks-rise-as-the-unemployment-rate-retreats\" rel=\"noreferrer noopener\"><span>January jobs report</span></a><span> was much better than expected. The unemployment rate dropped in the first month of the year, while the nonfarm payrolls gain of more than 100,000 topped estimates. </span></p> <p class=\"paywall-full-content\"><span>Early calls for the February employment gain are near +60k, as signs that the labor market is troughing offer some macro optimism.</span></p> <h2 class=\"paywall-full-content\">Strong January Jobs Report</h2> <p class=\"paywall-full-content\"><figure class=\"regular-img-figure paywall-full-content\" contenteditable=\"false\"><span><a href=\"https://static.seekingalpha.com/uploads/2026/2/27/36131525-1772222378060943_origin.png\" rel=\"lightbox\" data-width=\"921\" data-height=\"364\" data-og-image-twitter_small_card=\"true\" data-og-image-twitter_large_card=\"true\" data-og-image-twitter_image_post=\"true\" data-og-image-msn=\"true\" data-og-image-facebook=\"true\" data-og-image-google_news=\"true\" data-og-image-google_plus=\"true\" data-og-image-linkedin=\"true\" role=\"button\" aria-label=\"Expand image into lightbox view\"><img src=\"https://static.seekingalpha.com/uploads/2026/2/27/36131525-1772222378060943_origin.png?io=w640\" alt=\"Strong January Jobs Report\" width=\"640\" height=\"253\" contenteditable=\"false\" loading=\"lazy\" srcset=\"https://static.seekingalpha.com/uploads/2026/2/27/36131525-1772222378060943_origin.png?io=w640 640w,https://static.seekingalpha.com/uploads/2026/2/27/36131525-1772222378060943_origin.png?io=w480 480w,https://static.seekingalpha.com/uploads/2026/2/27/36131525-1772222378060943_origin.png?io=w320 320w,https://static.seekingalpha.com/uploads/2026/2/27/36131525-1772222378060943_origin.png?io=w240 240w\" sizes=\"(max-width: 767px) calc(100vw - 36px), (max-width: 1023px) calc(100vw - 180px), 552px\"></a></span><figcaption><p class=\"item-caption\"><span>BLS</span></p></figcaption></figure></p> <p class=\"paywall-full-content\"><span>A bit better jobs situation comes as indicators point to some softening in the consumer backdrop. The latest read we have on economy-wide spending is the December Retail Sales report. The all-important final month of the year was worse than expected in terms of total holiday spending. We’ll get the January Retail Sales report from the US Census Bureau next week, along with the usual slew of employment data. So, it will be a big week on the macro front. </span></p> <p class=\"paywall-full-content\"><span>And don’t overlook ISM and S&amp;P Global February PMI readings. Recall that the ISM Manufacturing PMI flipped positive for only the second time in the past three-plus years. It’s yet another sign that the Main Street economy could be turning a corner, all while AI pessimism grows.</span></p> <h2 class=\"paywall-full-content\">Weak December Retail Sales</h2> <p class=\"paywall-full-content\"><figure class=\"regular-img-figure paywall-full-content\" contenteditable=\"false\"><span><a href=\"https://static.seekingalpha.com/uploads/2026/2/27/36131525-17722223777917519_origin.png\" rel=\"lightbox\" data-width=\"921\" data-height=\"516\" data-og-image-twitter_small_card=\"true\" data-og-image-twitter_large_card=\"true\" data-og-image-twitter_image_post=\"true\" data-og-image-msn=\"true\" data-og-image-facebook=\"true\" data-og-image-google_news=\"true\" data-og-image-google_plus=\"true\" data-og-image-linkedin=\"true\" role=\"button\" aria-label=\"Expand image into lightbox view\"><img src=\"https://static.seekingalpha.com/uploads/2026/2/27/36131525-17722223777917519_origin.png?io=w640\" alt=\"Weak December Retail Sales\" width=\"640\" height=\"359\" contenteditable=\"false\" loading=\"lazy\" srcset=\"https://static.seekingalpha.com/uploads/2026/2/27/36131525-17722223777917519_origin.png?io=w640 640w,https://static.seekingalpha.com/uploads/2026/2/27/36131525-17722223777917519_origin.png?io=w480 480w,https://static.seekingalpha.com/uploads/2026/2/27/36131525-17722223777917519_origin.png?io=w320 320w,https://static.seekingalpha.com/uploads/2026/2/27/36131525-17722223777917519_origin.png?io=w240 240w\" sizes=\"(max-width: 767px) calc(100vw - 36px), (max-width: 1023px) calc(100vw - 180px), 552px\"></a></span><figcaption><p class=\"item-caption\"><span>Trading Economics</span></p></figcaption></figure></p> <p class=\"paywall-full-content\"><span>All the while, inflation just won’t quite go away. The </span><a href=\"https://seekingalpha.com/article/4870137-january-cpi-tame-but-pce-inflation-may-be-hotter\" rel=\"noreferrer noopener\"><span>headline CPI rate fell</span></a><span> to 2.4% in January, but the December PCE report and January PPI were notably to the hot side. What’s more, estimates call for a very warm January PCE Price Index update—the Fed’s preferred inflation gauge. </span></p> <p class=\"paywall-full-content\"><span>Going forward, the 1-year inflation swap is a touch under 2.5%, despite private-sector measures (such as Truflation) pointing to much colder US consumer price trends. The good news is that housing affordability is now at a 4-year high, while rent inflation is negative YoY, according to ApartmentList data.</span></p> <h2 class=\"paywall-full-content\">CPI Rate Fell to 2.4% YoY In April</h2> <p class=\"paywall-full-content\"><figure class=\"regular-img-figure paywall-full-content\" contenteditable=\"false\"><span><a href=\"https://static.seekingalpha.com/uploads/2026/2/27/36131525-17722223799762542_origin.png\" rel=\"lightbox\" data-width=\"921\" data-height=\"511\" data-og-image-twitter_small_card=\"true\" data-og-image-twitter_large_card=\"true\" data-og-image-twitter_image_post=\"true\" data-og-image-msn=\"true\" data-og-image-facebook=\"true\" data-og-image-google_news=\"true\" data-og-image-google_plus=\"true\" data-og-image-linkedin=\"true\" role=\"button\" aria-label=\"Expand image into lightbox view\"><img src=\"https://static.seekingalpha.com/uploads/2026/2/27/36131525-17722223799762542_origin.png?io=w640\" alt=\"CPI Rate Fell to 2.4% YoY In April\" width=\"640\" height=\"355\" contenteditable=\"false\" loading=\"lazy\" srcset=\"https://static.seekingalpha.com/uploads/2026/2/27/36131525-17722223799762542_origin.png?io=w640 640w,https://static.seekingalpha.com/uploads/2026/2/27/36131525-17722223799762542_origin.png?io=w480 480w,https://static.seekingalpha.com/uploads/2026/2/27/36131525-17722223799762542_origin.png?io=w320 320w,https://static.seekingalpha.com/uploads/2026/2/27/36131525-17722223799762542_origin.png?io=w240 240w\" sizes=\"(max-width: 767px) calc(100vw - 36px), (max-width: 1023px) calc(100vw - 180px), 552px\"></a></span><figcaption><p class=\"item-caption\"><span>Trading Economics</span></p></figcaption></figure></p> <p class=\"paywall-full-content\"><span>Where is there inflation? At the pump. AAA reports that the average cost of a regular of unleaded is very close to $3. </span></p> <p class=\"paywall-full-content\"><span>As the gasoline futures market (</span>XB1:COM) rolls to the more-expensive summer blend, commuters are sure to pay north of $3, on average, come this time next month.</p> <h2 class=\"paywall-full-content\">USA Gas Prices Tick Toward $3</h2> <p class=\"paywall-full-content\"><figure class=\"regular-img-figure paywall-full-content\" contenteditable=\"false\"><span><a href=\"https://static.seekingalpha.com/uploads/2026/2/27/36131525-17722223801933877_origin.png\" rel=\"lightbox\" data-width=\"921\" data-height=\"349\" data-og-image-twitter_small_card=\"true\" data-og-image-twitter_large_card=\"true\" data-og-image-twitter_image_post=\"true\" data-og-image-msn=\"true\" data-og-image-facebook=\"true\" data-og-image-google_news=\"true\" data-og-image-google_plus=\"true\" data-og-image-linkedin=\"true\" role=\"button\" aria-label=\"Expand image into lightbox view\"><img src=\"https://static.seekingalpha.com/uploads/2026/2/27/36131525-17722223801933877_origin.png?io=w640\" alt=\"USA Gas Prices Tick Toward $3\" width=\"640\" height=\"243\" contenteditable=\"false\" loading=\"lazy\" srcset=\"https://static.seekingalpha.com/uploads/2026/2/27/36131525-17722223801933877_origin.png?io=w640 640w,https://static.seekingalpha.com/uploads/2026/2/27/36131525-17722223801933877_origin.png?io=w480 480w,https://static.seekingalpha.com/uploads/2026/2/27/36131525-17722223801933877_origin.png?io=w320 320w,https://static.seekingalpha.com/uploads/2026/2/27/36131525-17722223801933877_origin.png?io=w240 240w\" sizes=\"(max-width: 767px) calc(100vw - 36px), (max-width: 1023px) calc(100vw - 180px), 552px\"></a></span><figcaption><p class=\"item-caption\"><span>AAA</span></p></figcaption></figure></p> <p class=\"paywall-full-content\"><span>All told for the Fed, it’s unlikely that the Powell-led FOMC will cut again. But it’s not out of the question. According to the CME FedWatch Tool, there’s a 23.4% market-implied chance that an ease will happen before May. </span></p> <p class=\"paywall-full-content\"><span>About two quarter-point cuts remain priced in for the balance of 2026.</span></p> <h2 class=\"paywall-full-content\">1-in-4 Chance of a Cut by May</h2> <p class=\"paywall-full-content\"><figure class=\"regular-img-figure paywall-full-content\" contenteditable=\"false\"><span><a href=\"https://static.seekingalpha.com/uploads/2026/2/27/36131525-17722223805003638_origin.png\" rel=\"lightbox\" data-width=\"831\" data-height=\"348\" data-og-image-twitter_small_card=\"true\" data-og-image-twitter_large_card=\"true\" data-og-image-twitter_image_post=\"true\" data-og-image-msn=\"true\" data-og-image-facebook=\"true\" data-og-image-google_news=\"true\" data-og-image-google_plus=\"true\" data-og-image-linkedin=\"true\" role=\"button\" aria-label=\"Expand image into lightbox view\"><img src=\"https://static.seekingalpha.com/uploads/2026/2/27/36131525-17722223805003638_origin.png?io=w640\" alt=\"1-in-4 Chance of a Cut by May\" width=\"640\" height=\"268\" contenteditable=\"false\" loading=\"lazy\" srcset=\"https://static.seekingalpha.com/uploads/2026/2/27/36131525-17722223805003638_origin.png?io=w640 640w,https://static.seekingalpha.com/uploads/2026/2/27/36131525-17722223805003638_origin.png?io=w480 480w,https://static.seekingalpha.com/uploads/2026/2/27/36131525-17722223805003638_origin.png?io=w320 320w,https://static.seekingalpha.com/uploads/2026/2/27/36131525-17722223805003638_origin.png?io=w240 240w\" sizes=\"(max-width: 767px) calc(100vw - 36px), (max-width: 1023px) calc(100vw - 180px), 552px\"></a></span><figcaption><p class=\"item-caption\"><span>CME FedWatch Tool</span></p></figcaption></figure></p> <p class=\"paywall-full-content\"><span>And while the Q4 GDP print disappointed, forecasts for Q1 GDP are just a bit above 3%. If that comes to fruition, then U.S. real economic growth from the middle of last year through March will have been incredibly strong. </span></p> <p class=\"paywall-full-content\"><span>High tax refunds and a potentially improving jobs market should help near-term consumption (which accounts for about two-thirds of U.S. GDP). Growth data remains wonky, given the extremely volatile trade data.</span></p> <h2 class=\"paywall-full-content\">Solid Q1 GDP Expected</h2> <p class=\"paywall-full-content\"><figure class=\"regular-img-figure paywall-full-content\" contenteditable=\"false\"><span><a href=\"https://static.seekingalpha.com/uploads/2026/2/27/36131525-17722223805802305_origin.png\" rel=\"lightbox\" data-width=\"927\" data-height=\"526\" data-og-image-twitter_small_card=\"true\" data-og-image-twitter_large_card=\"true\" data-og-image-twitter_image_post=\"true\" data-og-image-msn=\"true\" data-og-image-facebook=\"true\" data-og-image-google_news=\"true\" data-og-image-google_plus=\"true\" data-og-image-linkedin=\"true\" role=\"button\" aria-label=\"Expand image into lightbox view\"><img src=\"https://static.seekingalpha.com/uploads/2026/2/27/36131525-17722223805802305_origin.png?io=w640\" alt=\"Solid Q1 GDP Expected\" width=\"640\" height=\"363\" contenteditable=\"false\" loading=\"lazy\" srcset=\"https://static.seekingalpha.com/uploads/2026/2/27/36131525-17722223805802305_origin.png?io=w640 640w,https://static.seekingalpha.com/uploads/2026/2/27/36131525-17722223805802305_origin.png?io=w480 480w,https://static.seekingalpha.com/uploads/2026/2/27/36131525-17722223805802305_origin.png?io=w320 320w,https://static.seekingalpha.com/uploads/2026/2/27/36131525-17722223805802305_origin.png?io=w240 240w\" sizes=\"(max-width: 767px) calc(100vw - 36px), (max-width: 1023px) calc(100vw - 180px), 552px\"></a></span><figcaption><p class=\"item-caption\"><span>Kalshi</span></p></figcaption></figure></p> <p class=\"paywall-full-content\"><span>How are the biggest U.S. companies handling all of the macro fluctuations and uncertainty? Quite well. FactSet data show rising current-year and out-year EPS consensus forecasts. </span></p> <p class=\"paywall-full-content\"><span>In fact, as of the penultimate day of February, both years’ earnings estimates hit 52-week highs. That results in a sub-21 S&amp;P 500 price-to-earnings ratio based on forward 12-month earnings forecasts.</span></p> <h2 class=\"paywall-full-content\">Record-High S&amp;P 500 Earnings Forecasts</h2> <p class=\"paywall-full-content\"><figure class=\"regular-img-figure paywall-full-content\" contenteditable=\"false\"><span><a href=\"https://static.seekingalpha.com/uploads/2026/2/27/36131525-17722223808835356_origin.png\" rel=\"lightbox\" data-width=\"927\" data-height=\"535\" data-og-image-twitter_small_card=\"true\" data-og-image-twitter_large_card=\"true\" data-og-image-twitter_image_post=\"true\" data-og-image-msn=\"true\" data-og-image-facebook=\"true\" data-og-image-google_news=\"true\" data-og-image-google_plus=\"true\" data-og-image-linkedin=\"true\" role=\"button\" aria-label=\"Expand image into lightbox view\"><img src=\"https://static.seekingalpha.com/uploads/2026/2/27/36131525-17722223808835356_origin.png?io=w640\" alt=\"Record-High S&amp;P 500 Earnings Forecasts\" width=\"640\" height=\"369\" contenteditable=\"false\" loading=\"lazy\" srcset=\"https://static.seekingalpha.com/uploads/2026/2/27/36131525-17722223808835356_origin.png?io=w640 640w,https://static.seekingalpha.com/uploads/2026/2/27/36131525-17722223808835356_origin.png?io=w480 480w,https://static.seekingalpha.com/uploads/2026/2/27/36131525-17722223808835356_origin.png?io=w320 320w,https://static.seekingalpha.com/uploads/2026/2/27/36131525-17722223808835356_origin.png?io=w240 240w\" sizes=\"(max-width: 767px) calc(100vw - 36px), (max-width: 1023px) calc(100vw - 180px), 552px\"></a></span><figcaption><p class=\"item-caption\"><span>FactSet</span></p></figcaption></figure></p> <p class=\"paywall-full-content\"><span>Finally, March has tended to be a decent month. Over the past 15 years, the S&amp;P 500 ETF SPY has averaged a 0.97% gain, up 75% of the time. </span></p> <p class=\"paywall-full-content\"><span>Interestingly, February has been down in four of the past five instances.</span></p> <h2 class=\"paywall-full-content\">S&amp;P 500: Solid March Historical Trend</h2> <p class=\"paywall-full-content\"><figure class=\"regular-img-figure paywall-full-content\" contenteditable=\"false\"><span><a href=\"https://static.seekingalpha.com/uploads/2026/2/27/36131525-17722223818726068_origin.png\" rel=\"lightbox\" data-width=\"924\" data-height=\"517\" data-og-image-twitter_small_card=\"true\" data-og-image-twitter_large_card=\"true\" data-og-image-twitter_image_post=\"true\" data-og-image-msn=\"true\" data-og-image-facebook=\"true\" data-og-image-google_news=\"true\" data-og-image-google_plus=\"true\" data-og-image-linkedin=\"true\" role=\"button\" aria-label=\"Expand image into lightbox view\"><img src=\"https://static.seekingalpha.com/uploads/2026/2/27/36131525-17722223818726068_origin.png?io=w640\" alt=\"S&amp;P 500: Solid March Historical Trend\" width=\"640\" height=\"358\" contenteditable=\"false\" loading=\"lazy\" srcset=\"https://static.seekingalpha.com/uploads/2026/2/27/36131525-17722223818726068_origin.png?io=w640 640w,https://static.seekingalpha.com/uploads/2026/2/27/36131525-17722223818726068_origin.png?io=w480 480w,https://static.seekingalpha.com/uploads/2026/2/27/36131525-17722223818726068_origin.png?io=w320 320w,https://static.seekingalpha.com/uploads/2026/2/27/36131525-17722223818726068_origin.png?io=w240 240w\" sizes=\"(max-width: 767px) calc(100vw - 36px), (max-width: 1023px) calc(100vw - 180px), 552px\"></a></span><figcaption><p class=\"item-caption\"><span>Barchart</span></p></figcaption></figure></p> <h2 class=\"paywall-full-content\"><span>The Bottom Line</span></h2> <div class=\"before_last_paragraph-piano-placeholder paywall-full-content\"></div> <p class=\"paywall-full-content\"><span>The S&amp;P 500 dealt with fears around what AI will do to the software space, a major Supreme Court IEEPA tariff strike-down, private-credit cockroaches, and broad-based mega-cap weakness. But domestic SMID-caps jumped, and non-U.S. equities soared. Diversification paid proverbial and literal dividends. Attention now turns to key macro data next week.</span></p>",
            "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2187254257/image_2187254257.jpg",
            "link": "https://seekingalpha.com/article/4876544-s-and-p-500-slips-world-soars-a-massive-market-mood-shift-in-february",
            "pub_date": "2026-02-28 05:01:32",
            "source": "seekalpha_articles",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "4876527",
            "title": "Sabra Health Care: Leveraging SHOP To Capture Silver Tsunami Tailwinds",
            "description": "<p data-eci=\"true\"><figure class=\"getty-figure\" data-type=\"getty-image\"><picture> <img src=\"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/669938158/image_669938158.jpg?io=getty-c-w630\" alt=\"Getting older can bring senior health challenges\" data-id=\"669938158\" data-type=\"getty-image\" width=\"1536\" height=\"1024\" srcset=\"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/669938158/image_669938158.jpg?io=getty-c-w1536 1536w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/669938158/image_669938158.jpg?io=getty-c-w1280 1280w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/669938158/image_669938158.jpg?io=getty-c-w1080 1080w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/669938158/image_669938158.jpg?io=getty-c-w750 750w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/669938158/image_669938158.jpg?io=getty-c-w640 640w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/669938158/image_669938158.jpg?io=getty-c-w480 480w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/669938158/image_669938158.jpg?io=getty-c-w320 320w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/669938158/image_669938158.jpg?io=getty-c-w240 240w\" sizes=\"(max-width: 767px) calc(100vw - 36px), (max-width: 1023px) calc(100vw - 132px), (max-width: 1199px) calc(100vw - 666px), (max-width: 1307px) calc(100vw - 708px), 600px\" fetchpriority=\"high\"> </picture><figcaption><p class=\"item-caption\"> </p> <p class=\"item-credits\">PeopleImages/iStock via Getty Images</p></figcaption></figure></p> <div class=\"inline_ad_placeholder\"></div> <h2>Introduction</h2> <p><a href=\"https://seekingalpha.com/article/4862754-sabra-health-care-stock-compelling-reit-opportunity-shop-unlocks-hidden-value\">The last time I covered Sabra Health Care</a> (<span class=\"ticker-hover-wrapper\"><a href=\"https://seekingalpha.com/symbol/SBRA\" title=\"Sabra Health Care REIT, Inc.\">SBRA</a></span>), I highlighted their solid upside potential as they accelerate the SHOP model and attractive valuation, standing to benefit significantly from the Silver Tsunami.</p> <p>With a<span class=\"paywall-full-content\"> solid report released recently, good guidance and still an attractive yield with room to grow, I reiterate SBRA’s Buy rating, as the company remains in a good position to benefit from potential macro tailwinds.</span></p> <h2 class=\"paywall-full-content\">Internal Developments</h2> <p class=\"paywall-full-content\"><figure class=\"regular-img-figure paywall-full-content\" contenteditable=\"false\"><span><a href=\"https://static.seekingalpha.com/uploads/2026/2/26/60669497-17721113783057423_origin.png\" rel=\"lightbox\" data-width=\"849\" data-height=\"795\" data-og-image-twitter_small_card=\"true\" data-og-image-twitter_large_card=\"true\" data-og-image-twitter_image_post=\"true\" data-og-image-msn=\"true\" data-og-image-facebook=\"true\" data-og-image-google_news=\"true\" data-og-image-google_plus=\"true\" data-og-image-linkedin=\"true\" role=\"button\" aria-label=\"Expand image into lightbox view\"><img src=\"https://static.seekingalpha.com/uploads/2026/2/26/60669497-17721113783057423_origin.png?io=w640\" alt=\"Sabra Health Care REIT IR SBRA stock analysis seekingalpha valuation best reit dividend stocks to buy 2026\" width=\"640\" height=\"599\" contenteditable=\"false\" loading=\"lazy\" srcset=\"https://static.seekingalpha.com/uploads/2026/2/26/60669497-17721113783057423_origin.png?io=w640 640w,https://static.seekingalpha.com/uploads/2026/2/26/60669497-17721113783057423_origin.png?io=w480 480w,https://static.seekingalpha.com/uploads/2026/2/26/60669497-17721113783057423_origin.png?io=w320 320w,https://static.seekingalpha.com/uploads/2026/2/26/60669497-17721113783057423_origin.png?io=w240 240w\" sizes=\"(max-width: 767px) calc(100vw - 36px), (max-width: 1023px) calc(100vw - 180px), 552px\"></a></span><figcaption><p class=\"item-caption\"><span>Sabra Health Care REIT IR</span></p></figcaption></figure></p> <p class=\"paywall-full-content\">SBRA reported an overall solid Q4 and 2025, despite <a href=\"https://seekingalpha.com/news/4551495-sabra-health-care-ffo-of-0_36-misses-by-0_01-revenue-of-211_9m-beats-by-9_93m\">a slight miss on the market’s estimated FFO and a slight beat on revenue</a>, with a Normalized AFFO of $365.41 million, slightly below my previous estimate of $368.55 million, growing it from $1.49 per share from $1.44 back in 2024, for a roughly 3.5% increase YoY, which is not terrible for a REIT in this environment.</p> <p class=\"paywall-full-content\"><figure class=\"regular-img-figure paywall-full-content\" contenteditable=\"false\"><span><a href=\"https://static.seekingalpha.com/uploads/2026/2/26/60669497-17721113781346796_origin.png\" rel=\"lightbox\" data-width=\"1136\" data-height=\"308\" data-og-image-twitter_small_card=\"false\" data-og-image-twitter_large_card=\"false\" data-og-image-twitter_image_post=\"false\" data-og-image-msn=\"false\" data-og-image-facebook=\"false\" data-og-image-google_news=\"false\" data-og-image-google_plus=\"false\" data-og-image-linkedin=\"false\" role=\"button\" aria-label=\"Expand image into lightbox view\"><img src=\"https://static.seekingalpha.com/uploads/2026/2/26/60669497-17721113781346796_origin.png?io=w640\" alt=\"Sabra Health Care REIT IR SBRA stock analysis seekingalpha valuation best reit dividend stocks to buy 2026\" width=\"640\" height=\"174\" contenteditable=\"false\" loading=\"lazy\" srcset=\"https://static.seekingalpha.com/uploads/2026/2/26/60669497-17721113781346796_origin.png?io=w640 640w,https://static.seekingalpha.com/uploads/2026/2/26/60669497-17721113781346796_origin.png?io=w480 480w,https://static.seekingalpha.com/uploads/2026/2/26/60669497-17721113781346796_origin.png?io=w320 320w,https://static.seekingalpha.com/uploads/2026/2/26/60669497-17721113781346796_origin.png?io=w240 240w\" sizes=\"(max-width: 767px) calc(100vw - 36px), (max-width: 1023px) calc(100vw - 180px), 552px\"></a></span><figcaption><p class=\"item-caption\"><span>Sabra Health Care REIT IR</span></p></figcaption></figure></p> <p class=\"paywall-full-content\">As for the guidance, SBRA expects a 4.9% to 5.4% increase in FFO and roughly 5.37% growth in Normalized AFFO, planning to expand their SHOP portfolio while expecting more than $450 million worth of investments (the 2025 level) in 2026, with SBRA’s CEO highlighting the following during their <a href=\"https://seekingalpha.com/article/4870306-sabra-health-care-reit-inc-sbra-q4-2025-earnings-call-transcript\">Q4 Earnings Call</a>:</p> <blockquote class=\"paywall-full-content\"><p>Our guidance of 4.9% and 5.4% growth at the midpoint for normalized FFO and normalized AFFO, respectively, reflects continuing execution of our strategy. Our pipeline continues to be robust. We completed approximately $450 million in investments for 2025. We had discussed on our last call exceeding $500 million. A couple of those deals fell over into 2026, but no deals fell out. So we're closing on everything that we said we would close on, on our last call. Our investment activity has grown $200 million since our last call, and we're currently in the process of closing $240 million of awarded deals, most of which will close in Q1 and early Q2. Our expectation is that we will materially exceed the volume of 2025 investments and are clearly off to a strong start in 2026.</p></blockquote> <p class=\"paywall-full-content\"><figure class=\"regular-img-figure paywall-full-content\" contenteditable=\"false\"><span><a href=\"https://static.seekingalpha.com/uploads/2026/2/26/60669497-1772111378310656_origin.png\" rel=\"lightbox\" data-width=\"1042\" data-height=\"823\" data-og-image-twitter_small_card=\"true\" data-og-image-twitter_large_card=\"true\" data-og-image-twitter_image_post=\"true\" data-og-image-msn=\"true\" data-og-image-facebook=\"true\" data-og-image-google_news=\"true\" data-og-image-google_plus=\"true\" data-og-image-linkedin=\"true\" role=\"button\" aria-label=\"Expand image into lightbox view\"><img src=\"https://static.seekingalpha.com/uploads/2026/2/26/60669497-1772111378310656_origin.png?io=w640\" alt=\"Sabra Health Care REIT IR SBRA stock analysis seekingalpha valuation best reit dividend stocks to buy 2026\" width=\"640\" height=\"505\" contenteditable=\"false\" loading=\"lazy\" srcset=\"https://static.seekingalpha.com/uploads/2026/2/26/60669497-1772111378310656_origin.png?io=w640 640w,https://static.seekingalpha.com/uploads/2026/2/26/60669497-1772111378310656_origin.png?io=w480 480w,https://static.seekingalpha.com/uploads/2026/2/26/60669497-1772111378310656_origin.png?io=w320 320w,https://static.seekingalpha.com/uploads/2026/2/26/60669497-1772111378310656_origin.png?io=w240 240w\" sizes=\"(max-width: 767px) calc(100vw - 36px), (max-width: 1023px) calc(100vw - 180px), 552px\"></a></span><figcaption><p class=\"item-caption\"><span>Sabra Health Care REIT IR</span></p></figcaption></figure></p> <p class=\"paywall-full-content\">Financially, based on <a href=\"https://seekingalpha.com/symbol/SBRA/sec-filings\">SBRA’s latest report</a>, we continue to see a solid position, with the leverage remaining around their 5x target, with no maturity to worry about until 2027 and a significant swap of their 2026 notes for an unsecured term loan worth $500 million due in 2030, which they fixed at a 4.64% rate through interest rate swaps (compared to the 5.125% rate on the 2026 notes).</p> <p class=\"paywall-full-content\">As a note, this is very solid for a company like this, helping them withstand a higher-for-longer rate environment better, which is key especially in this environment.</p> <p class=\"paywall-full-content\">Regarding the dividend, we see them paying about $289.5 million in 2025, for a solid ~79.23% payout ratio based on their Normalized AFFO, which is not bad given the industry and ~5.84% yield they are trading at today.</p> <h2 class=\"paywall-full-content\">Macro Developments</h2> <p class=\"paywall-full-content\">Despite the previous article being published not long ago, we still had several factors that caused significant volatility across the broader market, with mixed <a href=\"https://www.msn.com/en-us/money/markets/economy-grew-2-2-in-2025-beating-predictions/ar-AA1WJTlf\" rel=\"nofollow\">recent data</a>, worries surrounding Japan’s moves that can crash the dollar and lift US treasury yields, political uncertainty, and many other factors coming out almost daily.</p> <p class=\"paywall-full-content\">What I want to reiterate here is that just because we don’t hear that much about something like <a href=\"https://www.aljazeera.com/economy/2026/1/27/why-japans-economic-plans-are-sending-jitters-through-global-markets\" rel=\"nofollow\">the situation in Japan</a> (the No. 1 foreign holder of US treasuries), it doesn’t mean it’s not an issue anymore.</p> <p class=\"paywall-full-content\">A potential selloff caused by Japan's domestic yields rising and attracting funds back into it could potentially cause a sudden jump in US bond supply since they would be sold, which would also weaken the dollar alongside the prices and consequently pushing the yield up (on top of the potential fear and volatility it can cause once again), leading to worse borrowing costs for SBRA and everyone around them.</p> <p class=\"paywall-full-content\"><figure class=\"regular-img-figure paywall-full-content\" contenteditable=\"false\"><span><a href=\"https://static.seekingalpha.com/uploads/2026/2/26/60669497-17721113781873071_origin.png\" rel=\"lightbox\" data-width=\"980\" data-height=\"535\" data-og-image-twitter_small_card=\"true\" data-og-image-twitter_large_card=\"true\" data-og-image-twitter_image_post=\"true\" data-og-image-msn=\"true\" data-og-image-facebook=\"true\" data-og-image-google_news=\"true\" data-og-image-google_plus=\"true\" data-og-image-linkedin=\"true\" role=\"button\" aria-label=\"Expand image into lightbox view\"><img src=\"https://static.seekingalpha.com/uploads/2026/2/26/60669497-17721113781873071_origin.png?io=w640\" alt=\"Sabra Health Care REIT IR SBRA stock analysis seekingalpha valuation best reit dividend stocks to buy 2026\" width=\"640\" height=\"349\" contenteditable=\"false\" loading=\"lazy\" srcset=\"https://static.seekingalpha.com/uploads/2026/2/26/60669497-17721113781873071_origin.png?io=w640 640w,https://static.seekingalpha.com/uploads/2026/2/26/60669497-17721113781873071_origin.png?io=w480 480w,https://static.seekingalpha.com/uploads/2026/2/26/60669497-17721113781873071_origin.png?io=w320 320w,https://static.seekingalpha.com/uploads/2026/2/26/60669497-17721113781873071_origin.png?io=w240 240w\" sizes=\"(max-width: 767px) calc(100vw - 36px), (max-width: 1023px) calc(100vw - 180px), 552px\"></a></span><figcaption><p class=\"item-caption\"><span>Federal Reserve Bank of New York</span></p></figcaption></figure></p> <p class=\"paywall-full-content\">I’ll also mention, however, that we see improvements, with the SOFR falling and still being down significantly from its peak, while the company’s stock is recovering pretty well (up over 10% since a month ago when I previously covered them), with the yield standing at 5.84% now, which isn’t amazing if they want to issue, but it’s improving.</p> <p class=\"paywall-full-content\"><figure class=\"regular-img-figure paywall-full-content\" contenteditable=\"false\"><span><a href=\"https://static.seekingalpha.com/uploads/2026/2/26/60669497-1772111378120349_origin.png\" rel=\"lightbox\" data-width=\"1278\" data-height=\"700\" data-og-image-twitter_small_card=\"true\" data-og-image-twitter_large_card=\"true\" data-og-image-twitter_image_post=\"true\" data-og-image-msn=\"true\" data-og-image-facebook=\"true\" data-og-image-google_news=\"true\" data-og-image-google_plus=\"true\" data-og-image-linkedin=\"true\" role=\"button\" aria-label=\"Expand image into lightbox view\"><img src=\"https://static.seekingalpha.com/uploads/2026/2/26/60669497-1772111378120349_origin.png?io=w640\" alt=\"Sabra Health Care REIT IR SBRA stock analysis seekingalpha valuation best reit dividend stocks to buy 2026\" width=\"640\" height=\"351\" contenteditable=\"false\" loading=\"lazy\" srcset=\"https://static.seekingalpha.com/uploads/2026/2/26/60669497-1772111378120349_origin.png?io=w640 640w,https://static.seekingalpha.com/uploads/2026/2/26/60669497-1772111378120349_origin.png?io=w480 480w,https://static.seekingalpha.com/uploads/2026/2/26/60669497-1772111378120349_origin.png?io=w320 320w,https://static.seekingalpha.com/uploads/2026/2/26/60669497-1772111378120349_origin.png?io=w240 240w\" sizes=\"(max-width: 767px) calc(100vw - 36px), (max-width: 1023px) calc(100vw - 180px), 552px\"></a></span><figcaption><p class=\"item-caption\"><span>Omega Healthcare Investors IR</span></p></figcaption></figure></p> <p class=\"paywall-full-content\">As mentioned, the company accelerates their SHOP (Seniors Housing Operating Portfolio; different companies use different terms, SBRA calls it Senior Housing - Managed/Communities) investments, allowing them to fully enjoy the potential upside backed by the industry’s long-term trends while they hire an independent third-party operator to manage it for them, allowing them to turn from a simple landlord into a direct beneficiary of any jump in occupancy.</p> <p class=\"paywall-full-content\">The potential comes thanks to a significant boost expected from Baby Boomers aging combined with a very fragmented market that SBRA can take advantage of. Virtually every peer does this nowadays, although RIDEA (the legislation that allows REITs to go into a SHOP model) was passed back in 2007. The company also commented on its performance during their Q4 Earnings Call:</p> <blockquote class=\"paywall-full-content\"><p>Moving on to our operational results. They continue to be impressive. Our SHOP operational performance showed strong occupancy gains and increased cash NOI margins. Our same-store Senior Housing also showed occupancy gains and margin improvement. Our same-store Senior Housing triple- net showed improved occupancy and maintained high rent coverage. The skilled nursing portfolio again showed increased rent coverage, hitting an all-time high, as well as increased occupancy, and our top 10 triple-net relationships also had another strong showing. Our leverage stayed steady at our current target of 5x and the regulatory environment remains stable.</p></blockquote> <p class=\"paywall-full-content\">However, I believe it’s also important to be aware of the risks this shift comes with. Sure, they can capture massive upside swings in occupancy and “milk” significantly more from their assets than just rent, but that also means they are assuming the downside risk as well, with the pandemic, for example, likely being something that would’ve ruined many of these players.</p> <p class=\"paywall-full-content\">Although I see it as a good move in the long term, this is quite a big shift from the triple-net lease model these companies were going for, which can go as far as resetting their shareholder base, as someone that bought them for the stability and yield may not be happy with taking the operational risk.</p> <p class=\"paywall-full-content\">Meanwhile, this can be worsened by the ongoing nursing crisis, which can limit their expansion potential and the outcome of this SHOP pivot given the potential pressure on the margins.</p> <p class=\"paywall-full-content\">Still, over the long term, population trends will very likely continue in a direction that can be very beneficial for LTC and the industry, while more and more REITs are switching to SHOP, allowing them to enjoy the potential rise in occupancy, while the market remains very fragmented, with potential supply issues given the potential hike in demand thanks to Baby Boomers.</p> <h2 class=\"paywall-full-content\">Risks Reiterated</h2> <p class=\"paywall-full-content\">At the end of the day, we should keep in mind that SBRA will always depend on the environment it plays in since we’re talking about a REIT, with their expansion, tenants, clients, and even operations now depending on what’s going on in the broader economy, as that can affect their borrowing costs and the valuation of their assets/stock.</p> <p class=\"paywall-full-content\">Meanwhile, I’ll reiterate that even though their transition to SHOP has great potential, it also brings a new layer of risk and volatility that may not be great for some of its older shareholders, exposing them even more to the environment, Medicaid and Medicare rates, politics, etc.</p> <h2 class=\"paywall-full-content\">Valuation</h2> <p class=\"paywall-full-content\"><figure class=\"regular-img-figure paywall-full-content\" contenteditable=\"false\"><span><a href=\"https://static.seekingalpha.com/uploads/2026/2/26/60669497-1772111378150975_origin.png\" rel=\"lightbox\" data-width=\"654\" data-height=\"298\" data-og-image-twitter_small_card=\"true\" data-og-image-twitter_large_card=\"true\" data-og-image-twitter_image_post=\"true\" data-og-image-msn=\"true\" data-og-image-facebook=\"false\" data-og-image-google_news=\"true\" data-og-image-google_plus=\"true\" data-og-image-linkedin=\"true\" role=\"button\" aria-label=\"Expand image into lightbox view\"><img src=\"https://static.seekingalpha.com/uploads/2026/2/26/60669497-1772111378150975_origin.png?io=w640\" alt=\"Sabra Health Care REIT IR SBRA stock analysis seekingalpha valuation best reit dividend stocks to buy 2026\" width=\"640\" height=\"292\" contenteditable=\"false\" loading=\"lazy\" srcset=\"https://static.seekingalpha.com/uploads/2026/2/26/60669497-1772111378150975_origin.png?io=w640 640w,https://static.seekingalpha.com/uploads/2026/2/26/60669497-1772111378150975_origin.png?io=w480 480w,https://static.seekingalpha.com/uploads/2026/2/26/60669497-1772111378150975_origin.png?io=w320 320w,https://static.seekingalpha.com/uploads/2026/2/26/60669497-1772111378150975_origin.png?io=w240 240w\" sizes=\"(max-width: 767px) calc(100vw - 36px), (max-width: 1023px) calc(100vw - 180px), 552px\"></a></span><figcaption><p class=\"item-caption\"><span>Author's Calculations</span></p></figcaption></figure></p> <p class=\"paywall-full-content\">For SBRA’s DCF to Equity valuation, starting with their Normalized AFFO midpoint of $400 million in 2026 (a couple million below their midpoint), I’ll continue to assume a 5% CAGR until 2030 given their focus on SHOP, potential macro improvements and long-term tailwinds given the demographics (below <a href=\"https://seekingalpha.com/symbol/SBRA/earnings/estimates\">the market’s estimates even for revenue</a>), followed by a 3.5% CAGR for the subsequent 5 years and a 2.5% terminal growth rate, with a 10% discount rate to take into account their solid size in this fragmented market but also the risks associated with SHOP (which represents about 22% of their total investments) and the industry in general, with 256 million shares outstanding that they use for their 2026 outlook.</p> <p class=\"paywall-full-content\">This way, we get to an equity value of $5.96 billion, for an intrinsic value of $23.30, which is still above the current $20.56.</p> <h2 class=\"paywall-full-content\">Conclusions</h2> <p class=\"paywall-full-content\">I reiterate SBRA’s Buy rating, as the company remains in a solid and overall balanced position to take advantage of the trends in the industry, paying a solid and sustainable dividend while waiting for macro tailwinds.</p> <div class=\"before_last_paragraph-piano-placeholder paywall-full-content\"></div> <p class=\"paywall-full-content\">There are risks especially as they focus more on SHOP, but the overall risk-reward continues to be in the investment’s favor, offering a solid way to get exposure to the industry’s long-term potential.</p>",
            "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/669938158/image_669938158.jpg",
            "link": "https://seekingalpha.com/article/4876527-sabra-health-care-leveraging-shop-to-capture-silver-tsunami-tailwinds",
            "pub_date": "2026-02-28 04:56:34",
            "source": "seekalpha_articles",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "4876526",
            "title": "Match Group: A Re-Rating Setup Backed By Double-Digit Yield (Rating Upgrade)",
            "description": "<p data-eci=\"true\"><figure class=\"getty-figure\" data-type=\"getty-image\"><picture> <img src=\"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1927819017/image_1927819017.jpg?io=getty-c-w630\" alt=\"Female using a dating app on smart phone\" data-id=\"1927819017\" data-type=\"getty-image\" width=\"1536\" height=\"1024\" srcset=\"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1927819017/image_1927819017.jpg?io=getty-c-w1536 1536w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1927819017/image_1927819017.jpg?io=getty-c-w1280 1280w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1927819017/image_1927819017.jpg?io=getty-c-w1080 1080w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1927819017/image_1927819017.jpg?io=getty-c-w750 750w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1927819017/image_1927819017.jpg?io=getty-c-w640 640w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1927819017/image_1927819017.jpg?io=getty-c-w480 480w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1927819017/image_1927819017.jpg?io=getty-c-w320 320w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1927819017/image_1927819017.jpg?io=getty-c-w240 240w\" sizes=\"(max-width: 767px) calc(100vw - 36px), (max-width: 1023px) calc(100vw - 132px), (max-width: 1199px) calc(100vw - 666px), (max-width: 1307px) calc(100vw - 708px), 600px\" fetchpriority=\"high\"> </picture><figcaption><p class=\"item-caption\"> </p> <p class=\"item-credits\">Uwe Krejci/DigitalVision via Getty Images</p></figcaption></figure></p> <div class=\"inline_ad_placeholder\"></div> <h2>Introduction</h2> <p><a href=\"https://seekingalpha.com/article/4856773-match-group-undervalued-cash-flow-powerhouse-with-double-digit-shareholder-returns\">The last time I covered Match Group, Inc</a>. (<span class=\"ticker-hover-wrapper\"><a href=\"https://seekingalpha.com/symbol/MTCH\" title=\"Match Group, Inc.\">MTCH</a></span>), I highlighted their attractive valuation, with a strong yield and overall great financial shape despite ongoing headwinds across many of their segments.</p> <p>Following a<span class=\"paywall-full-content\"> strong report and even better-than-expected guidance, I am upgrading MTCH to a Strong Buy, as the valuation is very attractive even for a very conservative outlook, while the company continues to deliver strong cash flow and a very attractive yield, standing to benefit from macro tailwinds and Tinder’s potential turnaround.</span></p> <h2 class=\"paywall-full-content\">Internal Developments</h2> <p class=\"paywall-full-content\"><figure class=\"regular-img-figure paywall-full-content\" contenteditable=\"false\"><span><a href=\"https://static.seekingalpha.com/uploads/2026/2/26/60669497-1772093033923769_origin.png\" rel=\"lightbox\" data-width=\"1254\" data-height=\"590\" data-og-image-twitter_small_card=\"true\" data-og-image-twitter_large_card=\"true\" data-og-image-twitter_image_post=\"true\" data-og-image-msn=\"true\" data-og-image-facebook=\"true\" data-og-image-google_news=\"true\" data-og-image-google_plus=\"true\" data-og-image-linkedin=\"true\" role=\"button\" aria-label=\"Expand image into lightbox view\"><img src=\"https://static.seekingalpha.com/uploads/2026/2/26/60669497-1772093033923769_origin.png?io=w640\" alt=\"Match Group IR MTCH tinder stock analysis seekingalpha valuation best value stocks to buy 2026\" width=\"640\" height=\"301\" contenteditable=\"false\" loading=\"lazy\" srcset=\"https://static.seekingalpha.com/uploads/2026/2/26/60669497-1772093033923769_origin.png?io=w640 640w,https://static.seekingalpha.com/uploads/2026/2/26/60669497-1772093033923769_origin.png?io=w480 480w,https://static.seekingalpha.com/uploads/2026/2/26/60669497-1772093033923769_origin.png?io=w320 320w,https://static.seekingalpha.com/uploads/2026/2/26/60669497-1772093033923769_origin.png?io=w240 240w\" sizes=\"(max-width: 767px) calc(100vw - 36px), (max-width: 1023px) calc(100vw - 180px), 552px\"></a></span><figcaption><p class=\"item-caption\"><span>Match Group IR</span></p></figcaption></figure></p> <p class=\"paywall-full-content\">Match reported a solid Q4 and 2025 overall, <a href=\"https://seekingalpha.com/news/4546631-match-group-gaap-eps-of-0_83-beats-by-0_12-revenue-of-878m-beats-by-4_92m\">beating the market’s top- and bottom-line estimates,</a> while we can see trends continuing, with Tinder, E&amp;E, and their Asian segments falling due to headwinds in terms of revenue but gaining either paying users or delivering higher revenue per payer, while Hinge continued to be a strong growth engine.</p> <p class=\"paywall-full-content\">Especially with Hinge growing so well and still having potential to expand abroad, I believe that if they manage to turn Tinder around or at least stop it from bleeding paying users (down 8% in Q4 YoY), there is massive potential given how much money this company makes, and there are certainly catalysts to pay attention to even in the macro environment.</p> <p class=\"paywall-full-content\"><figure class=\"regular-img-figure paywall-full-content\" contenteditable=\"false\"><span><a href=\"https://static.seekingalpha.com/uploads/2026/2/26/60669497-17720930338973062_origin.png\" rel=\"lightbox\" data-width=\"982\" data-height=\"394\" data-og-image-twitter_small_card=\"true\" data-og-image-twitter_large_card=\"true\" data-og-image-twitter_image_post=\"true\" data-og-image-msn=\"true\" data-og-image-facebook=\"true\" data-og-image-google_news=\"true\" data-og-image-google_plus=\"true\" data-og-image-linkedin=\"true\" role=\"button\" aria-label=\"Expand image into lightbox view\"><img src=\"https://static.seekingalpha.com/uploads/2026/2/26/60669497-17720930338973062_origin.png?io=w640\" alt=\"Match Group IR MTCH tinder stock analysis seekingalpha valuation best value stocks to buy 2026\" width=\"640\" height=\"257\" contenteditable=\"false\" loading=\"lazy\" srcset=\"https://static.seekingalpha.com/uploads/2026/2/26/60669497-17720930338973062_origin.png?io=w640 640w,https://static.seekingalpha.com/uploads/2026/2/26/60669497-17720930338973062_origin.png?io=w480 480w,https://static.seekingalpha.com/uploads/2026/2/26/60669497-17720930338973062_origin.png?io=w320 320w,https://static.seekingalpha.com/uploads/2026/2/26/60669497-17720930338973062_origin.png?io=w240 240w\" sizes=\"(max-width: 767px) calc(100vw - 36px), (max-width: 1023px) calc(100vw - 180px), 552px\"></a></span><figcaption><p class=\"item-caption\"><span>Match Group IR</span></p></figcaption></figure></p> <p class=\"paywall-full-content\">As we can see, Match reported yet another year of strong FCF, reaching $1.02 billion in 2025, with a very strong ~83% FCF conversion rate, placing them at a P/FCF ratio of ~7.14, which is already getting very solid even if we assume limited growth.</p> <p class=\"paywall-full-content\"><figure class=\"regular-img-figure paywall-full-content\" contenteditable=\"false\"><span><a href=\"https://static.seekingalpha.com/uploads/2026/2/26/60669497-17720930338838103_origin.png\" rel=\"lightbox\" data-width=\"1023\" data-height=\"364\" data-og-image-twitter_small_card=\"true\" data-og-image-twitter_large_card=\"true\" data-og-image-twitter_image_post=\"true\" data-og-image-msn=\"true\" data-og-image-facebook=\"true\" data-og-image-google_news=\"true\" data-og-image-google_plus=\"true\" data-og-image-linkedin=\"true\" role=\"button\" aria-label=\"Expand image into lightbox view\"><img src=\"https://static.seekingalpha.com/uploads/2026/2/26/60669497-17720930338838103_origin.png?io=w640\" alt=\"Match Group IR MTCH tinder stock analysis seekingalpha valuation best value stocks to buy 2026\" width=\"640\" height=\"228\" contenteditable=\"false\" loading=\"lazy\" srcset=\"https://static.seekingalpha.com/uploads/2026/2/26/60669497-17720930338838103_origin.png?io=w640 640w,https://static.seekingalpha.com/uploads/2026/2/26/60669497-17720930338838103_origin.png?io=w480 480w,https://static.seekingalpha.com/uploads/2026/2/26/60669497-17720930338838103_origin.png?io=w320 320w,https://static.seekingalpha.com/uploads/2026/2/26/60669497-17720930338838103_origin.png?io=w240 240w\" sizes=\"(max-width: 767px) calc(100vw - 36px), (max-width: 1023px) calc(100vw - 180px), 552px\"></a></span><figcaption><p class=\"item-caption\"><span>Match Group IR</span></p></figcaption></figure></p> <p class=\"paywall-full-content\">Not only that, but MTCH expects an even stronger FCF in 2026 despite relatively flat revenues, expecting between $1.085 billion and $1.135 billion, for a midpoint of $1.11 billion and an increase of ~8.8%, which is not bad at all despite the turnaround year for Tinder and is far from the distressed valuation the market is implying.</p> <p class=\"paywall-full-content\">They expect Tinder revenues to drop by the same as in 2025, although it's important to note that this assumes a 3-point headwind from the user experience tests they're rolling out and a 1-point headwind from facial verification, as well as $50 million in higher marketing spend, bringing the total marketing budget to $230 million to support their turnaround.</p> <p class=\"paywall-full-content\">During their <a href=\"https://seekingalpha.com/article/4865512-match-group-inc-mtch-q4-2025-earnings-call-transcript\">Q4 Earnings Call</a>, I’ll note that the company also mentioned their plans to reinvest the savings from the workforce cuts announced last year and the web-based payments savings from Apple (<a href=\"https://seekingalpha.com/symbol/AAPL\" title=\"Apple Inc.\">AAPL</a>) and potentially from Android (<a href=\"https://seekingalpha.com/symbol/GOOG\" title=\"Alphabet Inc.\">GOOG</a>) as well that I mentioned in the previous analysis:</p> <blockquote class=\"paywall-full-content\"><p>In 2026, we expect Tinder year-over-year direct revenue declines to be similar to 2025 as we continue to make product changes to improve user outcomes and drive long-term sustainable growth, but with short-term revenue trade-offs. Across the rest of the portfolio, we expect continued strong direct revenue growth at Hinge, while Evergreen &amp; Emerging, or E&amp;E, and MG Asia continued to face headwinds. We are reinvesting savings from last year's workforce reductions and alternative payments initiative into Tinder and Hinge product and marketing to drive long-term growth and shareholder value. Together, we expect this to result in relatively flat Match Group total revenue year-over-year in 2026 and adjusted EBITDA margins broadly in line with last year's, excluding the discrete items we've discussed.</p></blockquote> <p class=\"paywall-full-content\">Financially, based on <a href=\"https://seekingalpha.com/symbol/MTCH/sec-filings\">MTCH's latest report</a>, we continue to see a strong position, with current assets covering their current liabilities, while their debt schedule remains manageable and at a 3.2x gross leverage ratio, which is another advantage to keep in mind, as Match has access to issuing equity and debt at levels that are unrivaled by peers, which can allow them to keep acquiring competitors or invest much more aggressively in marketing or other turnaround initiatives.</p> <p class=\"paywall-full-content\">Using that strong FCF, the company returned roughly $788.8 million in buybacks and $186.26 million in dividends, repurchasing their shares outstanding by about 7% YoY on top of a ~2.5% dividend yield on today’s price, increasing the dividend by 5%, and remaining committed to returning meaningful capital through buybacks and dividends, so we could even expect low-double-digit combined yields in 2026 if they reach their guidance. Based on today’s price, last year’s returns would sum up to a ~13.4% combined yield.</p> <h2 class=\"paywall-full-content\">Macro Developments</h2> <p class=\"paywall-full-content\">Something important to understand is that Match ultimately relies on discretionary budgets, which exposes them to economic downturns. Right now, the consumer environment continues to be far from great, and that ultimately affects Match, as we’re talking about higher levels of stress, lower discretionary budgets, <a href=\"https://edition.cnn.com/2026/01/27/economy/us-consumer-confidence-january\" rel=\"nofollow\">weak confidence</a>, and trade-downs seen in virtually everything, which ultimately has an effect on the demand for Match’s platforms as well (at least the paid aspect), while Gen Z is already reportedly facing “dating app fatigue” that can push Match into lower ARPU or higher marketing spending.</p> <p class=\"paywall-full-content\">It’s true that we’re talking about some <a href=\"https://www.bls.gov/news.release/cpi.nr0.htm\" rel=\"nofollow\">near-term improvements</a> recently that resulted in lower treasury yields as the market’s optimism around the economy is now reflected in that; things remain uncertain. This can push treasury yields higher or at least keep them at elevated levels despite what the Fed does, potentially pressuring businesses and especially the consumer for even longer.</p> <p class=\"paywall-full-content\">Despite the US economy <a href=\"https://www.msn.com/en-us/money/markets/economy-grew-2-2-in-2025-beating-predictions/ar-AA1WJTlf\" rel=\"nofollow\">growing at 2.2% in 2025</a> and beating expectations, we’re still talking about the weakest level since 2016 (excluding the pandemic), while the market can easily face more shocks given the tariff situation, which is still ongoing despite the <a href=\"https://www.cnbc.com/2026/02/23/what-supreme-court-tariff-ruling-means-for-global-trade-us-economy.html\" rel=\"nofollow\">Supreme Court’s decision</a>, while the recent economic plans in Japan could even lead to a selloff of treasuries and artificially inflate these yields. Meanwhile, although Match is a global business, there is potential to see issues in the US scale into issues for pretty much everyone.</p> <p class=\"paywall-full-content\">Still, I wouldn't underestimate the potential behind the timing of their “Tinder relaunch,” the expected event in the summer of 2026, and potential macro improvements that could work in the company’s favor, as we are still talking about an industry leader that's able to spend a lot on something that works well.</p> <p class=\"paywall-full-content\"><figure class=\"regular-img-figure paywall-full-content\" contenteditable=\"false\"><span><a href=\"https://static.seekingalpha.com/uploads/2026/2/26/60669497-17720930340582087_origin.png\" rel=\"lightbox\" data-width=\"837\" data-height=\"436\" data-og-image-twitter_small_card=\"true\" data-og-image-twitter_large_card=\"true\" data-og-image-twitter_image_post=\"true\" data-og-image-msn=\"true\" data-og-image-facebook=\"true\" data-og-image-google_news=\"true\" data-og-image-google_plus=\"true\" data-og-image-linkedin=\"true\" role=\"button\" aria-label=\"Expand image into lightbox view\"><img src=\"https://static.seekingalpha.com/uploads/2026/2/26/60669497-17720930340582087_origin.png?io=w640\" alt=\"Match Group IR MTCH tinder stock analysis seekingalpha valuation best value stocks to buy 2026\" width=\"640\" height=\"333\" contenteditable=\"false\" loading=\"lazy\" srcset=\"https://static.seekingalpha.com/uploads/2026/2/26/60669497-17720930340582087_origin.png?io=w640 640w,https://static.seekingalpha.com/uploads/2026/2/26/60669497-17720930340582087_origin.png?io=w480 480w,https://static.seekingalpha.com/uploads/2026/2/26/60669497-17720930340582087_origin.png?io=w320 320w,https://static.seekingalpha.com/uploads/2026/2/26/60669497-17720930340582087_origin.png?io=w240 240w\" sizes=\"(max-width: 767px) calc(100vw - 36px), (max-width: 1023px) calc(100vw - 180px), 552px\"></a></span><figcaption><p class=\"item-caption\"><span>Grand View Research</span></p></figcaption></figure></p> <p class=\"paywall-full-content\">On the other hand, I believe the company’s operations remain very “future-proof” given the rising trends and expectations, with a <a href=\"https://www.grandviewresearch.com/industry-analysis/online-dating-market-report\" rel=\"nofollow\">CAGR of 7.4% from 2023 to 2030</a> globally and 6.7% in the US, which is not far from the mid-single-digit growth that Match is expecting during Tinder’s turnaround.</p> <p class=\"paywall-full-content\">I’ll also mention the possibility of the company expanding its sources of revenue through potential partnerships. For example, they can suggest local restaurants/locations that pay to get promoted for people who match each other, which is something that <a href=\"https://www.prnewswire.com/news-releases/dating-just-got-easier-hinge-and-opentable-partner-to-help-daters-choose-the-perfect-date-spot-300937503.html\" rel=\"nofollow\">Hinge tested with OpenTable back in 2019</a>, but nothing really happened after that.</p> <p class=\"paywall-full-content\">However, I want to reiterate that there is little loyalty in this industry, as users can ultimately use more than just one app, generally chasing whatever is more popular at the time. It’s true that Match has been able to buy competitors and scale their core Tinder/Hinge, but any competitor can rise in this industry, as the competitive advantage here stands in brand popularity and size, while the entry barrier is very thin.</p> <h2 class=\"paywall-full-content\">Risks Reiterated</h2> <p class=\"paywall-full-content\">Ultimately, Match will depend on discretionary budgets, which makes them susceptible to economic weakness and downturns, which can in turn result in more volatility, despite the company’s strong results.</p> <p class=\"paywall-full-content\">Meanwhile, even if their turnaround works - which in itself comes with risks - competition (current or future players) can still rise overnight thanks to going viral, trends, or a good campaign, as the moat ultimately stands mostly in their popularity.</p> <h2 class=\"paywall-full-content\">Valuation</h2> <p class=\"paywall-full-content\"><figure class=\"regular-img-figure paywall-full-content\" contenteditable=\"false\"><picture> <img src=\"https://static.seekingalpha.com/uploads/2026/2/26/60669497-177209303368735.png?io=w640\" alt=\"Match Group IR MTCH tinder stock analysis seekingalpha valuation best value stocks to buy 2026\" contenteditable=\"false\" width=\"640\" height=\"297\" loading=\"lazy\" srcset=\"https://static.seekingalpha.com/uploads/2026/2/26/60669497-177209303368735.png?io=w640 640w,https://static.seekingalpha.com/uploads/2026/2/26/60669497-177209303368735.png?io=w480 480w,https://static.seekingalpha.com/uploads/2026/2/26/60669497-177209303368735.png?io=w320 320w,https://static.seekingalpha.com/uploads/2026/2/26/60669497-177209303368735.png?io=w240 240w\" sizes=\"(max-width: 767px) calc(100vw - 36px), (max-width: 1023px) calc(100vw - 180px), 552px\"> </picture><figcaption><p class=\"item-caption\"><span>Author's Calculations</span></p></figcaption></figure></p> <p class=\"paywall-full-content\">For Match’s DCF to Equity valuation, I’ll use their midpoint guidance of $1.11 billion in FCF in 2026, without accounting for net borrowing changes to highlight their pure cash flow generation potential (basically assuming that the current level of debt remains unchanged, which has roughly been the case <a href=\"https://seekingalpha.com/symbol/MTCH/balance-sheet#:~:text=%28%242.53%29-,Total%20Debt,-4%2C077.0\">since about 2020</a>).</p> <p class=\"paywall-full-content\">If we assume a CAGR of only 4% until 2030, which is well below their 2026 FCF guidance and even above their buyback yield (which would improve the FCF/share significantly), <a href=\"https://seekingalpha.com/symbol/MTCH/earnings/estimates\">well below the market’s EPS and even the revenue estimates</a>, for example, potentially standing to benefit from Tinder’s/others’ turnaround, Hinge’s growth and an improving macro environment, followed by a 3.25% CAGR for the subsequent 5 years and a 2.5% terminal growth rate, with a 12.5% discount rate to assume a better margin of safety, using <a href=\"https://ir.mtch.com/investor-relations/news-events/news-events/news-details/2026/Match-Group-Announces-Fourth-Quarter-and-Full-Year-Results/#:~:text=Diluted%20shares%20outstanding-,254%2C087,-272%2C549\" rel=\"noopener\">254.09 million</a> diluted shares outstanding as of their Q4 report.</p> <p class=\"paywall-full-content\">This way, we get to an equity value of $11.86 billion, for an intrinsic value of $46.67 per share, which is significantly above the current $31.38 at the moment of writing this despite using conservative valuations.</p> <h2 class=\"paywall-full-content\">Conclusions</h2> <p class=\"paywall-full-content\">I am upgrading MTCH to a Strong Buy given their valuation, as Tinder’s turnaround is advancing, they continue to make very solid cash flow, the yield is strong, and the company stands to benefit from macro improvements and trends.</p> <div class=\"before_last_paragraph-piano-placeholder paywall-full-content\"></div> <p class=\"paywall-full-content\">There are definitely risks to keep in mind given the “dating fatigue” trends, competition, exposure to the economy, or even AI, but the valuation, cash flows, yield, and potential are significantly outweighing these risks, in my opinion, and I placed an order to buy not long ago.</p>",
            "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1927819017/image_1927819017.jpg",
            "link": "https://seekingalpha.com/article/4876526-match-group-a-re-rating-setup-backed-by-double-digit-yield-rating-upgrade",
            "pub_date": "2026-02-28 04:51:04",
            "source": "seekalpha_articles",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "4876525",
            "title": "Cinemark: Strongest Performer In A Weak Industry",
            "description": "<p data-eci=\"true\">As we prepare for the last weekend in February, I took a look at Cinemark Holdings, Inc. (<span class=\"ticker-hover-wrapper\"><a href=\"https://seekingalpha.com/symbol/CNK\" title=\"Cinemark Holdings, Inc.\">CNK</a></span>) after they <a href=\"https://ir.cinemark.com/sec-filings/annual-reports\" rel=\"nofollow\">released their earnings report</a> last week.</p> <h2>Author History</h2> <p>I have been following Cinemark for several years but never actually opened<span class=\"paywall-full-content\"> a position in it. My </span><a href=\"https://seekingalpha.com/article/4318756-cinemark-a-buy-but-not-yet\" class=\"paywall-full-content\">first article on it</a><span class=\"paywall-full-content\"> was just as the COVID lockdown was starting; hard as it is to believe now, there were some who wanted to buy into Cinemark in early 2020, convinced that any theater closures would be short. I counseled against that, saying that both the short- and long-term prospects of the exhibitor industry were cloudy at best.</span></p> <p class=\"paywall-full-content\">That was good advice; Cinemark is actually down since my first article, even as the market has doubled over the same time frame. I did miss a chance to buy in later that year, when COVID was at its peak. Cinemark bottomed at $9 per share and is now trading at $27. A missed opportunity, perhaps, but before vaccines became available, it wasn’t entirely clear when life would be returning to normal. Altogether, I am not too dissatisfied with how I’ve played—or not played, really—this stock.</p> <h2 class=\"paywall-full-content\">Early Box Office Performance</h2> <p class=\"paywall-full-content\">While there are individual operational characteristics that vary between the three major players in the theater space—Cinemark, AMC (<a href=\"https://seekingalpha.com/symbol/AMC\" title=\"AMC Entertainment Holdings, Inc.\">AMC</a>), and Regal—hands down the single biggest factor in profitability is simply the health of the overall box office. The picture here is mixed, much as it has been for years since COVID. While January represented a <a href=\"https://www.boxofficemojo.com/month/january/2026/?ref_=bo_ml_table_1\" rel=\"nofollow\">substantial outperformance of the year prior</a>, that owed almost entirely to a single film, Disney’s third <em>Avatar</em> entry, which two months into the year is still the only film to crack $100 million domestic - despite the fact that <em>Avatar </em>actually opened in 2025.</p> <p class=\"paywall-full-content\">Disney’s <em>Avatar</em> franchise is always somewhat of a slant factor in the box office analysis. Because <em>Avatar </em>films always launch in December, they are spread across two years; the year it launches is back-end weighted, and the following year, which catches the tail end of the boost from the film, is front-year weighted. Were <em>Avatar</em> to be a more normal film and to have posted the same numbers in January as the second-best film (<em>Zootopia 2</em>, another top performer from last year, so hardly a slouch), veritably all of January’s Y/Y growth would vanish.</p> <p class=\"paywall-full-content\">The <a href=\"https://www.boxofficemojo.com/month/february/2026/?grossesOption=calendarGrosses\" rel=\"nofollow\">picture is a little better in February</a>, where <em>Wuthering Heights</em> mild <a href=\"https://seekingalpha.com/article/4874026-warner-bros-discovery-merger-how-to-play-three-scenarios\">underperformance relative to expectations</a> means it’s not inconceivable the wait for a proper 2026 $100 million entry could go on a little longer. Even if <em>Heights</em> does make it, growth will be difficult to come by; February will probably finish in the red Y/Y. Altogether, we will probably go into March up less than a percentage point Y/Y YTD.</p> <h2 class=\"paywall-full-content\">Potential Box Office Upside In 2026</h2> <p class=\"paywall-full-content\">No on will be surprise by this who has followed theaters in the post-COVID era. It’s been the same story with a different cheer every year. “We just need to push through to 2022.” No, that didn’t work? Well, no matter, we’ll “tee off in ’23.”</p> <p class=\"paywall-full-content\">No, no, no, that’s not it; movies will “soar in ’24.” <a href=\"https://www.boxofficemojo.com/year/2024/?ref_=bo_yl_table_3\" rel=\"nofollow\">Since they didn’t, though</a>, what’s important now is to “survive till ’25.” And since <a href=\"https://www.boxofficemojo.com/year/2025/?ref_=bo_yl_table_2\" rel=\"nofollow\">we all know how well that went</a>, the problem is supposed to be “fixed in ’26.” Though, since that plan isn’t off to a good start, the whispers about “revvin in ’27” are probably already being trotted out for testing somewhere.</p> <p class=\"paywall-full-content\">For the record, as someone who has been a perpetual skeptic about all these post-COVID rebound theories, I’m actually going to go against type and say I’m not quite ready to write off the idea yet that 2026 might actually be the year that finally takes the box office over $10 billion. Shocking, coming from me, I know. But there’s enough meat on the bone to keep the industry in contention until December, when the launch of Disney’s (<a href=\"https://seekingalpha.com/symbol/DIS\" title=\"The Walt Disney Company\">DIS</a>) <em>Avengers: Doomsday </em>will probably decide the issue.</p> <p class=\"paywall-full-content\">The other heavy lifter this year will be <em>Spider-Man: Brand New Day</em>, the one Marvel property that hasn’t really seen any sort of real decline since COVID and the exit of Robert Downey Jr., which sent the franchise into a bit of a tailspin. If you think that’s too strong, I refer you to <a href=\"https://seekingalpha.com/article/4808582-disney-amidst-exaggerated-movie-woes-is-stock-preparing-to-sell-espn\">this analysis of Marvel’s performance</a> I wrote last year.</p> <p class=\"paywall-full-content\">But I’ve also said <em>Spider-Man </em>seems to be the exception, and my research suggests a $2 billion global cume is not out of the question. The real question will be whether <em>Avengers</em> plays like <em>Endgame</em> did or like Marvel’s more recent iterations.</p> <h2 class=\"paywall-full-content\">Operational Trends</h2> <p class=\"paywall-full-content\">Cinemark has tried to counteract this steady box-office malaise by increasing sales of concessions. <a href=\"https://ir.cinemark.com/sec-filings/annual-reports/content/0001193125-26-056015/0001193125-26-056015.pdf\" rel=\"nofollow\">Earnings announced last week</a> showed that Cinemark is now growing concessions revenue faster than admissions revenue, not just in percentage terms but in absolute numbers as well. In fact, Cinemark admissions revenue was actually <em>lower</em> than it was two years ago. Concessions revenue is now more than 80% of admissions, quite a remarkable turnaround from pre-COVID, when it was usually more like 50%.</p> <p class=\"paywall-full-content\">Despite the growth, Cinemark's operating income declined. The primary culprit was the fact that while admissions revenue is down compared to two years ago, “rental costs”—the box office money paid to film producers—actually <em>rose</em>, putting pressure on film gross margins. This reflects something I have long worried about with theaters: the shift towards franchises and away from original films increases the bargaining power of producers and reduces the leverage of exhibitors, who have a smaller pool of films to show, and veritably all of which become “must-have.”</p> <p class=\"paywall-full-content\">I have outlined before why I consider exhibitors failure to make any changes to the cross-subsidy scheme in theaters to be a bearish indicator. I won’t repeat all of that again; those who are interested can read the relevant information in <a href=\"https://seekingalpha.com/article/4498213-amc-entertainment-up-50-percent-in-a-month-is-there-more-upside\">my previous article</a>.</p> <p class=\"paywall-full-content\">The general and administrative category also showed outsized cost growth. Altogether, Cinemark reported an almost 10% drop in operating income for 2025 Y/Y despite growing revenues.</p> <h2 class=\"paywall-full-content\">Subscriptions Have Potential, But Unexploited</h2> <p class=\"paywall-full-content\">My prior cautious optimism on Cinemark was based in substantial part on the potential of their new subscription service to alter the long-term dynamics governing the industry and allow them to break out of the debilitating cycle of franchise films over originals that is ossifying the industry.</p> <p class=\"paywall-full-content\">Six years later, Movie Club isn’t a failure—Cinemark reported that <a href=\"https://seekingalpha.com/article/4871486-cinemark-holdings-inc-cnk-q4-2025-earnings-call-transcript\">30% of all sales are now Movie Club members</a>—but nor has the company really leaned into it enough to substantially alter its prospects. While I still think Movie Club could be a significant factor in restoring Cinemark’s long-term profit potential, I no longer have confidence management has any intention to make a major push in this area.</p> <h2 class=\"paywall-full-content\">Long-Term Industry Recession</h2> <p class=\"paywall-full-content\">There are also long-term risks. For one thing, the news today that Paramount (<a href=\"https://seekingalpha.com/symbol/PSKY\" title=\"Paramount Skydance Corporation\">PSKY</a>) <a href=\"https://seekingalpha.com/news/4558365-paramount-wins-the-bidding-war-for-warner-bros-as-netflix-walks-away\">will purchase</a> Warner Bros. Discovery (<a href=\"https://seekingalpha.com/symbol/WBD\" title=\"Warner Bros. Discovery, Inc.\">WBD</a>) instead of Netflix (<a href=\"https://seekingalpha.com/symbol/NFLX\" title=\"Netflix, Inc.\">NFLX</a>) is probably a net negative for theaters. While many theater owners feared that Netflix would pull Warner’s entire film slate out of the theater system, Netflix management had been <a href=\"https://puck.news/ted-sarandos-case-for-warners-netflix-ceo-on-16-billion-synergies-claim/\" rel=\"nofollow\">mounting a major charm offensive</a> to convince them it had no intentions of doing so, and there was always the chance they meant it.</p> <p class=\"paywall-full-content\">In contrast, Paramount likely won’t put Warner’s movies on streaming or in theaters; it simply won’t make them. Or, more accurately, it will stop making Paramount movies and focus exclusively on Warner once it owns it, which, to theaters already desperately short of volume, comes to much the same thing.</p> <p class=\"paywall-full-content\">That has been the pattern of past mergers; Disney is going to <a href=\"https://boardwalktimes.net/most-anticipated-disney-films-of-2026-3e9f79180a6e\" rel=\"nofollow\">release roughly a dozen films this year</a> in theaters, barely exceeding <a href=\"https://www.the-numbers.com/market/2018/distributor/Walt-Disney\" rel=\"nofollow\">the total it released in 2018</a>. Almost the entire Fox studio output from that year is now simply gone from the system. That number too may shrink in future years; I <a href=\"https://seekingalpha.com/article/4854815-disney-can-the-mouse-house-bring-back-the-movie-magic\">wrote just a few short months ago</a> that the <em>Avatar</em> franchise would surely go the full five-film distance. Less than a month later, <em>Avatar 3</em> came in a staggering <em>$1 billion short of projections.</em><strong> </strong>A Disney abort cannot be ruled out now, which would sunset one of the biggest franchises left in theaters.</p> <h2 class=\"paywall-full-content\">Investment Summary</h2> <p class=\"paywall-full-content\">Cinemark may well end up performing better than expected this year if, in fact, this is the year that we finally get back over $10 billion domestic. That is somewhat on the optimistic side, however, and even if it did, it would not alter the long-term trends, which I believe are what is really holding the stock down.</p> <p class=\"paywall-full-content\">I sound like a bit of a broken record, but my view hasn’t changed; Cinemark will probably perform better than other theater stocks, but not as well as other industries. I rate CNK stock a Hold only and will not be opening a position.</p> <div class=\"before_last_paragraph-piano-placeholder paywall-full-content\"></div> <p class=\"paywall-full-content\"><figure class=\"getty-figure\" data-type=\"getty-image\"><picture><img src=\"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1153688000/image_1153688000.jpg?io=getty-c-w630\" alt=\"Exterior of Cinemark Paradise 24 movie theater with Egyptian theme - Davie, Florida, USA\" data-id=\"1153688000\" data-type=\"getty-image\" width=\"3898\" height=\"2554\" srcset=\"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1153688000/image_1153688000.jpg?io=getty-c-w1536 1536w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1153688000/image_1153688000.jpg?io=getty-c-w1280 1280w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1153688000/image_1153688000.jpg?io=getty-c-w1080 1080w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1153688000/image_1153688000.jpg?io=getty-c-w750 750w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1153688000/image_1153688000.jpg?io=getty-c-w640 640w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1153688000/image_1153688000.jpg?io=getty-c-w480 480w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1153688000/image_1153688000.jpg?io=getty-c-w320 320w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1153688000/image_1153688000.jpg?io=getty-c-w240 240w\" sizes=\"(max-width: 767px) calc(100vw - 36px), (max-width: 1023px) calc(100vw - 132px), (max-width: 1199px) calc(100vw - 666px), (max-width: 1307px) calc(100vw - 708px), 600px\" fetchpriority=\"high\"> </picture><figcaption><p class=\"item-caption\"> </p> <p class=\"item-credits\">Holly Guerrio/iStock Editorial via Getty Images</p></figcaption></figure></p> <div class=\"inline_ad_placeholder paywall-full-content\"></div>",
            "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1153688000/image_1153688000.jpg",
            "link": "https://seekingalpha.com/article/4876525-cinemark-strongest-performer-in-a-weak-industry",
            "pub_date": "2026-02-28 04:41:52",
            "source": "seekalpha_articles",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "4876522",
            "title": "Neurogene: Stock Soars On FDA Designation For Rett Gene Therapy - I'd Remain Cautious",
            "description": "<p data-eci=\"true\"><figure class=\"getty-figure\" data-type=\"getty-image\"><picture> <img src=\"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1487894866/image_1487894866.jpg?io=getty-c-w630\" alt=\"Increasing in stock prices. Stock market data.\" data-id=\"1487894866\" data-type=\"getty-image\" width=\"1536\" height=\"1025\" srcset=\"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1487894866/image_1487894866.jpg?io=getty-c-w1536 1536w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1487894866/image_1487894866.jpg?io=getty-c-w1280 1280w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1487894866/image_1487894866.jpg?io=getty-c-w1080 1080w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1487894866/image_1487894866.jpg?io=getty-c-w750 750w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1487894866/image_1487894866.jpg?io=getty-c-w640 640w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1487894866/image_1487894866.jpg?io=getty-c-w480 480w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1487894866/image_1487894866.jpg?io=getty-c-w320 320w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1487894866/image_1487894866.jpg?io=getty-c-w240 240w\" sizes=\"(max-width: 767px) calc(100vw - 36px), (max-width: 1023px) calc(100vw - 132px), (max-width: 1199px) calc(100vw - 666px), (max-width: 1307px) calc(100vw - 708px), 600px\" fetchpriority=\"high\"> </picture><figcaption><p class=\"item-caption\"> </p> <p class=\"item-credits\">tadamichi/iStock via Getty Images</p></figcaption></figure></p> <div class=\"inline_ad_placeholder\"></div> <h2>Breaking News - Neurogene snags Breakthrough Therapy Designation For Gene Therapy</h2> <p>Neurogene (<span class=\"ticker-hover-wrapper\"><a href=\"https://seekingalpha.com/symbol/NGNE\" title=\"Neurogene Inc.\">NGNE</a></span>) stock is buoyant in trading today - shares have risen in value by &gt;25% at the time of writing, to $25.4 per share, valuing the company at a<span class=\"paywall-full-content\"> market cap of ~$393m, after the company issued a press release last night noting it had been awarded a Breakthrough Therapy Designation from the FDA for its Rett Syndrome candidate NGN-401.</span></p> <p class=\"paywall-full-content\">In a <a href=\"https://ir.neurogene.com/news-releases/news-release-details/neurogene-announces-fda-breakthrough-therapy-designation-ngn-401\" rel=\"nofollow\">press release</a>, the company noted that the award was based on:</p> <blockquote class=\"paywall-full-content\"><p><em>interim NGN-401 Phase 1/2 data demonstrating clinically meaningful, durable and multidomain functional improvements.</em></p></blockquote> <p class=\"paywall-full-content\">The company also discussed NGN-401 as follows:</p> <blockquote class=\"paywall-full-content\"> <p>NGN-401 is being evaluated as a one-time treatment for Rett syndrome and is designed to deliver the full-length human <em>MECP2</em> gene under the control of Neurogene’s proprietary EXACT™ transgene regulation technology.</p> <p>It is delivered through intracerebroventricular administration to achieve the broadest targeting directly to the brain and nervous system based on nonclinical biodistribution data. NGN-401 is currently being evaluated in the Embolden™ registrational clinical trial, with completion of dosing expected in the second quarter of 2026.</p> </blockquote> <h2 class=\"paywall-full-content\">Neurogene Overview - Updates &amp; Analysis From My Last Note</h2> <p class=\"paywall-full-content\">The last time I covered Neurogene, a New York rare disease/gene therapy specialist drug developer, in a note for Seeking Alpha, it was March 2024, and I awarded the stock a <a href=\"https://seekingalpha.com/article/4680543-neurogene-stock-gene-therapy-specialist-may-break-chain-of-failed-mergers\">Hold rating</a>.</p> <p class=\"paywall-full-content\">Shares traded at $49.5 at that time, having gained &gt;250% since Neurogene listed on the Nasdaq via a merger with Neoleukin Therapeutics (more detail in my last post), but they have since lost ~50% of their value, trading at $25 today. Market cap valuation today is ~$400m.</p> <p class=\"paywall-full-content\">In my last post I discussed Neurogene's EXACT technology platform for precise transgene expression - for an in-depth discussion of the platform and its merits, see my last post - and its two clinical candidates, NGN-401, indicated for Rett Syndrome, and NGN-101 for the ultra-rare CLN5 Batten Disease.</p> <p class=\"paywall-full-content\">Although Neurogene stock actually reached a high of nearly $70 per share in early November 2024, the company was then hit by a double dose of bad news.</p> <p class=\"paywall-full-content\">Firstly, Neurogene<a href=\"https://www.businesswire.com/news/home/20241118334218/en/Neurogene-Provides-Update-on-NGN-401-Gene-Therapy-Clinical-Trial-for-Rett-Syndrome\" rel=\"nofollow\"> revealed</a> it had stopped the higher dose cohort of its Phase 1/2 open label clinical trial of NGN-401, after a patient who had received the dose became critically ill with a severe hyperinflammatory condition called hemophagocytic lymphohistiocytosis (\"HLH\") (the patient later <a href=\"https://www.fiercebiotech.com/biotech/neurogene-details-severe-aav-reaction-led-young-patients-death-rett-syndrome-gene-therapy\" rel=\"nofollow\">died</a>), although the FDA permitted the lower-dose cohort to continue.</p> <p class=\"paywall-full-content\">Secondly, the FDA <a href=\"https://www.fiercebiotech.com/biotech/neurogene-stops-batten-gene-therapy-after-fda-denies-request-dealing-double-dose-bad-news\" rel=\"noopener\">rejected</a> Neurogene's Regenerative Medicine Advanced Therapy (\"RMAT\") application for candidate NGN-101, leading the company to make a decision to stop developing its second pipeline asset.</p> <p class=\"paywall-full-content\">By mid-November, Neurogene stock traded ~$20 per share, and amid a <a href=\"https://www.fiercebiotech.com/biotech/talking-brick-wall-senate-hearing-takes-aim-fdas-rare-disease-review-process\" rel=\"nofollow\">backdrop</a> of controversy at the FDA with regard to gene therapy development, have struggled to gain much momentum since.</p> <p class=\"paywall-full-content\">In May 2025 Seeking Alpha<a href=\"https://seekingalpha.com/news/4449647-neurogene-downgraded-to-neutral-at-baird-on-regulatory-uncertainty\"> reported</a> that:</p> <blockquote class=\"paywall-full-content\"> <p></p> <ul> <li>Neurogene (NASDAQ:<a href=\"https://seekingalpha.com/symbol/NGNE\" title=\"Neurogene Inc.\">NGNE</a>) was downgraded to Neutral from Outperform at Baird, citing increasing regulatory uncertainty and a higher approval bar at the FDA under new leadership.</li> <li>The downgrade comes at a time when Neurogene (NASDAQ:<a href=\"https://seekingalpha.com/symbol/NGNE\" title=\"Neurogene Inc.\">NGNE</a>) plans to provide an update on a registrational trial plan for its gene therapy NGN-401 targeted at a rare neurological disorder called Rett syndrome during H1 2025.</li> <li>The analysts at Baird said that despite the stock's rebound since April, they believe the FDA's bar for approval is indeed moving higher, as former head of the Center for Biologics Evaluation and Research, Peter Marks, has been replaced by a far more data-driven Vinay Prasad.</li> </ul> </blockquote> <p class=\"paywall-full-content\">In October last year Neurogene <a href=\"https://ir.neurogene.com/news-releases/news-release-details/neurogene-announces-positive-regulatory-update-ngn-401-gene\" rel=\"nofollow\">shared</a> a \"positive regulatory update\", announcing it:</p> <blockquote class=\"paywall-full-content\"><p>has completed discussions with the U.S. Food and Drug Administration (FDA) on its Embolden™ registrational trial protocol and plans to initiate dosing in the fourth quarter of 2025. In response to strong interest from the Rett syndrome community, the trial is expected to enroll across 13 sites.</p></blockquote> <p class=\"paywall-full-content\">The news triggered a (brief) spike in the pharma's share price, to ~$35 per share, although these gains were seemingly wiped out when Neurogene shared updated interim clinical data in the pediatric cohort (ages 4-10 cohort) of its Phase 1/2 clinical trial of females with Rett Syndrome.</p> <p class=\"paywall-full-content\">The website <a href=\"https://reverserett.org/about-rett-syndrome/?gad_source=1&amp;gad_campaignid=23508201090&amp;gbraid=0AAAAAoNClu3OHvDrWilQVMVQOGEsLrmZX&amp;gclid=CjwKCAiAnoXNBhAZEiwAnItcGz5_w_AxZPfwm0VllIDwEEd22ILEFgwwp621MzV8HwHdZSLDxfDQFBoC3vQQAvD_BwE\" rel=\"nofollow\">reverserett.org</a> shares the following description of Rett Syndrome:</p> <blockquote class=\"paywall-full-content\"> <p>Rett syndrome is a severe neurological disorder that is diagnosed primarily in girls and begins to manifest during the toddler years. After a seemingly normal first year the child begins to regress with developmental milestones.</p> <p>This regression can happen quickly over a number of days or very gradually over months. Often the first noticeable symptoms include: low muscle tone (hypotonia), eye crossing, decreased interactions with people or surroundings, and loss of hand function. The hallmark symptom of Rett is repetitive hand movements and wringing that can be constant, especially in younger children.</p> <p>As time passes additional symptoms may include: loss of speech, trouble with balance and motor coordination, irritability and crying, and disrupted sleep patterns. Many also develop seizures, anxiety, breathing problems, gastrointestinal issues, orthopedic complications, as well as oral motor difficulties.</p> </blockquote> <p class=\"paywall-full-content\">Neurogene disclosed that from a safety perspective:</p> <blockquote class=\"paywall-full-content\"><p>All treatment-related adverse events have been mild (Grade 1) or moderate (Grade 2) in severity and the majority are known potential risks of AAV and have resolved or are resolving</p></blockquote> <p class=\"paywall-full-content\">And from an efficacy perspective, that</p> <blockquote class=\"paywall-full-content\"> <p>All pediatric participants experienced functional gains across the spectrum of disease severity, with an aggregate 35 developmental milestones/skills gained across core clinical domains of Rett syndrome – hand function/fine motor, language/communication and ambulation/gross motor</p> <ul><li>All developmental milestones/skills gained have been durable, with multidomain improvements observed in key domains</li></ul> </blockquote> <p class=\"paywall-full-content\">It seems odd with hindsight that shares lost value after this update, as it seems to have been the basis for the FDA's award of its Breakthrough Therapy Designation - nevertheless, Neurogene has also achieved alignment with the FDA on a \"single registrational trial to support BLA submission\", its Embolden study, which is already underway. Details (from a Neurogene corporate presentation) are shown below:</p> <p class=\"paywall-full-content\"><figure class=\"regular-img-figure paywall-full-content\" contenteditable=\"false\"><picture> <span><a href=\"https://static.seekingalpha.com/uploads/2026/2/27/49171940-17722163376257613_origin.png\" rel=\"lightbox\" data-width=\"1230\" data-height=\"703\" data-og-image-twitter_small_card=\"true\" data-og-image-twitter_large_card=\"true\" data-og-image-twitter_image_post=\"true\" data-og-image-msn=\"true\" data-og-image-facebook=\"true\" data-og-image-google_news=\"true\" data-og-image-google_plus=\"true\" data-og-image-linkedin=\"true\" role=\"button\" aria-label=\"Expand image into lightbox view\"><img src=\"https://static.seekingalpha.com/uploads/2026/2/27/49171940-17722163376257613_origin.png?io=w640\" alt=\"chart\" width=\"640\" height=\"366\" contenteditable=\"false\" data-width=\"640\" data-height=\"366\" loading=\"lazy\" srcset=\"https://static.seekingalpha.com/uploads/2026/2/27/49171940-17722163376257613_origin.png?io=w640 640w,https://static.seekingalpha.com/uploads/2026/2/27/49171940-17722163376257613_origin.png?io=w480 480w,https://static.seekingalpha.com/uploads/2026/2/27/49171940-17722163376257613_origin.png?io=w320 320w,https://static.seekingalpha.com/uploads/2026/2/27/49171940-17722163376257613_origin.png?io=w240 240w\" sizes=\"(max-width: 767px) calc(100vw - 36px), (max-width: 1023px) calc(100vw - 180px), 552px\"></a></span> </picture><figcaption><p class=\"item-caption\">Embolden study design <span>(presentation)</span></p></figcaption></figure></p> <p class=\"paywall-full-content\">An overview of the market opportunity is also provided by the company, below:</p> <p class=\"paywall-full-content\"><figure class=\"regular-img-figure paywall-full-content\" contenteditable=\"false\"><picture> <span><a href=\"https://static.seekingalpha.com/uploads/2026/2/27/49171940-17722164324069319_origin.png\" rel=\"lightbox\" data-width=\"1270\" data-height=\"710\" data-og-image-twitter_small_card=\"true\" data-og-image-twitter_large_card=\"true\" data-og-image-twitter_image_post=\"true\" data-og-image-msn=\"true\" data-og-image-facebook=\"true\" data-og-image-google_news=\"true\" data-og-image-google_plus=\"true\" data-og-image-linkedin=\"true\" role=\"button\" aria-label=\"Expand image into lightbox view\"><img src=\"https://static.seekingalpha.com/uploads/2026/2/27/49171940-17722164324069319_origin.png?io=w640\" alt=\"chart\" width=\"640\" height=\"358\" contenteditable=\"false\" data-width=\"640\" data-height=\"358\" loading=\"lazy\" srcset=\"https://static.seekingalpha.com/uploads/2026/2/27/49171940-17722164324069319_origin.png?io=w640 640w,https://static.seekingalpha.com/uploads/2026/2/27/49171940-17722164324069319_origin.png?io=w480 480w,https://static.seekingalpha.com/uploads/2026/2/27/49171940-17722164324069319_origin.png?io=w320 320w,https://static.seekingalpha.com/uploads/2026/2/27/49171940-17722164324069319_origin.png?io=w240 240w\" sizes=\"(max-width: 767px) calc(100vw - 36px), (max-width: 1023px) calc(100vw - 180px), 552px\"></a></span> </picture><figcaption><p class=\"item-caption\">Rett syndrome - market opportunity <span>(presentation)</span></p></figcaption></figure></p> <h2 class=\"paywall-full-content\">Analysis - A Dark Day For Gene Therapies May Have Gotten Brighter</h2> <p class=\"paywall-full-content\">Earlier today, I <a href=\"https://seekingalpha.com/article/4876320-uniqure-shares-tumble-on-fresh-fda-controversy-what-investors-should-know\">shared a note</a> with Seeking Alpha readers on UniQure (<a href=\"https://seekingalpha.com/symbol/QURE\" title=\"uniQure N.V.\">QURE</a>), a Dutch biotech whose share price soared last year based on positive data in relation to its gene therapy candidate AMT-130, indicated for Huntington's Disease.</p> <p class=\"paywall-full-content\">The company's study compared patients' efficacy scores to a set of natural history uniQure said it had agreed with the FDA; however, the FDA subsequently told uniQure it would no longer consider the natural history data in an approval submission, seemingly scuppering any chance of the drug being approved.</p> <p class=\"paywall-full-content\">Yesterday, many market-watchers believed that the FDA's Commissioner, Dr Marty Makary, may have been referring to uniQure's therapy when he <a href=\"https://www.statnews.com/2026/02/26/makary-fda-rare-disease-vinay-prasad-cnbc/#:~:text=FDA's%20Marty%20Makary%20defends%20rare,rejected%20many%20of%20those%20drugs.\" rel=\"nofollow\">discussed</a> being put under pressure to approve a certain drug \"where the researchers drilled a burr hole, literally a hole in people's skulls\", despite it not showing sufficient signs of efficacy.</p> <p class=\"paywall-full-content\">uniQure stock fell by ~30% yesterday, and for some time now, the FDA has been perceived as somewhat anti-gene therapies, but ironically (or perhaps not?) Neurogene seems to have reported a successful outcome from negotiations with the FDA for its gene therapy. Could the pharma be being rewarded for what the FDA perceives is a superior study design, or a more effective drug?</p> <p class=\"paywall-full-content\">In my view, one of the difficulties when conducting clinical studies into neurological diseases such as Rett Syndrome, or Huntington's, is measuring efficacy. Unless you are a patient's caregiver, recognizing signs of deterioration or improvement cannot be easy, and while scoring systems have been developed, it has to be said some gene therapies have been approved on slight evidence of efficacy.</p> <p class=\"paywall-full-content\">I noted in my last post on Neurogene:</p> <blockquote class=\"paywall-full-content\"><p>At least three gene therapies have been approved in the US by the Food and Drug Agency (\"FDA\") using a similar delivery mechanism (to Neurogene's, an AAV vector) - Swiss Pharma giant Novartis' (<a href=\"https://seekingalpha.com/symbol/NVS\" title=\"Novartis AG\">NVS</a>) Zolgensma, indicated for spinal muscular atrophy (\"SMA\"), BioMarin's (<a href=\"https://seekingalpha.com/symbol/BMRN\" title=\"BioMarin Pharmaceutical Inc.\">BMRN</a>) hemophilia gene therapy roctavian, and Sarepta Therapeutics' (<a href=\"https://seekingalpha.com/symbol/SRPT\" title=\"Sarepta Therapeutics, Inc.\">SRPT</a>) Elevidys, indicated for Duchenne Muscular Dystrophy (\"DMD\").</p></blockquote> <p class=\"paywall-full-content\">On February 24th - a few days ago - it was<a href=\"https://www.fiercepharma.com/pharma/biomarin-officially-pulls-plug-hemophilia-gene-therapy-roctavian-taking-119m-write-after\" rel=\"nofollow\"> reported t</a>hat Biomarin would pull Roctavian off the market, due to a lack of commercial uptake. Last year, Sarepta's gene therapy Elevidys was briefly withdrawn from the market after <a href=\"https://www.bmj.com/content/390/bmj.r1548\" rel=\"nofollow\">patient deaths</a> were reported. The drug actually failed to meet the primary endpoint in its pivotal phase 3 Embark study, but was still granted approval. </p> <p class=\"paywall-full-content\">In summary, then, we might conclude it has been a difficult year for the field of gene therapies, and that stricter approval criteria may not be such a bad idea, but there is of course the alternative argument that patients are in desperate need of better therapies, and any sign of efficacy - however faint, marks a significant step forward, and that drugs displaying such efficacy should be made available to the public as quickly as possible.</p> <p class=\"paywall-full-content\">It seems as though Neurogene has the FDA's support over its pivotal study design, but by no means does that guarantee that the study will be a successful one - sterner tests lie ahead.</p> <p class=\"paywall-full-content\">We must also consider the financials of Neurogene. The company <a href=\"https://seekingalpha.com/pr/20307555-neurogene-reports-third-quarter-2025-financial-results-and-highlights-recent-updates#hasComeFromMpArticle=false\">reported</a> cash and equivalents of $71m, plus $194m of short-term investments as of the end of Q3, with total liabilities of just $22m.</p> <p class=\"paywall-full-content\">Nine month net loss amounted to $(65.6m), and Neurogene says (in its latest corporate presentation) that its cash is expected to last into 2028 and is \"expected to fund operations through Embolden data readout, BLA submission and key pre-launch activities\".</p> <p class=\"paywall-full-content\"><figure class=\"regular-img-figure paywall-full-content\" contenteditable=\"false\"><picture> <span><a href=\"https://static.seekingalpha.com/uploads/2026/2/27/49171940-17722182955691018_origin.png\" rel=\"lightbox\" data-width=\"1257\" data-height=\"627\" data-og-image-twitter_small_card=\"true\" data-og-image-twitter_large_card=\"true\" data-og-image-twitter_image_post=\"true\" data-og-image-msn=\"true\" data-og-image-facebook=\"true\" data-og-image-google_news=\"true\" data-og-image-google_plus=\"true\" data-og-image-linkedin=\"true\" role=\"button\" aria-label=\"Expand image into lightbox view\"><img src=\"https://static.seekingalpha.com/uploads/2026/2/27/49171940-17722182955691018_origin.png?io=w640\" alt=\"chart\" width=\"640\" height=\"319\" contenteditable=\"false\" data-width=\"640\" data-height=\"319\" loading=\"lazy\" srcset=\"https://static.seekingalpha.com/uploads/2026/2/27/49171940-17722182955691018_origin.png?io=w640 640w,https://static.seekingalpha.com/uploads/2026/2/27/49171940-17722182955691018_origin.png?io=w480 480w,https://static.seekingalpha.com/uploads/2026/2/27/49171940-17722182955691018_origin.png?io=w320 320w,https://static.seekingalpha.com/uploads/2026/2/27/49171940-17722182955691018_origin.png?io=w240 240w\" sizes=\"(max-width: 767px) calc(100vw - 36px), (max-width: 1023px) calc(100vw - 180px), 552px\"></a></span> </picture><figcaption><p class=\"item-caption\">Neurogene upcoming catalysts <span>(presentation )</span></p></figcaption></figure></p> <p class=\"paywall-full-content\">As we can see above, Neurogene does have some intriguing catalysts upcoming for 2026, including a key data readout in mid-2026, and its share price has finally discovered some upside momentum.</p> <p class=\"paywall-full-content\">That may be enough to make the bull case in some readers eyes - the bear case would be based on a data failure or safety issue, which could see NGN-401 shelved altogether, leaving the business with no clinical stage assets, in which case investors would likely suffer heavy losses.</p> <div class=\"before_last_paragraph-piano-placeholder paywall-full-content\"></div> <p class=\"paywall-full-content\">Frankly, given the current environment, I would urge extreme caution when investing in any gene therapy stock at this time, so I am issuing a second straight Hold recommendation, but remain hopeful that Neurogene might deliver a study win this year to revive a sector that is enduring a troubled time presently.</p>",
            "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1487894866/image_1487894866.jpg",
            "link": "https://seekingalpha.com/article/4876522-neurogene-stock-soars-on-fda-designation-for-rett-gene-therapy-remain-cautious",
            "pub_date": "2026-02-28 04:36:16",
            "source": "seekalpha_articles",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "4876519",
            "title": "Day One Biopharmaceuticals: Commercial Performance With Catalysts Ahead",
            "description": "<p data-eci=\"true\"><figure class=\"getty-figure\" data-type=\"getty-image\"><picture> <img src=\"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/921577312/image_921577312.jpg?io=getty-c-w630\" alt=\"I recommend you take this daily to clear your symptoms\" data-id=\"921577312\" data-type=\"getty-image\" width=\"1536\" height=\"1025\" srcset=\"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/921577312/image_921577312.jpg?io=getty-c-w1536 1536w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/921577312/image_921577312.jpg?io=getty-c-w1280 1280w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/921577312/image_921577312.jpg?io=getty-c-w1080 1080w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/921577312/image_921577312.jpg?io=getty-c-w750 750w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/921577312/image_921577312.jpg?io=getty-c-w640 640w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/921577312/image_921577312.jpg?io=getty-c-w480 480w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/921577312/image_921577312.jpg?io=getty-c-w320 320w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/921577312/image_921577312.jpg?io=getty-c-w240 240w\" sizes=\"(max-width: 767px) calc(100vw - 36px), (max-width: 1023px) calc(100vw - 132px), (max-width: 1199px) calc(100vw - 666px), (max-width: 1307px) calc(100vw - 708px), 600px\" fetchpriority=\"high\"> </picture><figcaption><p class=\"item-caption\"> </p> <p class=\"item-credits\">PeopleImages/iStock via Getty Images</p></figcaption></figure></p> <div class=\"inline_ad_placeholder\"></div> <p>The launch of Day One Biopharmaceuticals, Inc.'s (<span class=\"ticker-hover-wrapper\"><a href=\"https://seekingalpha.com/symbol/DAWN\" title=\"Day One Biopharmaceuticals, Inc.\">DAWN</a></span>) Ojemda has been a focus of commentary around the company, but the story has gained complexity with the company's developmental efforts coming into focus in 2026. I <a href=\"https://seekingalpha.com/article/4792496-day-one-biopharmaceuticals-strong-ojemda-potential-in-q2-and-solid-rationale-for-day-301\" class=\"paywall-full-content\">wrote about</a><span class=\"paywall-full-content\"> DAWN in June 2025, rating it a Buy, based on the strength of the Ojemda launch, the valuation, and the antibody-drug conjugate (ADC) DAY-301 having a validated target. This article checks back in with the Ojemda launch and the catalysts ahead for the company.</span></p> <h2 class=\"paywall-full-content\">Ojemda Launch Continues Upward</h2> <p class=\"paywall-full-content\"><a href=\"https://seekingalpha.com/pr/20411977-day-one-reports-fourth-quarter-and-full-year-2025-financial-results-and-reaffirms-2026#hasComeFromMpArticle=false\">DAWN's Q4 '25</a> net product revenues of $52.8M represent a breakout quarter for the company. Those numbers also came with guidance for U.S. net product revenues of $225M-$250M in 2026 (representing 50% growth at the midpoint compared to $155.4M for 2025).</p> <p class=\"paywall-full-content\"><figure class=\"regular-img-figure paywall-full-content\" contenteditable=\"false\"><picture> <span><a href=\"https://static.seekingalpha.com/uploads/2026/2/27/8054501-17721819787344055_origin.png\" rel=\"lightbox\" data-width=\"1854\" data-height=\"1039\" data-og-image-twitter_small_card=\"true\" data-og-image-twitter_large_card=\"true\" data-og-image-twitter_image_post=\"true\" data-og-image-msn=\"true\" data-og-image-facebook=\"true\" data-og-image-google_news=\"true\" data-og-image-google_plus=\"true\" data-og-image-linkedin=\"true\" role=\"button\" aria-label=\"Expand image into lightbox view\"><img src=\"https://static.seekingalpha.com/uploads/2026/2/27/8054501-17721819787344055_origin.png?io=w640\" alt=\"Ojemda revenues by quarter.\" contenteditable=\"false\" width=\"640\" height=\"359\" loading=\"lazy\" srcset=\"https://static.seekingalpha.com/uploads/2026/2/27/8054501-17721819787344055_origin.png?io=w640 640w,https://static.seekingalpha.com/uploads/2026/2/27/8054501-17721819787344055_origin.png?io=w480 480w,https://static.seekingalpha.com/uploads/2026/2/27/8054501-17721819787344055_origin.png?io=w320 320w,https://static.seekingalpha.com/uploads/2026/2/27/8054501-17721819787344055_origin.png?io=w240 240w\" sizes=\"(max-width: 767px) calc(100vw - 36px), (max-width: 1023px) calc(100vw - 180px), 552px\"></a></span> </picture><figcaption><p class=\"item-caption\"><span>DAWN Presentation, February 2026.</span></p></figcaption></figure></p> <p class=\"paywall-full-content\"><a href=\"https://seekingalpha.com/news/4556548-day-one-biopharmaceuticals-reiterates-225m-250m-ojemda-revenue-target-as-pipeline-expands\">DAWN's guidance</a> is in part the result of updated FIREFLY-1 data (3-year follow-up) which was presented in November 2025, so the impact of that might not have even been reflected in <a href=\"https://seekingalpha.com/pr/20411977-day-one-reports-fourth-quarter-and-full-year-2025-financial-results-and-reaffirms-2026#hasComeFromMpArticle=false\">Q4 '25 numbers</a> in earnest.</p> <h2 class=\"paywall-full-content\">Catalysts Ahead For DAY-301, Emi-Le And Ojemda</h2> <p class=\"paywall-full-content\">As for the road ahead, DAWN has the potential to expand Ojemda into front-line usage in pediatric low-grade glioma with the FIREFLY-2 trial. Investors should look out for timely completion of enrollment, since at the time of Q4 '25 earnings, the trial was not yet fully enrolled, but guidance was for H1'26 completion of enrollment. DAWN is also guiding for a topline readout from FIREFLY-2 in mid-2027. Meeting that guidance would, of course, be more plausible if the trial completes enrollment on schedule.</p> <p class=\"paywall-full-content\">The nearer-term readout, however, comes from work with DAWN's new drug emiltatug ledadotin (Emi-Le), a B7-H4-targeting ADC. DAWN picked up Emi-Le via its acquisition of Mersana Therapeutics, which it <a href=\"https://ir.dayonebio.com/news-releases/news-release-details/day-one-acquire-mersana-therapeutics-advance-mission-bring-new\" rel=\"nofollow\">announced</a> in November 2025 and <a href=\"https://ir.dayonebio.com/news-releases/news-release-details/day-one-completes-acquisition-mersana-therapeutics\" rel=\"nofollow\">completed</a> in January 2026. At the time of the acquisition, DAWN noted the potential of Emi-Le in adenoid cystic carcinoma type-1 (ACC-1), a rare cancer with unmet need. Data from a <a href=\"https://clinicaltrials.gov/study/NCT05377996\" rel=\"noopener\">phase 1 trial</a> of Emi-Le, <a href=\"https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.3009\" rel=\"nofollow\">reported at</a> the ASCO Conference in mid-2025, demonstrated activity of the agent in other tumor types, not just ACC-1, including triple-negative breast cancer (TNBC). That phase 1 work included dose escalation with 130 patients and saw no grade 4 or grade 5 treatment-related adverse events.</p> <blockquote class=\"paywall-full-content\"> <p> </p> <p><em>The Phase I data set with Emi-Le has advanced in both patient number and follow-up. We look forward to sharing an update on the ACC patient cohort and the expanded safety data set since ASCO 2025 at a medical meeting in mid-2026. In parallel, we intend to initiate discussions with the FDA in the United States to discuss our intended approach for accelerated clinical development for this patient population in desperate need of new therapies.</em></p> <p>Michael Vasconcelles, Head of R&amp;D at DAWN, Q4'25 <a href=\"https://seekingalpha.com/article/4874403-day-one-biopharmaceuticals-inc-dawn-q4-2025-earnings-call-transcript\">earnings call</a>.</p> </blockquote> <p class=\"paywall-full-content\">DAWN's Head of R&amp;D, Michael Vasconcelles, has noted the company's primary focus on ACC but did also note the potential to work with Emi-Le in other indications, with TNBC being noted explicitly. A mid-year update on the data from the phase 1 Emi-Le trial, plus the outcome of discussions with the U.S. FDA, represent the near-term events to watch for Emi-Le. Additional comments later in the Q4 '25 earnings call noted the company's hope that a single-arm data set could satisfy a regulator, pending discussions with the regulator that haven't happened yet, because Emi-Le could provide sufficient response rates and duration of response to show Emi-Le clearly outperforms current therapy. It would be disappointing then for the company to come back from the regulator with news that it has to run a head-to-head study against existing chemotherapy regimens, despite the fact it is known those regimens are quite poor.</p> <p class=\"paywall-full-content\"><figure class=\"regular-img-figure paywall-full-content\" contenteditable=\"false\"><picture> <span><a href=\"https://static.seekingalpha.com/uploads/2026/2/27/8054501-17721827965437846_origin.png\" rel=\"lightbox\" data-width=\"1989\" data-height=\"1114\" data-og-image-twitter_small_card=\"true\" data-og-image-twitter_large_card=\"true\" data-og-image-twitter_image_post=\"true\" data-og-image-msn=\"true\" data-og-image-facebook=\"true\" data-og-image-google_news=\"true\" data-og-image-google_plus=\"true\" data-og-image-linkedin=\"true\" role=\"button\" aria-label=\"Expand image into lightbox view\"><img src=\"https://static.seekingalpha.com/uploads/2026/2/27/8054501-17721827965437846_origin.png?io=w640\" alt=\"DAWN pipeline.\" contenteditable=\"false\" width=\"640\" height=\"358\" loading=\"lazy\" srcset=\"https://static.seekingalpha.com/uploads/2026/2/27/8054501-17721827965437846_origin.png?io=w640 640w,https://static.seekingalpha.com/uploads/2026/2/27/8054501-17721827965437846_origin.png?io=w480 480w,https://static.seekingalpha.com/uploads/2026/2/27/8054501-17721827965437846_origin.png?io=w320 320w,https://static.seekingalpha.com/uploads/2026/2/27/8054501-17721827965437846_origin.png?io=w240 240w\" sizes=\"(max-width: 767px) calc(100vw - 36px), (max-width: 1023px) calc(100vw - 180px), 552px\"></a></span> </picture><figcaption><p class=\"item-caption\">DAWN pipeline. Note Emi-Le may produce additional data prior to DAY-301. <span>(DAWN Presentation, February 2026.)</span></p></figcaption></figure></p> <p class=\"paywall-full-content\">Lastly, I covered DAY-301 in more detail in my prior article in mid-2025, noting activity of a prior PTK7-targeting ADC but believing DAY-301 (also a PTK7-targeting ADC) could perform better. An update from the DAY-301 work is set for H2'26 and so seems not to be the near-term catalyst (Emi-Le data would likely come first) but is on the list for 2026.</p> <blockquote class=\"paywall-full-content\"> <p> </p> <p><em>We are encouraged by early signs of antitumor activity even at this relatively early stage of clinical development.</em></p> <p>Michael Vasconcelles, Head of R&amp;D at DAWN, Q4'25 <a href=\"https://seekingalpha.com/article/4874403-day-one-biopharmaceuticals-inc-dawn-q4-2025-earnings-call-transcript\">earnings call</a>.</p> </blockquote> <p class=\"paywall-full-content\">DAWN's Head of R&amp;D may have already revealed that DAY-301 is active or showing signs of activity with Q4 '25 earnings. Further comments, in response to analyst questions, from the CEO also suggest DAWN isn't done with DAY-301, instead referring to continued development and a prospective set of studies.</p> <blockquote class=\"paywall-full-content\"> <p> </p> <p><em>The program is in dose escalation. We have been backfilling at certain doses to evaluate those doses more comprehensively and to enrich for specific patient populations that we think may benefit. As Mike emphasized, <strong>we are seeing both an efficacy and a safety profile consistent with continued development</strong>, and we're enthusiastic about what that <strong>prospective set of studies</strong> may look like.</em></p> <p>Jeremy Bender, CEO, President and Director at DAWN, Q4'25 earnings call (emphasis added).</p> </blockquote> <p class=\"paywall-full-content\">The CEO's comments could be consistent with the company looking to continue to develop DAY-301 in multiple indications. These comments might allay concerns for some that were worried the Mersana acquisition, which brought in Emi-Le, could be in response to disappointing performance of DAY-301. Of course, even if the company likes what it is seeing with DAY-301, there is no guarantee that the market will agree.</p> <h2 class=\"paywall-full-content\">Financial Overview</h2> <p class=\"paywall-full-content\">DAWN <a href=\"https://seekingalpha.com/symbol/DAWN/balance-sheet\">finished Q4 '25</a> with cash, cash equivalents, and short-term investments of $441.1M. Since the Mersana acquisition completed in 2025 and involved an upfront payment of $25 per share, or $128.8M (there is also one contingent value right per share worth up to $30.25). That being said, Mersana had <a href=\"https://seekingalpha.com/pr/20307899-mersana-therapeutics-provides-business-update-and-announces-third-quarter-2025-financial#hasComeFromMpArticle=false\">$56.4M</a> in cash at the end of Q3'25 and had used just $3.2M in cash in that quarter, albeit aided by a $15M milestone payment. Mersana's net cash used in operating activities was <a href=\"https://seekingalpha.com/filing/42712321\">$55.1M</a> in the first nine months of 2025, so we might calculate year-end cash and cash equivalents of $38M for Mersana.</p> <p class=\"paywall-full-content\">DAWN's recent 10-K notes it was due to receive an $8M milestone from Janssen Biotech Inc. that otherwise would've been paid to Mersana under an agreement between Mersana and Janssen Biotech (<a href=\"https://seekingalpha.com/filing/169275532\">page F-38</a>). As such, we might say that while the Mersana acquisition involves an outlay of $128.8M, it would also bring in $38M and a Q1 '26 $8M payment from Janssen. As such, we might calculate <em>pro forma </em>cash of $358.3M for DAWN.</p> <p class=\"paywall-full-content\">For Q4 '25, DAWN also reported license revenue of $0.9M, R&amp;D expenses of $40.9M, SG&amp;A expenses of $34.2M, and a net loss of $21.3M. DAWN's net cash used in operating activities was $103.8M in 2025, so at the current rate, DAWN might have ~3.5 years of cash remaining. Of course, DAWN is predicting its revenues to grow a further 50% (midpoint of guidance) in 2026, so even if R&amp;D expenses increase as the company starts new trials, it could offset this with revenues somewhat or entirely. As such, I don't expect DAWN to have to raise cash soon, although it might decide it wants to take advantage of subsequent clinical updates (if they provide a rally) to raise further cash.</p> <p class=\"paywall-full-content\">DAWN trades with a market cap of $1.1B ($10.65 per share).</p> <h2 class=\"paywall-full-content\">Risks</h2> <p class=\"paywall-full-content\">There are multiple risks to a long position in DAWN, a few of which will be considered in this section.</p> <p class=\"paywall-full-content\">Firstly, DAWN has provided guidance for readouts from its clinical trials, but slippage in timelines can still occur. Further, even if timelines are met, the readouts themselves can disappoint the market, causing the stock to fall.</p> <p class=\"paywall-full-content\">Additionally, DAWN's Ojemda has performed to date, but subsequent updates, even if they include further revenue growth, can still lag behind expectations, triggering a pullback in the stock.</p> <p class=\"paywall-full-content\">Lastly, DAWN could decide it wishes to build its pipeline further, but the terms of any new deals, such as in-licensing a drug, might not be well received by the market.</p> <h2 class=\"paywall-full-content\">Conclusions</h2> <div class=\"before_last_paragraph-piano-placeholder paywall-full-content\"></div> <p class=\"paywall-full-content\">DAWN's Ojemda launch has taken a step forward, with strong Q4 '25 revenue performance, and the company is guiding for further growth in 2026. The company also has multiple clinical catalysts ahead, with Emi-Le data set for mid-2026, DAY-301 data in H2'26, and FIREFLY-2 data providing a readout in 2027. Given Emi-Le has already produced data showing activity and good tolerability and the comments on DAY-301 that hint at activity, there is a possibility the market is at least somewhat impressed with one of those two updates in 2026. Given the recent strength of the Ojemda launch, multiple shots on goal in the clinic, several years of cash runway, and a <a href=\"https://seekingalpha.com/symbol/DAWN/valuation/metrics#hasComeFromMpArticle=false\">valuation</a> that hasn't run too far yet (EV/Sales TTM of 4.3 or EV/Sales FWD of 2.83), I currently rate DAWN a buy (I'm long).</p>",
            "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/921577312/image_921577312.jpg",
            "link": "https://seekingalpha.com/article/4876519-day-one-biopharmaceuticals-commercial-performance-with-catalysts-ahead",
            "pub_date": "2026-02-28 04:31:27",
            "source": "seekalpha_articles",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "4876514",
            "title": "Consensus Cloud Solutions Aims For Transition, But Revenue Remains Flat",
            "description": "<p data-eci=\"true\"><figure class=\"getty-figure\" data-type=\"getty-image\"><picture> <img src=\"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2215172750/image_2215172750.jpg?io=getty-c-w630\" alt=\"Digital healthcare concept with doctor updating electronic health records, showcasing health information EMR system, medical data, online documentation and patient files.\" data-id=\"2215172750\" data-type=\"getty-image\" width=\"1536\" height=\"692\" srcset=\"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2215172750/image_2215172750.jpg?io=getty-c-w1536 1536w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2215172750/image_2215172750.jpg?io=getty-c-w1280 1280w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2215172750/image_2215172750.jpg?io=getty-c-w1080 1080w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2215172750/image_2215172750.jpg?io=getty-c-w750 750w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2215172750/image_2215172750.jpg?io=getty-c-w640 640w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2215172750/image_2215172750.jpg?io=getty-c-w480 480w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2215172750/image_2215172750.jpg?io=getty-c-w320 320w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2215172750/image_2215172750.jpg?io=getty-c-w240 240w\" sizes=\"(max-width: 767px) calc(100vw - 36px), (max-width: 1023px) calc(100vw - 132px), (max-width: 1199px) calc(100vw - 666px), (max-width: 1307px) calc(100vw - 708px), 600px\" fetchpriority=\"high\"> </picture><figcaption><p class=\"item-caption\"> </p> <p class=\"item-credits\">hirun/iStock via Getty Images</p></figcaption></figure></p> <div class=\"inline_ad_placeholder\"></div> <h2>Investment Outlook</h2> <p><strong>Consensus Cloud Solutions (<span class=\"ticker-hover-wrapper\"><a href=\"https://seekingalpha.com/symbol/CCSI\" title=\"Consensus Cloud Solutions, Inc.\">CCSI</a></span>)</strong> recently reported its Q4 2025 <a href=\"https://seekingalpha.com/news/4549264-consensus-cloud-solutions-beats-top-line-and-bottom-line-estimates-initiates-q1-and-fy26-outlook\">financial results</a>, beating revenue and earnings estimates.</p> <p>I previously analyzed CCSI in September 2023 with a <a href=\"https://seekingalpha.com/article/4636092-consensus-cloud-sees-slow-client-decision-making-weighing-on-growth\">Hold</a> outlook due to slow client decision-making.</p> <p>The<span class=\"paywall-full-content\"> company is executing on a transition away from its SoHo segment and focusing on its Corporate, Federal, and AI initiatives.</span></p> <p class=\"paywall-full-content\">Managing such a major shift is frequently a recipe for a prolonged period of treading water, and I remain in a ‘wait-and-see’ mode for evidence of net new growth.</p> <p class=\"paywall-full-content\">So, my outlook remains a neutral Hold.</p> <h2 class=\"paywall-full-content\">Consensus’ Market And Approach</h2> <p class=\"paywall-full-content\">Consensus Cloud Solutions provides a range of data exchange and interoperability technology services to companies in various regulated industries such as healthcare, insurance, finance, legal, manufacturing, and real estate.</p> <p class=\"paywall-full-content\">CCSI was spun off from J2 Global in 2021 as part of its effort to divide into Ziff Davis and CCSI.</p> <p class=\"paywall-full-content\">Company CEO Scott Turicchi was previously J2 Global's president and held a Managing Director position at the investment banking firm DLJ.</p> <p class=\"paywall-full-content\">CCSI's primary offerings include:</p> <ul class=\"paywall-full-content\"> <li><p>Artificial Intelligence</p></li> <li><p>Clinical Documentation</p></li> <li><p>HIPAA Compliance</p></li> <li><p>Natural Language Processing</p></li> <li><p>Interoperability</p></li> <li><p>eSignatures</p></li> <li><p>Cloud Fax</p></li> </ul> <p class=\"paywall-full-content\">The firm is shifting its focus away from legacy eFax services and towards information exchange solutions for both structured and unstructured applications.</p> <p class=\"paywall-full-content\">It has integrated generative AI technologies to help advance its transition.</p> <p class=\"paywall-full-content\">The company is also focusing more on medium and large enterprises and deemphasizing its small and home office segment.</p> <p class=\"paywall-full-content\">The pie chart below shows a breakdown of the firm’s 2025 revenue contribution, with a continued increase in the Corporate percentage:</p> <p class=\"paywall-full-content\"><figure class=\"regular-img-figure paywall-full-content\" contenteditable=\"false\"><picture> <span><a href=\"https://static.seekingalpha.com/uploads/2026/2/27/12102811-1772203875865157_origin.png\" rel=\"lightbox\" data-width=\"1264\" data-height=\"757\" data-og-image-twitter_small_card=\"true\" data-og-image-twitter_large_card=\"true\" data-og-image-twitter_image_post=\"true\" data-og-image-msn=\"true\" data-og-image-facebook=\"true\" data-og-image-google_news=\"true\" data-og-image-google_plus=\"true\" data-og-image-linkedin=\"true\" role=\"button\" aria-label=\"Expand image into lightbox view\"><img src=\"https://static.seekingalpha.com/uploads/2026/2/27/12102811-1772203875865157_origin.png?io=w640\" alt=\"Revenue Contribution\" contenteditable=\"false\" width=\"640\" height=\"383\" loading=\"lazy\" srcset=\"https://static.seekingalpha.com/uploads/2026/2/27/12102811-1772203875865157_origin.png?io=w640 640w,https://static.seekingalpha.com/uploads/2026/2/27/12102811-1772203875865157_origin.png?io=w480 480w,https://static.seekingalpha.com/uploads/2026/2/27/12102811-1772203875865157_origin.png?io=w320 320w,https://static.seekingalpha.com/uploads/2026/2/27/12102811-1772203875865157_origin.png?io=w240 240w\" sizes=\"(max-width: 767px) calc(100vw - 36px), (max-width: 1023px) calc(100vw - 180px), 552px\"></a></span> </picture><figcaption><p class=\"item-caption\"><span>SEC</span></p></figcaption></figure></p> <p class=\"paywall-full-content\">To pursue new business, CCSI uses its direct sales and marketing efforts and a network of partners such as resellers, solution providers, and white-label partners.</p> <p class=\"paywall-full-content\">The global healthcare interoperability solutions market was an estimated $3.4 billion in 2023 and was forecast to reach $8.6 billion by 2030.</p> <p class=\"paywall-full-content\">If accomplished, this growth would be a CAGR of 14.2% from 2024 to 2030, a fairly robust rate of growth.</p> <p class=\"paywall-full-content\">The primary drivers for this expected growth are an increasing adoption by healthcare authorities for efficiency gains, growth in investments to enhance facilities, and a focus on patient-centric care.</p> <p class=\"paywall-full-content\">By region, North America accounted for nearly 42% of the total market share in 2023, with the hospital segment dominating demand by end-user type.</p> <p class=\"paywall-full-content\">The Asia Pacific region is expected to grow at the fastest rate of growth through 2030.</p> <p class=\"paywall-full-content\">The chart below shows the historical and projected future growth trajectory of the US healthcare interoperability solutions market through 2030:</p> <p class=\"paywall-full-content\"><figure class=\"regular-img-figure paywall-full-content\" contenteditable=\"false\"><picture> <span><a href=\"https://static.seekingalpha.com/uploads/2026/2/27/12102811-17722038759951327_origin.png\" rel=\"lightbox\" data-width=\"1166\" data-height=\"630\" data-og-image-twitter_small_card=\"true\" data-og-image-twitter_large_card=\"true\" data-og-image-twitter_image_post=\"true\" data-og-image-msn=\"true\" data-og-image-facebook=\"true\" data-og-image-google_news=\"true\" data-og-image-google_plus=\"true\" data-og-image-linkedin=\"true\" role=\"button\" aria-label=\"Expand image into lightbox view\"><img src=\"https://static.seekingalpha.com/uploads/2026/2/27/12102811-17722038759951327_origin.png?io=w640\" alt=\"US Healthcare Interoperability Market\" contenteditable=\"false\" width=\"640\" height=\"346\" loading=\"lazy\" srcset=\"https://static.seekingalpha.com/uploads/2026/2/27/12102811-17722038759951327_origin.png?io=w640 640w,https://static.seekingalpha.com/uploads/2026/2/27/12102811-17722038759951327_origin.png?io=w480 480w,https://static.seekingalpha.com/uploads/2026/2/27/12102811-17722038759951327_origin.png?io=w320 320w,https://static.seekingalpha.com/uploads/2026/2/27/12102811-17722038759951327_origin.png?io=w240 240w\" sizes=\"(max-width: 767px) calc(100vw - 36px), (max-width: 1023px) calc(100vw - 180px), 552px\"></a></span> </picture><figcaption><p class=\"item-caption\"><span>Grand View Research</span></p></figcaption></figure></p> <p class=\"paywall-full-content\">Competitors in the healthcare interoperability market include:</p> <ul class=\"paywall-full-content\"> <li><p>Infor (Koch Industries)</p></li> <li><p>Koninklijke Philips N.V. (<a href=\"https://seekingalpha.com/symbol/PHG\" title=\"Koninklijke Philips N.V.\">PHG</a>)</p></li> <li><p>Cerner (Oracle)</p></li> <li><p>Orion Health</p></li> <li><p>NXGN Management</p></li> <li><p>OSP</p></li> <li><p>Epic Systems</p></li> <li><p><a href=\"https://visolve.com\" rel=\"nofollow\">ViSolve.com</a></p></li> <li><p>InterSystems Corporation</p></li> <li><p>INTERFACEWARE Inc.</p></li> <li><p>Jitterbit</p></li> <li><p>Veradigm (<a href=\"https://seekingalpha.com/symbol/MDRX\" title=\"Veradigm Inc.\">MDRX</a>)</p></li> </ul> <p class=\"paywall-full-content\">CCSI’s strengths include its legacy digital fax installed base in the healthcare industry and its regulatory-compliant messaging system, both of which it hopes to leverage as it shifts its focus toward interoperability functions.</p> <p class=\"paywall-full-content\">Since the company has operated at the communication layer, it has been less capital-intensive but also more modular and less structurally dominant than EHR incumbents.</p> <p class=\"paywall-full-content\">CCSI is also active in providing its solutions to other industries outside of healthcare as well as through its FedRAMP High certification.</p> <h2 class=\"paywall-full-content\">Recent Financial Trends</h2> <p class=\"paywall-full-content\">Topline revenue (blue columns) has remained essentially flat, with the most recent quarter near the midpoint of previous guidance. SoHo revenue was down 11% YoY, while corporate revenue was up 6.5%. Operating income (red line) has dipped on higher SG&amp;A expenses from incremental hiring and salary increases.</p> <p class=\"paywall-full-content\"><figure class=\"regular-img-figure paywall-full-content\" contenteditable=\"false\"><picture> <span><a href=\"https://static.seekingalpha.com/uploads/2026/2/27/12102811-17722038757282207_origin.png\" rel=\"lightbox\" data-width=\"1200\" data-height=\"741\" data-og-image-twitter_small_card=\"true\" data-og-image-twitter_large_card=\"true\" data-og-image-twitter_image_post=\"true\" data-og-image-msn=\"true\" data-og-image-facebook=\"true\" data-og-image-google_news=\"true\" data-og-image-google_plus=\"true\" data-og-image-linkedin=\"true\" role=\"button\" aria-label=\"Expand image into lightbox view\"><img src=\"https://static.seekingalpha.com/uploads/2026/2/27/12102811-17722038757282207_origin.png?io=w640\" alt=\"Total Revenue and Operating Income\" contenteditable=\"false\" width=\"640\" height=\"395\" loading=\"lazy\" srcset=\"https://static.seekingalpha.com/uploads/2026/2/27/12102811-17722038757282207_origin.png?io=w640 640w,https://static.seekingalpha.com/uploads/2026/2/27/12102811-17722038757282207_origin.png?io=w480 480w,https://static.seekingalpha.com/uploads/2026/2/27/12102811-17722038757282207_origin.png?io=w320 320w,https://static.seekingalpha.com/uploads/2026/2/27/12102811-17722038757282207_origin.png?io=w240 240w\" sizes=\"(max-width: 767px) calc(100vw - 36px), (max-width: 1023px) calc(100vw - 180px), 552px\"></a></span> </picture><figcaption><p class=\"item-caption\"><span>Seeking Alpha</span></p></figcaption></figure></p> <p class=\"paywall-full-content\">Core operating leverage has also remained essentially flat in recent quarters.</p> <p class=\"paywall-full-content\"><figure class=\"regular-img-figure paywall-full-content\" contenteditable=\"false\"><picture> <span><a href=\"https://static.seekingalpha.com/uploads/2026/2/27/12102811-17722038758336985_origin.png\" rel=\"lightbox\" data-width=\"1200\" data-height=\"741\" data-og-image-twitter_small_card=\"true\" data-og-image-twitter_large_card=\"true\" data-og-image-twitter_image_post=\"true\" data-og-image-msn=\"true\" data-og-image-facebook=\"true\" data-og-image-google_news=\"true\" data-og-image-google_plus=\"true\" data-og-image-linkedin=\"true\" role=\"button\" aria-label=\"Expand image into lightbox view\"><img src=\"https://static.seekingalpha.com/uploads/2026/2/27/12102811-17722038758336985_origin.png?io=w640\" alt=\"Degree of Operating Leverage\" contenteditable=\"false\" width=\"640\" height=\"395\" loading=\"lazy\" srcset=\"https://static.seekingalpha.com/uploads/2026/2/27/12102811-17722038758336985_origin.png?io=w640 640w,https://static.seekingalpha.com/uploads/2026/2/27/12102811-17722038758336985_origin.png?io=w480 480w,https://static.seekingalpha.com/uploads/2026/2/27/12102811-17722038758336985_origin.png?io=w320 320w,https://static.seekingalpha.com/uploads/2026/2/27/12102811-17722038758336985_origin.png?io=w240 240w\" sizes=\"(max-width: 767px) calc(100vw - 36px), (max-width: 1023px) calc(100vw - 180px), 552px\"></a></span> </picture><figcaption><p class=\"item-caption\"><span>Seeking Alpha</span></p></figcaption></figure></p> <p class=\"paywall-full-content\">Gross margin has proceeded with no discernible trend, but SG&amp;A has increased due to more hiring and salary increases, while R&amp;D has remained flat.</p> <p class=\"paywall-full-content\"><figure class=\"regular-img-figure paywall-full-content\" contenteditable=\"false\"><picture> <span><a href=\"https://static.seekingalpha.com/uploads/2026/2/27/12102811-17722038759366558_origin.png\" rel=\"lightbox\" data-width=\"1200\" data-height=\"741\" data-og-image-twitter_small_card=\"true\" data-og-image-twitter_large_card=\"true\" data-og-image-twitter_image_post=\"true\" data-og-image-msn=\"true\" data-og-image-facebook=\"true\" data-og-image-google_news=\"true\" data-og-image-google_plus=\"true\" data-og-image-linkedin=\"true\" role=\"button\" aria-label=\"Expand image into lightbox view\"><img src=\"https://static.seekingalpha.com/uploads/2026/2/27/12102811-17722038759366558_origin.png?io=w640\" alt=\"Revenue Percentage Performance\" contenteditable=\"false\" width=\"640\" height=\"395\" loading=\"lazy\" srcset=\"https://static.seekingalpha.com/uploads/2026/2/27/12102811-17722038759366558_origin.png?io=w640 640w,https://static.seekingalpha.com/uploads/2026/2/27/12102811-17722038759366558_origin.png?io=w480 480w,https://static.seekingalpha.com/uploads/2026/2/27/12102811-17722038759366558_origin.png?io=w320 320w,https://static.seekingalpha.com/uploads/2026/2/27/12102811-17722038759366558_origin.png?io=w240 240w\" sizes=\"(max-width: 767px) calc(100vw - 36px), (max-width: 1023px) calc(100vw - 180px), 552px\"></a></span> </picture><figcaption><p class=\"item-caption\"><span>Seeking Alpha</span></p></figcaption></figure></p> <p class=\"paywall-full-content\">Earnings remained within the normal range for recent quarters despite slightly higher sequential SG&amp;A expenses.</p> <p class=\"paywall-full-content\"><figure class=\"regular-img-figure paywall-full-content\" contenteditable=\"false\"><picture> <span><a href=\"https://static.seekingalpha.com/uploads/2026/2/27/12102811-17722039399208097_origin.png\" rel=\"lightbox\" data-width=\"1200\" data-height=\"741\" data-og-image-twitter_small_card=\"true\" data-og-image-twitter_large_card=\"true\" data-og-image-twitter_image_post=\"true\" data-og-image-msn=\"true\" data-og-image-facebook=\"true\" data-og-image-google_news=\"true\" data-og-image-google_plus=\"true\" data-og-image-linkedin=\"true\" role=\"button\" aria-label=\"Expand image into lightbox view\"><img src=\"https://static.seekingalpha.com/uploads/2026/2/27/12102811-17722039399208097_origin.png?io=w640\" alt=\"9 Quarter Earnings Per Share\" contenteditable=\"false\" width=\"640\" height=\"395\" loading=\"lazy\" srcset=\"https://static.seekingalpha.com/uploads/2026/2/27/12102811-17722039399208097_origin.png?io=w640 640w,https://static.seekingalpha.com/uploads/2026/2/27/12102811-17722039399208097_origin.png?io=w480 480w,https://static.seekingalpha.com/uploads/2026/2/27/12102811-17722039399208097_origin.png?io=w320 320w,https://static.seekingalpha.com/uploads/2026/2/27/12102811-17722039399208097_origin.png?io=w240 240w\" sizes=\"(max-width: 767px) calc(100vw - 36px), (max-width: 1023px) calc(100vw - 180px), 552px\"></a></span> </picture><figcaption><p class=\"item-caption\"><span>Seeking Alpha</span></p></figcaption></figure></p> <p class=\"paywall-full-content\">A table of various forward and trailing twelve-month metrics for CCSI is shown here for handy reference:</p> <div class=\"table-responsive paywall-full-content\"> <span class=\"sa-table-scroll-wrapper sa-hide-scrollbar\"><span data-intersection-boundary=\"start\" data-test-id=\"table-scroll-wrapper-boundary-start\"></span><table> <colgroup> <col> <col> </colgroup> <tr> <td><p><strong>Metric</strong></p></td> <td><p><strong>Amount</strong></p></td> </tr> <tr> <td><p>EV/Sales - FWD</p></td> <td><p>3.0</p></td> </tr> <tr> <td><p>EV/EBITDA - FWD</p></td> <td><p>5.6</p></td> </tr> <tr> <td><p>Rev. Growth Rate Est. - FWD</p></td> <td><p>1.3%</p></td> </tr> <tr> <td><p>2026 FWD EPS Estimate</p></td> <td><p>$5.68</p></td> </tr> <tr> <td><p>Price/Sales - TTM</p></td> <td><p>1.6</p></td> </tr> <tr> <td><p>P/E GAAP - TTM</p></td> <td><p>6.81</p></td> </tr> <tr> <td><p>Revenue Growth Rate - TTM</p></td> <td><p>-0.2%</p></td> </tr> <tr> <td><p>Net Income Margin - TTM</p></td> <td><p>24.2%</p></td> </tr> <tr> <td><p>EBITDA Margin - TTM</p></td> <td><p>48.3%</p></td> </tr> <tr> <td><p>Market Capitalization</p></td> <td><p>$559,280,000</p></td> </tr> <tr> <td><p>Enterprise Value</p></td> <td><p>$1,060,000,000</p></td> </tr> <tr> <td><p>Operating Cash Flow</p></td> <td><p>$136,090,000</p></td> </tr> <tr> <td><p>EPS (Fully Diluted)</p></td> <td><p>$4.35</p></td> </tr> <tr> <td><p>Free Cash Flow per Share - TTM</p></td> <td><p>$5.50</p></td> </tr> <tr> <td><p>Seeking Alpha Quant Score</p></td> <td><p>Hold: 3.15</p></td> </tr> </table> <span data-intersection-boundary=\"end\" data-test-id=\"table-scroll-wrapper-boundary-end\"></span></span><button type=\"button\" class=\"sa-table-enlarge-button\">Click to enlarge</button> </div> <p class=\"paywall-full-content\">(Source: Seeking Alpha)</p> <h2 class=\"paywall-full-content\">Capital Allocation</h2> <p class=\"paywall-full-content\">As of the end of 2025, CCSI had $74.7 million in cash and equivalents and $558.3 million in total debt, of which $7.0 million was due within twelve months.</p> <p class=\"paywall-full-content\">Free cash flow for the twelve months ended December 31, 2025, was $166.3 million, while stock-based compensation [SBC] was $17.7 million, leaving FCF net of SBC at $148.6 million, a strong result.</p> <p class=\"paywall-full-content\">The company is essentially a high-margin, low-growth compounder.</p> <p class=\"paywall-full-content\">Stock-based compensation [SBC] has been around 5% of revenue, which is moderate and reasonable compared to SaaS companies, which frequently award 8%–15% of revenue in SBC.</p> <p class=\"paywall-full-content\">Capex intensity is also reasonable and disciplined, leading to strong free cash flow per share ($5.50) and FCF yield of around 18%.</p> <p class=\"paywall-full-content\">The Board is offsetting SBC with net stock purchases, producing shareholder-friendly capital accretion.</p> <h2 class=\"paywall-full-content\">Why I’m Neutral On Consensus</h2> <p class=\"paywall-full-content\">Consensus is seeking to leverage its legacy eFax business into a higher growth and value-add market space of interoperability, with the healthcare industry as its primary focus.</p> <p class=\"paywall-full-content\">Management has seen hospital budgeting pause amid regulatory uncertainties, and its FedRAMP High certification appears to be driving interest from government when it isn’t shut down over political fights.</p> <p class=\"paywall-full-content\">So, CCSI has yet to produce growth in its financial results, so this narrative is primarily aspirational at this point.</p> <p class=\"paywall-full-content\">And against this is a managed decline in its SoHo segment, likely around 10% per year, so management has a significant lift just to compensate for that expected decline.</p> <p class=\"paywall-full-content\">The firm has made its AI moves for its Clarity and Harmony products for document indexing, workflow automation, and structured data extraction functions, but revenue contribution is still at an early stage for these capabilities.</p> <p class=\"paywall-full-content\">The chart below shows the frequency of various keywords with a generally negative valence in the most recent management conference call with analysts.</p> <p class=\"paywall-full-content\"><figure class=\"regular-img-figure paywall-full-content\" contenteditable=\"false\"><picture> <span><a href=\"https://static.seekingalpha.com/uploads/2026/2/27/12102811-17722038756091864_origin.png\" rel=\"lightbox\" data-width=\"1200\" data-height=\"741\" data-og-image-twitter_small_card=\"true\" data-og-image-twitter_large_card=\"true\" data-og-image-twitter_image_post=\"true\" data-og-image-msn=\"true\" data-og-image-facebook=\"true\" data-og-image-google_news=\"true\" data-og-image-google_plus=\"true\" data-og-image-linkedin=\"true\" role=\"button\" aria-label=\"Expand image into lightbox view\"><img src=\"https://static.seekingalpha.com/uploads/2026/2/27/12102811-17722038756091864_origin.png?io=w640\" alt=\"Earnings Transcript Key Terms Frequency\" contenteditable=\"false\" width=\"640\" height=\"395\" loading=\"lazy\" srcset=\"https://static.seekingalpha.com/uploads/2026/2/27/12102811-17722038756091864_origin.png?io=w640 640w,https://static.seekingalpha.com/uploads/2026/2/27/12102811-17722038756091864_origin.png?io=w480 480w,https://static.seekingalpha.com/uploads/2026/2/27/12102811-17722038756091864_origin.png?io=w320 320w,https://static.seekingalpha.com/uploads/2026/2/27/12102811-17722038756091864_origin.png?io=w240 240w\" sizes=\"(max-width: 767px) calc(100vw - 36px), (max-width: 1023px) calc(100vw - 180px), 552px\"></a></span> </picture><figcaption><p class=\"item-caption\"><span>Seeking Alpha</span></p></figcaption></figure></p> <p class=\"paywall-full-content\">The graphic illustrates that Q4 2025 was the company's most challenging quarter, and its SoHo segment continues its managed decline, with headwinds from changes in the search environment negatively affecting its results.</p> <p class=\"paywall-full-content\">The SoHo decline is being managed by the company as a ‘strategic cash engine’ in order to fund its corporate channel growth efforts, and management has realigned its go-to-market approach to that end.</p> <p class=\"paywall-full-content\">Prospective investors would therefore be betting that management can ignite growth from this transition to a focus on the corporate market, Federal efforts, and its AI product initiatives.</p> <p class=\"paywall-full-content\">It’s a tall order to grow a company that is in a transition like this; many such software-based firms have languished for years making a strategic shift over time, rather than ‘ripping the bandaid off’ and jettisoning their legacy business.</p> <p class=\"paywall-full-content\">I understand management’s rationale for leveraging its legacy business to move into higher value-add and more promising market segments, but I take a ‘show me the money’ approach to these types of transitions, especially after seeing so many software companies tread water for years.</p> <p class=\"paywall-full-content\">As long as CCSI continues to integrate GenAI capabilities into its offerings wherever appropriate and remains focused on highly regulated industries like healthcare and customer segments like FedRAMP, both of which tend to be slow in adopting disruptive technologies, its revenue streams could remain less vulnerable to immediate disruption from generative AI technologies.</p> <div class=\"before_last_paragraph-piano-placeholder paywall-full-content\"></div> <p class=\"paywall-full-content\">However, I still remain at a neutral Hold for CCSI as I await more indications that it can restart net growth while managing its SoHo decline.</p>",
            "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2215172750/image_2215172750.jpg",
            "link": "https://seekingalpha.com/article/4876514-consensus-cloud-solutions-aims-for-transition-but-revenue-remains-flat",
            "pub_date": "2026-02-28 04:26:05",
            "source": "seekalpha_articles",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "4876511",
            "title": "Eli Lilly Vs. Novo Nordisk: The Valuation Gap Is Unreasonable",
            "description": "<p data-eci=\"true\"><figure class=\"getty-figure\" data-type=\"getty-image\"><picture> <img src=\"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2195158078/image_2195158078.jpg?io=getty-c-w630\" alt=\"Person administering insulin injection using a pen\" data-id=\"2195158078\" data-type=\"getty-image\" width=\"1536\" height=\"1025\" srcset=\"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2195158078/image_2195158078.jpg?io=getty-c-w1536 1536w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2195158078/image_2195158078.jpg?io=getty-c-w1280 1280w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2195158078/image_2195158078.jpg?io=getty-c-w1080 1080w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2195158078/image_2195158078.jpg?io=getty-c-w750 750w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2195158078/image_2195158078.jpg?io=getty-c-w640 640w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2195158078/image_2195158078.jpg?io=getty-c-w480 480w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2195158078/image_2195158078.jpg?io=getty-c-w320 320w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2195158078/image_2195158078.jpg?io=getty-c-w240 240w\" sizes=\"(max-width: 767px) calc(100vw - 36px), (max-width: 1023px) calc(100vw - 132px), (max-width: 1199px) calc(100vw - 666px), (max-width: 1307px) calc(100vw - 708px), 600px\" fetchpriority=\"high\"> </picture><figcaption><p class=\"item-caption\"> </p> <p class=\"item-credits\">blackCAT/E+ via Getty Images</p></figcaption></figure></p> <div class=\"inline_ad_placeholder\"></div> <p>Novo Nordisk (<a href=\"https://seekingalpha.com/symbol/NVO\" title=\"Novo Nordisk A/S\">NVO</a>) has experienced a hefty sell-off following worse-than-expected trial results of their weight loss drug CagriSema. Simultaneously, their main competitor, Eli Lilly (<span class=\"ticker-hover-wrapper\"><a href=\"https://seekingalpha.com/symbol/LLY\" title=\"Eli Lilly and Company\">LLY</a></span>), managed to keep or even expand their edge.</p> <p><figure class=\"sa-widget sa-ycharts paywall-full-content\"><img src=\"https://static.seekingalpha.com/uploads/2026/2/27/saupload_84d767cadb48b61cfc5dc0cae214f9aa.png?io=w640\" alt=\"Chart\" width=\"635\" height=\"366\" class=\"sa-ycharts-img\" data-width=\"635\" data-height=\"366\" loading=\"lazy\" srcset=\"https://static.seekingalpha.com/uploads/2026/2/27/saupload_84d767cadb48b61cfc5dc0cae214f9aa.png?io=w480 480w,https://static.seekingalpha.com/uploads/2026/2/27/saupload_84d767cadb48b61cfc5dc0cae214f9aa.png?io=w320 320w,https://static.seekingalpha.com/uploads/2026/2/27/saupload_84d767cadb48b61cfc5dc0cae214f9aa.png?io=w240 240w\" sizes=\"(max-width: 767px) calc(100vw - 36px), (max-width: 1023px) calc(100vw - 180px), 552px\"><figcaption>Data by <a href=\"https://ycharts.com\" rel=\"nofollow\" class=\"paywall-full-content\">YCharts</a></figcaption></figure><figure class=\"sa-widget sa-ycharts paywall-full-content\"><img src=\"https://static.seekingalpha.com/uploads/2026/2/27/saupload_50a4ecd3e3870cc0afd75a40f4f77a48.png?io=w640\" alt=\"Chart\" width=\"635\" height=\"366\" class=\"sa-ycharts-img\" data-width=\"635\" data-height=\"366\" loading=\"lazy\" srcset=\"https://static.seekingalpha.com/uploads/2026/2/27/saupload_50a4ecd3e3870cc0afd75a40f4f77a48.png?io=w480 480w,https://static.seekingalpha.com/uploads/2026/2/27/saupload_50a4ecd3e3870cc0afd75a40f4f77a48.png?io=w320 320w,https://static.seekingalpha.com/uploads/2026/2/27/saupload_50a4ecd3e3870cc0afd75a40f4f77a48.png?io=w240 240w\" sizes=\"(max-width: 767px) calc(100vw - 36px), (max-width: 1023px) calc(100vw - 180px), 552px\"><figcaption>Data by <a href=\"https://ycharts.com\" rel=\"nofollow\">YCharts</a></figcaption></figure></p> <p class=\"paywall-full-content\">I believe that this is once again a massive overreaction by the market, and here is why.</p> <h2 class=\"paywall-full-content\">What Caused The Sell-Off And Why Is It Excessive?</h2> <p class=\"paywall-full-content\">Several headlines stated that <a href=\"https://www.cnbc.com/2026/02/23/novo-nordisk-stock-cagrisema-trial-fails-weight-loss.html\" rel=\"nofollow\">NVO's CagriSema failed to beat LLY's Zepbound</a>. These were based on the latest Phase III REDEFINE 4 trial results, where CagriSema (combination of semaglutide and cagrilintide) achieved an average weight loss of <a href=\"https://www.novonordisk.ca/content/dam/nncorp/ca/en/press-releases/2025/redefine-canadian-press-release-english.pdf\" rel=\"nofollow\">22.7% over 84 weeks</a>—compared to Zepbound's mean efficacy of <a href=\"https://www.clinicaltrialsarena.com/news/novo-nordisks-cagrisema-bested-by-lillys-zepbound-in-head-to-head-trial/\" rel=\"nofollow\">25.5%</a> in the same time frame. This is a miss of 280 basis points that caused Novo's stock to sell off by more than 20%.</p> <p class=\"paywall-full-content\">The market is also missing one critical detail about the trial result: Novo seems to be conservative with its dosing.</p> <p class=\"paywall-full-content\">The current clinical trial utilized a 2.4mg dose, while in contrast, Lilly achieved the higher weight loss with a dosage of 15mg. First trials already indicate that a higher dosage of 7.2mg could boost Novo's efficacy <a href=\"https://www.clinicaltrialsarena.com/news/novo-nordisks-cagrisema-bested-by-lillys-zepbound-in-head-to-head-trial/\" rel=\"nofollow\">by up to 18.3%</a>—matching or even exceeding Lilly's metrics. If we apply this improvement to the current trial, I think NVO could achieve a weight loss of 26.8% over 84 weeks.</p> <p class=\"paywall-full-content\">Novo's decision to stay at 2.4mg seems like a strategic move to prioritize safety and minimize potential side effects. While I personally like this move, I believe it should have communicated this more openly, which would have certainly helped to ease investors' concerns.</p> <p class=\"paywall-full-content\">Even if Lilly's drug will eventually come out on top, it is highly unlikely that they will manage to dominate the massive weight loss medication market—expected to reach <a href=\"https://www.fortunebusinessinsights.com/anti-obesity-drugs-market-104783#:~:text=The%20global%20anti%2Dobesity%20drugs,period%20%282024%2D2032%29.\" rel=\"nofollow\">$67 billion by 2034</a>—on their own. Convenience, for example through Novo's recently approved weight loss pill, and pricing, as well as potential side effects of each drug, will certainly leave plenty of room for Novo to navigate in.</p> <p class=\"paywall-full-content\">But let's take a look at the valuation and analyze whether the data confirms my take.</p> <h2 class=\"paywall-full-content\">Valuation: Discounted Cash Flow Analysis</h2> <p class=\"paywall-full-content\">Let's first take a look at the revenue distribution of each company.</p> <p class=\"paywall-full-content\"><a href=\"https://investor.lilly.com/financial-information/quarterly-results\" rel=\"nofollow\">Eli Lilly—2025 Revenue Distribution</a></p> <div class=\"table-responsive paywall-full-content\"> <span class=\"sa-table-scroll-wrapper sa-hide-scrollbar\"><span data-intersection-boundary=\"start\" data-test-id=\"table-scroll-wrapper-boundary-start\"></span><table> <colgroup> <col span=\"2\"> <col> <col> </colgroup> <tr> <td><strong>Segment</strong></td> <td><strong>Revenue (mill. USD)</strong></td> <td><strong>Share</strong></td> </tr> <tr> <td>Diabetes Care</td> <td>34,679</td> <td>53%</td> </tr> <tr> <td>Obesity care (Zepbound)</td> <td>13,542</td> <td>21%</td> </tr> <tr> <td>Immunology</td> <td>5,247</td> <td>8%</td> </tr> <tr> <td>Neuroscience</td> <td>1,391</td> <td>2%</td> </tr> <tr> <td>Oncology</td> <td>9,376</td> <td>14%</td> </tr> <tr> <td>Other</td> <td>944</td> <td>1%</td> </tr> </table> <span data-intersection-boundary=\"end\" data-test-id=\"table-scroll-wrapper-boundary-end\"></span></span><button type=\"button\" class=\"sa-table-enlarge-button\">Click to enlarge</button> </div> <p class=\"paywall-full-content\"><a href=\"https://www.novonordisk.com/investors/financial-results.html\" rel=\"nofollow\">Novo Nordisk—2025 Revenue Distribution</a></p> <div class=\"table-responsive paywall-full-content\"> <span class=\"sa-table-scroll-wrapper sa-hide-scrollbar\"><span data-intersection-boundary=\"start\" data-test-id=\"table-scroll-wrapper-boundary-start\"></span><table> <tr> <td><strong>Segment</strong></td> <td><strong>Revenue (mill. USD) </strong></td> <td><strong>Share</strong></td> </tr> <tr> <td><strong>Diabetes Care</strong></td> <td><strong>32,711</strong></td> <td><strong>67%</strong></td> </tr> <tr> <td><em>GLP-1</em></td> <td>24,039</td> <td><em>49%</em></td> </tr> <tr> <td><em>Insulin</em></td> <td>8,392</td> <td><em>17%</em></td> </tr> <tr> <td><strong>Obesity Care</strong></td> <td><strong>13,006</strong></td> <td><strong>27%</strong></td> </tr> <tr> <td><em>Wegovy</em></td> <td>12,494</td> <td><em>26%</em></td> </tr> <tr> <td><em>Saxenda</em></td> <td>512</td> <td><em>1%</em></td> </tr> <tr> <td><strong>Total Rare Diseases</strong></td> <td><strong>3,097</strong></td> <td><strong>6%</strong></td> </tr> </table> <span data-intersection-boundary=\"end\" data-test-id=\"table-scroll-wrapper-boundary-end\"></span></span><button type=\"button\" class=\"sa-table-enlarge-button\">Click to enlarge</button> </div> <p class=\"paywall-full-content\">Both companies dominate the Diabetes and Obesity Care market. According to Novo Nordisk, they currently have a global market share of 47% in the GLP-1 diabetes and obesity market.</p> <p class=\"paywall-full-content\"><figure class=\"regular-img-figure paywall-full-content\" contenteditable=\"false\"><picture> <img src=\"https://static.seekingalpha.com/uploads/2026/2/27/51058349-17722032781683018.png?io=w640\" alt=\"Novo Global GLP-1 Diabetes and Obesity Market Share\" contenteditable=\"false\" width=\"640\" height=\"532\" loading=\"lazy\" srcset=\"https://static.seekingalpha.com/uploads/2026/2/27/51058349-17722032781683018.png?io=w640 640w,https://static.seekingalpha.com/uploads/2026/2/27/51058349-17722032781683018.png?io=w480 480w,https://static.seekingalpha.com/uploads/2026/2/27/51058349-17722032781683018.png?io=w320 320w,https://static.seekingalpha.com/uploads/2026/2/27/51058349-17722032781683018.png?io=w240 240w\" sizes=\"(max-width: 767px) calc(100vw - 36px), (max-width: 1023px) calc(100vw - 180px), 552px\"> </picture><figcaption><p class=\"item-caption\">Novo Global GLP-1 Diabetes and Obesity Market Share <span>(Novo Q4 Earnings)</span></p></figcaption></figure></p> <p class=\"paywall-full-content\">Eli Lilly, on the other hand, published a Mounjaro (diabetes) and Zepbound (obesity) US market share of ~45% and ~60%, respectively, in their <a href=\"https://investor.lilly.com/static-files/45a92498-43d0-4e2d-a4e6-a9131841cfd6\" rel=\"nofollow\">latest earnings</a>.</p> <p class=\"paywall-full-content\"><figure class=\"regular-img-figure paywall-full-content\" contenteditable=\"false\"><span><a href=\"https://static.seekingalpha.com/uploads/2026/2/27/51058349-17722034971841307_origin.png\" rel=\"lightbox\" data-width=\"1199\" data-height=\"480\" data-og-image-twitter_small_card=\"true\" data-og-image-twitter_large_card=\"true\" data-og-image-twitter_image_post=\"true\" data-og-image-msn=\"true\" data-og-image-facebook=\"true\" data-og-image-google_news=\"true\" data-og-image-google_plus=\"true\" data-og-image-linkedin=\"true\" role=\"button\" aria-label=\"Expand image into lightbox view\"><img src=\"https://static.seekingalpha.com/uploads/2026/2/27/51058349-17722034971841307_origin.png?io=w640\" alt=\"Q4 Mounjaro US Sales and Market Share\" width=\"640\" height=\"256\" contenteditable=\"false\" loading=\"lazy\" srcset=\"https://static.seekingalpha.com/uploads/2026/2/27/51058349-17722034971841307_origin.png?io=w640 640w,https://static.seekingalpha.com/uploads/2026/2/27/51058349-17722034971841307_origin.png?io=w480 480w,https://static.seekingalpha.com/uploads/2026/2/27/51058349-17722034971841307_origin.png?io=w320 320w,https://static.seekingalpha.com/uploads/2026/2/27/51058349-17722034971841307_origin.png?io=w240 240w\" sizes=\"(max-width: 767px) calc(100vw - 36px), (max-width: 1023px) calc(100vw - 180px), 552px\"></a></span><figcaption><p class=\"item-caption\">Q4 Mounjaro US Sales and Market Share <span>(Lilly Q4 Earnings)</span></p></figcaption></figure><figure class=\"regular-img-figure paywall-full-content\" contenteditable=\"false\"><span><a href=\"https://static.seekingalpha.com/uploads/2026/2/27/51058349-17722035625468833_origin.png\" rel=\"lightbox\" data-width=\"1197\" data-height=\"474\" data-og-image-twitter_small_card=\"true\" data-og-image-twitter_large_card=\"true\" data-og-image-twitter_image_post=\"true\" data-og-image-msn=\"true\" data-og-image-facebook=\"true\" data-og-image-google_news=\"true\" data-og-image-google_plus=\"true\" data-og-image-linkedin=\"true\" role=\"button\" aria-label=\"Expand image into lightbox view\"><img src=\"https://static.seekingalpha.com/uploads/2026/2/27/51058349-17722035625468833_origin.png?io=w640\" alt=\"Q4 Zepbound US Sales and Market Share\" width=\"640\" height=\"253\" contenteditable=\"false\" loading=\"lazy\" srcset=\"https://static.seekingalpha.com/uploads/2026/2/27/51058349-17722035625468833_origin.png?io=w640 640w,https://static.seekingalpha.com/uploads/2026/2/27/51058349-17722035625468833_origin.png?io=w480 480w,https://static.seekingalpha.com/uploads/2026/2/27/51058349-17722035625468833_origin.png?io=w320 320w,https://static.seekingalpha.com/uploads/2026/2/27/51058349-17722035625468833_origin.png?io=w240 240w\" sizes=\"(max-width: 767px) calc(100vw - 36px), (max-width: 1023px) calc(100vw - 180px), 552px\"></a></span><figcaption><p class=\"item-caption\">Q4 Zepbound US Sales and Market Share <span>(Lilly Q4 Earnings)</span></p></figcaption></figure></p> <p class=\"paywall-full-content\">In terms of revenue and market share, the companies appear to be fairly evenly matched in these two key markets, but how is this reflected in the current valuation?</p> <p class=\"paywall-full-content\">For our valuation model, we first need some general assumptions.</p> <h2 class=\"paywall-full-content\"> </h2> <div class=\"table-responsive paywall-full-content\"> <span class=\"sa-table-scroll-wrapper sa-hide-scrollbar\"><span data-intersection-boundary=\"start\" data-test-id=\"table-scroll-wrapper-boundary-start\"></span><table> <tr> <td><strong>Metric</strong></td> <td><strong>Eli Lilly</strong></td> <td><strong>Novo Nordisk</strong></td> </tr> <tr> <td>EBIT Margin</td> <td>Current rate of 46%</td> <td>Average of the last 4 years: 44%</td> </tr> <tr> <td>Cash Conversion</td> <td>The best rate of the last 4 years: 2022: 57%</td> <td>Average of the last 4 years:76%</td> </tr> <tr> <td>WACC</td> <td colspan=\"2\">9%</td> </tr> <tr> <td>Perpetuity Growth</td> <td colspan=\"2\">3.5%</td> </tr> </table> <span data-intersection-boundary=\"end\" data-test-id=\"table-scroll-wrapper-boundary-end\"></span></span><button type=\"button\" class=\"sa-table-enlarge-button\">Click to enlarge</button> </div> <h4 class=\"paywall-full-content\">Required Growth</h4> <p class=\"paywall-full-content\">Out of these assumptions and the current market caps, we can calculate the required growth rate needed to justify the current valuation for each company.</p> <h5 class=\"paywall-full-content\">Eli Lilly</h5> <p class=\"paywall-full-content\"><figure class=\"regular-img-figure paywall-full-content\" contenteditable=\"false\"><span><a href=\"https://static.seekingalpha.com/uploads/2026/2/27/51058349-17721987924276133_origin.png\" rel=\"lightbox\" data-width=\"3822\" data-height=\"753\" data-og-image-twitter_small_card=\"false\" data-og-image-twitter_large_card=\"false\" data-og-image-twitter_image_post=\"false\" data-og-image-msn=\"false\" data-og-image-facebook=\"false\" data-og-image-google_news=\"false\" data-og-image-google_plus=\"false\" data-og-image-linkedin=\"false\" role=\"button\" aria-label=\"Expand image into lightbox view\"><img src=\"https://static.seekingalpha.com/uploads/2026/2/27/51058349-17721987924276133_origin.png?io=w640\" alt=\"Eli Lilly Discounted Cash Flow Analysis - Required Growth (I)\" width=\"640\" height=\"126\" contenteditable=\"false\" loading=\"lazy\" srcset=\"https://static.seekingalpha.com/uploads/2026/2/27/51058349-17721987924276133_origin.png?io=w640 640w,https://static.seekingalpha.com/uploads/2026/2/27/51058349-17721987924276133_origin.png?io=w480 480w,https://static.seekingalpha.com/uploads/2026/2/27/51058349-17721987924276133_origin.png?io=w320 320w,https://static.seekingalpha.com/uploads/2026/2/27/51058349-17721987924276133_origin.png?io=w240 240w\" sizes=\"(max-width: 767px) calc(100vw - 36px), (max-width: 1023px) calc(100vw - 180px), 552px\"></a></span><figcaption><p class=\"item-caption\">Eli Lilly Discounted Cash Flow Analysis - Required Growth (I) <span>(own assumptions)</span></p></figcaption></figure><figure class=\"regular-img-figure paywall-full-content\" contenteditable=\"false\"><span><a href=\"https://static.seekingalpha.com/uploads/2026/2/27/51058349-17721987926552494_origin.png\" rel=\"lightbox\" data-width=\"3822\" data-height=\"1500\" data-og-image-twitter_small_card=\"true\" data-og-image-twitter_large_card=\"true\" data-og-image-twitter_image_post=\"true\" data-og-image-msn=\"true\" data-og-image-facebook=\"true\" data-og-image-google_news=\"true\" data-og-image-google_plus=\"true\" data-og-image-linkedin=\"true\" role=\"button\" aria-label=\"Expand image into lightbox view\"><img src=\"https://static.seekingalpha.com/uploads/2026/2/27/51058349-17721987926552494_origin.png?io=w640\" alt=\"Eli Lilly Discounted Cash Flow Analysis - Required Growth (I)\" width=\"640\" height=\"251\" contenteditable=\"false\" loading=\"lazy\" srcset=\"https://static.seekingalpha.com/uploads/2026/2/27/51058349-17721987926552494_origin.png?io=w640 640w,https://static.seekingalpha.com/uploads/2026/2/27/51058349-17721987926552494_origin.png?io=w480 480w,https://static.seekingalpha.com/uploads/2026/2/27/51058349-17721987926552494_origin.png?io=w320 320w,https://static.seekingalpha.com/uploads/2026/2/27/51058349-17721987926552494_origin.png?io=w240 240w\" sizes=\"(max-width: 767px) calc(100vw - 36px), (max-width: 1023px) calc(100vw - 180px), 552px\"></a></span><figcaption><p class=\"item-caption\">Eli Lilly Discounted Cash Flow Analysis - Required Growth (II) <span>(own assumptions)</span></p></figcaption></figure></p> <p class=\"paywall-full-content\">Considering our assumptions, Eli Lilly needs to achieve an average growth rate of 21.7% per year for the next eight years to justify their current market cap of $913 billion.</p> <h5 class=\"paywall-full-content\">Novo Nordisk</h5> <p class=\"paywall-full-content\"><figure class=\"regular-img-figure paywall-full-content\" contenteditable=\"false\"><span><a href=\"https://static.seekingalpha.com/uploads/2026/2/27/51058349-17721988019426782_origin.png\" rel=\"lightbox\" data-width=\"3822\" data-height=\"753\" data-og-image-twitter_small_card=\"false\" data-og-image-twitter_large_card=\"false\" data-og-image-twitter_image_post=\"false\" data-og-image-msn=\"false\" data-og-image-facebook=\"false\" data-og-image-google_news=\"false\" data-og-image-google_plus=\"false\" data-og-image-linkedin=\"false\" role=\"button\" aria-label=\"Expand image into lightbox view\"><img src=\"https://static.seekingalpha.com/uploads/2026/2/27/51058349-17721988019426782_origin.png?io=w640\" alt=\"Novo Nordisk Discounted Cash Flow Analysis - Required Growth (I)\" width=\"640\" height=\"126\" contenteditable=\"false\" loading=\"lazy\" srcset=\"https://static.seekingalpha.com/uploads/2026/2/27/51058349-17721988019426782_origin.png?io=w640 640w,https://static.seekingalpha.com/uploads/2026/2/27/51058349-17721988019426782_origin.png?io=w480 480w,https://static.seekingalpha.com/uploads/2026/2/27/51058349-17721988019426782_origin.png?io=w320 320w,https://static.seekingalpha.com/uploads/2026/2/27/51058349-17721988019426782_origin.png?io=w240 240w\" sizes=\"(max-width: 767px) calc(100vw - 36px), (max-width: 1023px) calc(100vw - 180px), 552px\"></a></span><figcaption><p class=\"item-caption\">Novo Nordisk Discounted Cash Flow Analysis - Required Growth (I) <span>(own assumptions)</span></p></figcaption></figure><figure class=\"regular-img-figure paywall-full-content\" contenteditable=\"false\"><span><a href=\"https://static.seekingalpha.com/uploads/2026/2/27/51058349-17721988022840123_origin.png\" rel=\"lightbox\" data-width=\"3822\" data-height=\"1500\" data-og-image-twitter_small_card=\"true\" data-og-image-twitter_large_card=\"true\" data-og-image-twitter_image_post=\"true\" data-og-image-msn=\"true\" data-og-image-facebook=\"true\" data-og-image-google_news=\"true\" data-og-image-google_plus=\"true\" data-og-image-linkedin=\"true\" role=\"button\" aria-label=\"Expand image into lightbox view\"><img src=\"https://static.seekingalpha.com/uploads/2026/2/27/51058349-17721988022840123_origin.png?io=w640\" alt=\"Novo Nordisk Discounted Cash Flow Analysis - Required Growth (I)\" width=\"640\" height=\"251\" contenteditable=\"false\" loading=\"lazy\" srcset=\"https://static.seekingalpha.com/uploads/2026/2/27/51058349-17721988022840123_origin.png?io=w640 640w,https://static.seekingalpha.com/uploads/2026/2/27/51058349-17721988022840123_origin.png?io=w480 480w,https://static.seekingalpha.com/uploads/2026/2/27/51058349-17721988022840123_origin.png?io=w320 320w,https://static.seekingalpha.com/uploads/2026/2/27/51058349-17721988022840123_origin.png?io=w240 240w\" sizes=\"(max-width: 767px) calc(100vw - 36px), (max-width: 1023px) calc(100vw - 180px), 552px\"></a></span><figcaption><p class=\"item-caption\">Novo Nordisk Discounted Cash Flow Analysis - Required Growth (II) <span>(own assumptions)</span></p></figcaption></figure></p> <p class=\"paywall-full-content\">Novo Nordisk, on the other hand, needs no additional growth for the featured time frame to justify their current valuation.</p> <p class=\"paywall-full-content\">But like mentioned before, the market is currently expecting Lilly to outgrow Novo in the next few years, so let's try to incorporate this into the valuation models.</p> <h4 class=\"paywall-full-content\">Realistic Growth</h4> <p class=\"paywall-full-content\">To get realistic growth rates for Lilly, I weighted the expected market growth rate of each business segment with the current revenue share.</p> <h5 class=\"paywall-full-content\">Eli Lilly</h5> <div class=\"table-responsive paywall-full-content\"> <span class=\"sa-table-scroll-wrapper sa-hide-scrollbar\"><span data-intersection-boundary=\"start\" data-test-id=\"table-scroll-wrapper-boundary-start\"></span><table> <colgroup> <col span=\"2\"> <col> <col> </colgroup> <tr> <td><strong>Segment</strong></td> <td><strong>Revenue (mill. USD)</strong></td> <td><strong>Share</strong></td> <td><strong>Expected Market CAGR</strong></td> </tr> <tr> <td>Diabetes Care</td> <td>34,679</td> <td>53%</td> <td><a href=\"https://www.fortunebusinessinsights.com/industry-reports/diabetes-drugs-market-100570#:~:text=KEY%20MARKET%20INSIGHTS&amp;text=The%20global%20diabetes%20drugs%20market,12.7%25%20during%20the%20forecast%20period.\" rel=\"nofollow noopener\">12%</a></td> </tr> <tr> <td>Obesity care (Zepbound)</td> <td>13,542</td> <td>21%</td> <td><a href=\"https://www.fortunebusinessinsights.com/anti-obesity-drugs-market-104783#:~:text=The%20global%20anti%2Dobesity%20drugs,period%20%282024%2D2032%29.\" rel=\"nofollow noopener noopener noopener\">29%</a></td> </tr> <tr> <td>Immunology</td> <td>5,247</td> <td>8%</td> <td><a href=\"https://www.precedenceresearch.com/immunology-market#:~:text=The%20global%20immunology%20market%20size,10.20%25%20from%202025%20to%202034.\" rel=\"nofollow noopener\">10%</a></td> </tr> <tr> <td>Neuroscience</td> <td>1,391</td> <td>2%</td> <td><a href=\"https://www.grandviewresearch.com/industry-analysis/neuroscience-market#:~:text=The%20global%20neuroscience%20market%20size,5.56%25%20from%202023%20to%202030.\" rel=\"nofollow noopener\">5%</a></td> </tr> <tr> <td>Oncology</td> <td>9,376</td> <td>14%</td> <td><a href=\"https://www.towardshealthcare.com/insights/immuno-oncology-drugs-market-sizing#:~:text=The%20global%20immuno%2Doncology%20drugs,16.34%25%20between%202025%20and%202034.\" rel=\"nofollow noopener\">16%</a></td> </tr> <tr> <td>Other</td> <td>944</td> <td>1%</td> <td>0%</td> </tr> </table> <span data-intersection-boundary=\"end\" data-test-id=\"table-scroll-wrapper-boundary-end\"></span></span><button type=\"button\" class=\"sa-table-enlarge-button\">Click to enlarge</button> </div> <p class=\"paywall-full-content\">Weighted Anticipated Growth: 15.6%</p> <p class=\"paywall-full-content\">If we apply this expected growth rate to our DCF, Eli Lilly seems to currently be overvalued by up to 32%.</p> <p class=\"paywall-full-content\"><figure class=\"regular-img-figure paywall-full-content\" contenteditable=\"false\"><span><a href=\"https://static.seekingalpha.com/uploads/2026/2/27/51058349-1772198825243967_origin.png\" rel=\"lightbox\" data-width=\"3822\" data-height=\"753\" data-og-image-twitter_small_card=\"false\" data-og-image-twitter_large_card=\"false\" data-og-image-twitter_image_post=\"false\" data-og-image-msn=\"false\" data-og-image-facebook=\"false\" data-og-image-google_news=\"false\" data-og-image-google_plus=\"false\" data-og-image-linkedin=\"false\" role=\"button\" aria-label=\"Expand image into lightbox view\"><img src=\"https://static.seekingalpha.com/uploads/2026/2/27/51058349-1772198825243967_origin.png?io=w640\" alt=\"Eli Lilly Discounted Cash Flow Analysis - Realistic Growth (I)\" width=\"640\" height=\"126\" contenteditable=\"false\" loading=\"lazy\" srcset=\"https://static.seekingalpha.com/uploads/2026/2/27/51058349-1772198825243967_origin.png?io=w640 640w,https://static.seekingalpha.com/uploads/2026/2/27/51058349-1772198825243967_origin.png?io=w480 480w,https://static.seekingalpha.com/uploads/2026/2/27/51058349-1772198825243967_origin.png?io=w320 320w,https://static.seekingalpha.com/uploads/2026/2/27/51058349-1772198825243967_origin.png?io=w240 240w\" sizes=\"(max-width: 767px) calc(100vw - 36px), (max-width: 1023px) calc(100vw - 180px), 552px\"></a></span><figcaption><p class=\"item-caption\">Eli Lilly Discounted Cash Flow Analysis - Realistic Growth (I) <span>(own assumptions)</span></p></figcaption></figure><figure class=\"regular-img-figure paywall-full-content\" contenteditable=\"false\"><span><a href=\"https://static.seekingalpha.com/uploads/2026/2/27/51058349-17722053680982301_origin.png\" rel=\"lightbox\" data-width=\"3822\" data-height=\"1500\" data-og-image-twitter_small_card=\"true\" data-og-image-twitter_large_card=\"true\" data-og-image-twitter_image_post=\"true\" data-og-image-msn=\"true\" data-og-image-facebook=\"true\" data-og-image-google_news=\"true\" data-og-image-google_plus=\"true\" data-og-image-linkedin=\"true\" role=\"button\" aria-label=\"Expand image into lightbox view\"><img src=\"https://static.seekingalpha.com/uploads/2026/2/27/51058349-17722053680982301_origin.png?io=w640\" alt=\"Eli Lilly Discounted Cash Flow Analysis - Realistic Growth (I)\" width=\"640\" height=\"251\" contenteditable=\"true\" data-width=\"640\" data-height=\"251\" loading=\"lazy\" srcset=\"https://static.seekingalpha.com/uploads/2026/2/27/51058349-17722053680982301_origin.png?io=w640 640w,https://static.seekingalpha.com/uploads/2026/2/27/51058349-17722053680982301_origin.png?io=w480 480w,https://static.seekingalpha.com/uploads/2026/2/27/51058349-17722053680982301_origin.png?io=w320 320w,https://static.seekingalpha.com/uploads/2026/2/27/51058349-17722053680982301_origin.png?io=w240 240w\" sizes=\"(max-width: 767px) calc(100vw - 36px), (max-width: 1023px) calc(100vw - 180px), 552px\"></a></span><figcaption><p class=\"item-caption\">Eli Lilly Discounted Cash Flow Analysis - Realistic Growth (II) <span>(own assumptions)</span></p></figcaption></figure></p> <h5 class=\"paywall-full-content\">Novo Nordisk</h5> <p class=\"paywall-full-content\">To reflect the current pessimism, I assumed no growth at all for the obesity division in the first scenario of Novo. Additionally, I also only expected a growth rate of 10% in the Diabetes segment—compared to the expected market rate of 12%.</p> <div class=\"table-responsive paywall-full-content\"> <span class=\"sa-table-scroll-wrapper sa-hide-scrollbar\"><span data-intersection-boundary=\"start\" data-test-id=\"table-scroll-wrapper-boundary-start\"></span><table> <tr> <td><strong>Segment</strong></td> <td><strong>Revenue (mill. DKK)</strong></td> <td><strong>Share</strong></td> <td><strong> Anticipated CAGR </strong></td> </tr> <tr> <td>Diabetes Care</td> <td>207,109</td> <td>67%</td> <td><p>10%</p></td> </tr> <tr> <td>Obesity Care</td> <td>82,347</td> <td>27%</td> <td>0%</td> </tr> <tr> <td>Total Rare Diseases</td> <td>19,608</td> <td>6%</td> <td>0%</td> </tr> </table> <span data-intersection-boundary=\"end\" data-test-id=\"table-scroll-wrapper-boundary-end\"></span></span><button type=\"button\" class=\"sa-table-enlarge-button\">Click to enlarge</button> </div> <p class=\"paywall-full-content\">Weighted Anticipated Growth: 6.7%</p> <p class=\"paywall-full-content\">Even with these rather conservative assumptions, Novo Nordisk seems to currently be undervalued by up to 60%.</p> <p class=\"paywall-full-content\"><figure class=\"regular-img-figure paywall-full-content\" contenteditable=\"false\"><span><a href=\"https://static.seekingalpha.com/uploads/2026/2/27/51058349-17721988354434044_origin.png\" rel=\"lightbox\" data-width=\"3822\" data-height=\"753\" data-og-image-twitter_small_card=\"false\" data-og-image-twitter_large_card=\"false\" data-og-image-twitter_image_post=\"false\" data-og-image-msn=\"false\" data-og-image-facebook=\"false\" data-og-image-google_news=\"false\" data-og-image-google_plus=\"false\" data-og-image-linkedin=\"false\" role=\"button\" aria-label=\"Expand image into lightbox view\"><img src=\"https://static.seekingalpha.com/uploads/2026/2/27/51058349-17721988354434044_origin.png?io=w640\" alt=\"Novo Nordisk Discounted Cash Flow Analysis - Realistic Growth (I)\" width=\"640\" height=\"126\" contenteditable=\"false\" loading=\"lazy\" srcset=\"https://static.seekingalpha.com/uploads/2026/2/27/51058349-17721988354434044_origin.png?io=w640 640w,https://static.seekingalpha.com/uploads/2026/2/27/51058349-17721988354434044_origin.png?io=w480 480w,https://static.seekingalpha.com/uploads/2026/2/27/51058349-17721988354434044_origin.png?io=w320 320w,https://static.seekingalpha.com/uploads/2026/2/27/51058349-17721988354434044_origin.png?io=w240 240w\" sizes=\"(max-width: 767px) calc(100vw - 36px), (max-width: 1023px) calc(100vw - 180px), 552px\"></a></span><figcaption><p class=\"item-caption\">Novo Nordisk Discounted Cash Flow Analysis - Realistic Growth (I) <span>(own assumptions)</span></p></figcaption></figure><figure class=\"regular-img-figure paywall-full-content\" contenteditable=\"false\"><span><a href=\"https://static.seekingalpha.com/uploads/2026/2/27/51058349-17721988356880953_origin.png\" rel=\"lightbox\" data-width=\"3822\" data-height=\"1500\" data-og-image-twitter_small_card=\"true\" data-og-image-twitter_large_card=\"true\" data-og-image-twitter_image_post=\"true\" data-og-image-msn=\"true\" data-og-image-facebook=\"true\" data-og-image-google_news=\"true\" data-og-image-google_plus=\"true\" data-og-image-linkedin=\"true\" role=\"button\" aria-label=\"Expand image into lightbox view\"><img src=\"https://static.seekingalpha.com/uploads/2026/2/27/51058349-17721988356880953_origin.png?io=w640\" alt=\"Novo Nordisk Discounted Cash Flow Analysis - Realistic Growth (I)\" width=\"640\" height=\"251\" contenteditable=\"false\" loading=\"lazy\" srcset=\"https://static.seekingalpha.com/uploads/2026/2/27/51058349-17721988356880953_origin.png?io=w640 640w,https://static.seekingalpha.com/uploads/2026/2/27/51058349-17721988356880953_origin.png?io=w480 480w,https://static.seekingalpha.com/uploads/2026/2/27/51058349-17721988356880953_origin.png?io=w320 320w,https://static.seekingalpha.com/uploads/2026/2/27/51058349-17721988356880953_origin.png?io=w240 240w\" sizes=\"(max-width: 767px) calc(100vw - 36px), (max-width: 1023px) calc(100vw - 180px), 552px\"></a></span><figcaption><p class=\"item-caption\">Novo Nordisk Discounted Cash Flow Analysis - Realistic Growth (II) <span>(own assumptions)</span></p></figcaption></figure></p> <p class=\"paywall-full-content\">For our second scenario and as our \"Bull-Case\" for Novo Nordisk, I anticipated an Obesity Care growth rate of 10% p.a.—still only 1/3 of the expected market rate.</p> <div class=\"table-responsive paywall-full-content\"> <span class=\"sa-table-scroll-wrapper sa-hide-scrollbar\"><span data-intersection-boundary=\"start\" data-test-id=\"table-scroll-wrapper-boundary-start\"></span><table> <tr> <td><strong>Segment</strong></td> <td><strong>Revenue (mill. DKK)</strong></td> <td><strong>Share</strong></td> <td><strong> Anticipated CAGR </strong></td> </tr> <tr> <td>Diabetes Care</td> <td>207,109</td> <td>67%</td> <td><p>10%</p></td> </tr> <tr> <td>Obesity Care</td> <td>82,347</td> <td>27%</td> <td>10%</td> </tr> <tr> <td>Total Rare Diseases</td> <td>19,608</td> <td>6%</td> <td>0%</td> </tr> </table> <span data-intersection-boundary=\"end\" data-test-id=\"table-scroll-wrapper-boundary-end\"></span></span><button type=\"button\" class=\"sa-table-enlarge-button\">Click to enlarge</button> </div> <p class=\"paywall-full-content\">Weighted Anticipated Growth: 9.4%</p> <p class=\"paywall-full-content\">With these growth rates, the potential upside improves to up to 92% for Novo Nordisk.</p> <p class=\"paywall-full-content\"><figure class=\"regular-img-figure paywall-full-content\" contenteditable=\"false\"><span><a href=\"https://static.seekingalpha.com/uploads/2026/2/27/51058349-17721988420342872_origin.png\" rel=\"lightbox\" data-width=\"3822\" data-height=\"753\" data-og-image-twitter_small_card=\"false\" data-og-image-twitter_large_card=\"false\" data-og-image-twitter_image_post=\"false\" data-og-image-msn=\"false\" data-og-image-facebook=\"false\" data-og-image-google_news=\"false\" data-og-image-google_plus=\"false\" data-og-image-linkedin=\"false\" role=\"button\" aria-label=\"Expand image into lightbox view\"><img src=\"https://static.seekingalpha.com/uploads/2026/2/27/51058349-17721988420342872_origin.png?io=w640\" alt=\"Novo Nordisk Discounted Cash Flow Analysis - Realistic Growth (I)\" width=\"640\" height=\"126\" contenteditable=\"false\" loading=\"lazy\" srcset=\"https://static.seekingalpha.com/uploads/2026/2/27/51058349-17721988420342872_origin.png?io=w640 640w,https://static.seekingalpha.com/uploads/2026/2/27/51058349-17721988420342872_origin.png?io=w480 480w,https://static.seekingalpha.com/uploads/2026/2/27/51058349-17721988420342872_origin.png?io=w320 320w,https://static.seekingalpha.com/uploads/2026/2/27/51058349-17721988420342872_origin.png?io=w240 240w\" sizes=\"(max-width: 767px) calc(100vw - 36px), (max-width: 1023px) calc(100vw - 180px), 552px\"></a></span><figcaption><p class=\"item-caption\">Novo Nordisk Discounted Cash Flow Analysis - Realistic Growth (III) <span>(own assumptions)</span></p></figcaption></figure><figure class=\"regular-img-figure paywall-full-content\" contenteditable=\"false\"><span><a href=\"https://static.seekingalpha.com/uploads/2026/2/27/51058349-17721988420844944_origin.png\" rel=\"lightbox\" data-width=\"3822\" data-height=\"1500\" data-og-image-twitter_small_card=\"true\" data-og-image-twitter_large_card=\"true\" data-og-image-twitter_image_post=\"true\" data-og-image-msn=\"true\" data-og-image-facebook=\"true\" data-og-image-google_news=\"true\" data-og-image-google_plus=\"true\" data-og-image-linkedin=\"true\" role=\"button\" aria-label=\"Expand image into lightbox view\"><img src=\"https://static.seekingalpha.com/uploads/2026/2/27/51058349-17721988420844944_origin.png?io=w640\" alt=\"Novo Nordisk Discounted Cash Flow Analysis - Realistic Growth (IV)\" width=\"640\" height=\"251\" contenteditable=\"false\" loading=\"lazy\" srcset=\"https://static.seekingalpha.com/uploads/2026/2/27/51058349-17721988420844944_origin.png?io=w640 640w,https://static.seekingalpha.com/uploads/2026/2/27/51058349-17721988420844944_origin.png?io=w480 480w,https://static.seekingalpha.com/uploads/2026/2/27/51058349-17721988420844944_origin.png?io=w320 320w,https://static.seekingalpha.com/uploads/2026/2/27/51058349-17721988420844944_origin.png?io=w240 240w\" sizes=\"(max-width: 767px) calc(100vw - 36px), (max-width: 1023px) calc(100vw - 180px), 552px\"></a></span><figcaption><p class=\"item-caption\">Novo Nordisk Discounted Cash Flow Analysis - Realistic Growth (IV) <span>(own assumptions)</span></p></figcaption></figure></p> <h2 class=\"paywall-full-content\">Risks To Consider</h2> <p class=\"paywall-full-content\">Like mentioned above, the weight loss market is expected to reach a TAM of $67 billion by 2034. This will certainly lead to competitors vying for market share in the future. Any breakthrough drug by competition could destroy the duopoly between Novo and Lilly and, in turn, damage the top- and bottom-line for both companies.</p> <p class=\"paywall-full-content\">While these new drugs are screened heavily before approval, potential long-term and rare side effects are hard to detect. They are now used by millions of people for the first time, which might lead to unexpected complications.</p> <p class=\"paywall-full-content\">As shown in the revenue table, both companies, but especially Novo, are very reliant on their GLP-1 medication. Should any regulatory change or a safety concern emerge with this drug type in particular, Novo would be impacted more than diversified peers.</p> <h2 class=\"paywall-full-content\">Conclusion</h2> <p class=\"paywall-full-content\">The valuation gap between Lilly and Novo is an exaggeration. Novo appears to be significantly undervalued, whereas Lilly appears to be priced for perfection right now, even after using more optimistic assumptions for Lilly and conservative ones for Novo.</p> <p class=\"paywall-full-content\">At current prices, Novo Nordisk is a Strong Buy. Their dominant position in the Diabetes market alone justifies higher valuations. This, paired with the still promising Obesity market as well as a potential undervaluation of up to 92%, makes it a compelling pick right now.</p> <p class=\"paywall-full-content\">Eli Lilly is a high-quality company that is very well positioned to benefit from the growing obesity market. Their other segments—especially Oncology and Immunology—also seem promising. At current prices, I, however, believe that there are better opportunities in the market, which is why I rate Lilly a Hold.</p> <div class=\"before_last_paragraph-piano-placeholder paywall-full-content\"></div> <p class=\"paywall-full-content\">Editor's Note: This article discusses one or more securities that do not trade on a major U.S. exchange. Please be aware of the risks associated with these stocks.</p>",
            "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2195158078/image_2195158078.jpg",
            "link": "https://seekingalpha.com/article/4876511-eli-lilly-vs-novo-nordisk-the-valuation-gap-is-unreasonable",
            "pub_date": "2026-02-28 04:20:57",
            "source": "seekalpha_articles",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "4876510",
            "title": "CoreWeave: From Growth Story To Capital Story",
            "description": "<p data-eci=\"true\"><figure class=\"getty-figure\" data-type=\"getty-image\"><picture> <img src=\"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2254337477/image_2254337477.jpg?io=getty-c-w630\" alt=\"Data Center Server Racks with Purple Neon Lights in Dark Room\" data-id=\"2254337477\" data-type=\"getty-image\" width=\"1536\" height=\"1024\" srcset=\"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2254337477/image_2254337477.jpg?io=getty-c-w1536 1536w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2254337477/image_2254337477.jpg?io=getty-c-w1280 1280w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2254337477/image_2254337477.jpg?io=getty-c-w1080 1080w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2254337477/image_2254337477.jpg?io=getty-c-w750 750w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2254337477/image_2254337477.jpg?io=getty-c-w640 640w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2254337477/image_2254337477.jpg?io=getty-c-w480 480w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2254337477/image_2254337477.jpg?io=getty-c-w320 320w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2254337477/image_2254337477.jpg?io=getty-c-w240 240w\" sizes=\"(max-width: 767px) calc(100vw - 36px), (max-width: 1023px) calc(100vw - 132px), (max-width: 1199px) calc(100vw - 666px), (max-width: 1307px) calc(100vw - 708px), 600px\" fetchpriority=\"high\"> </picture><figcaption><p class=\"item-caption\"> </p> <p class=\"item-credits\">asbe/iStock via Getty Images</p></figcaption></figure></p> <div class=\"inline_ad_placeholder\"></div> <h2>Investment Thesis</h2> <p>CoreWeave, Inc. (<span class=\"ticker-hover-wrapper\"><a href=\"https://seekingalpha.com/symbol/CRWV\" title=\"CoreWeave, Inc.\">CRWV</a></span>) just had one of the best infrastructure growth quarters in cloud history, growing revenues by 110% and growing its backlog to $66.8 billion. Even though CRWV is down since my <a href=\"https://seekingalpha.com/article/4863334-why-coreweave-suddenly-de-risked\" class=\"paywall-full-content\">last coverage</a><span class=\"paywall-full-content\">, the post-earnings </span><a href=\"https://seekingalpha.com/news/4558575-biggest-stock-movers-friday-nflx-xyz-dell-and-more\" class=\"paywall-full-content\">drop</a><span class=\"paywall-full-content\"> is not due to weakening demand but due to the magnitude of the required CapEx in 2026 and the rise in interest expense, which has changed the narrative from a growth play to a capital allocation play.</span></p> <p class=\"paywall-full-content\">The fundamentals are still very favorable if management can successfully execute on improving margins and converting the backlog. This is a high-upside AI infrastructure compounder, but the key now is the timing and the <a href=\"https://seekingalpha.com/symbol/CRWV/balance-sheet\">balance sheet</a>.</p> <p class=\"paywall-full-content\"><figure class=\"sa-widget sa-ycharts paywall-full-content\"><img src=\"https://static.seekingalpha.com/uploads/2026/2/27/saupload_0e7cd207272d5e7b08c2214ba26ee92f.png?io=w640\" alt=\"Chart\" width=\"635\" height=\"366\" class=\"sa-ycharts-img\" data-width=\"635\" data-height=\"366\" loading=\"lazy\" srcset=\"https://static.seekingalpha.com/uploads/2026/2/27/saupload_0e7cd207272d5e7b08c2214ba26ee92f.png?io=w480 480w,https://static.seekingalpha.com/uploads/2026/2/27/saupload_0e7cd207272d5e7b08c2214ba26ee92f.png?io=w320 320w,https://static.seekingalpha.com/uploads/2026/2/27/saupload_0e7cd207272d5e7b08c2214ba26ee92f.png?io=w240 240w\" sizes=\"(max-width: 767px) calc(100vw - 36px), (max-width: 1023px) calc(100vw - 180px), 552px\"><figcaption>Data by <a href=\"https://ycharts.com\" rel=\"nofollow\">YCharts</a></figcaption></figure></p> <h2 class=\"paywall-full-content\">From Backlog Euphoria to Balance Sheet Reality</h2> <p class=\"paywall-full-content\">CoreWeave’s Q4 earnings were the type of report that can be considered technically strong but also emotionally uncomfortable at the same time. They beat with <a href=\"https://seekingalpha.com/news/4558179-coreweave-gaap-eps-of-0_89-misses-by-0_21-revenue-of-1_57b-beats-by-40m\">$1.572 billion</a> of revenue, up 110% YoY, and extended their contracted revenue backlog to <a href=\"https://static.seekingalpha.com/uploads/sa_presentations/248/123248/original.pdf\">$66.8 billion</a>.</p> <p class=\"paywall-full-content\"><figure class=\"regular-img-figure paywall-full-content\" contenteditable=\"false\"><span><a href=\"https://static.seekingalpha.com/uploads/2026/2/27/49853134-17721868655569086_origin.png\" rel=\"lightbox\" data-width=\"2048\" data-height=\"1105\" data-og-image-twitter_small_card=\"true\" data-og-image-twitter_large_card=\"true\" data-og-image-twitter_image_post=\"true\" data-og-image-msn=\"true\" data-og-image-facebook=\"true\" data-og-image-google_news=\"true\" data-og-image-google_plus=\"true\" data-og-image-linkedin=\"true\" role=\"button\" aria-label=\"Expand image into lightbox view\"><img src=\"https://static.seekingalpha.com/uploads/2026/2/27/49853134-17721868655569086_origin.png?io=w640\" alt=\"CRWV\" width=\"640\" height=\"345\" contenteditable=\"false\" loading=\"lazy\" srcset=\"https://static.seekingalpha.com/uploads/2026/2/27/49853134-17721868655569086_origin.png?io=w640 640w,https://static.seekingalpha.com/uploads/2026/2/27/49853134-17721868655569086_origin.png?io=w480 480w,https://static.seekingalpha.com/uploads/2026/2/27/49853134-17721868655569086_origin.png?io=w320 320w,https://static.seekingalpha.com/uploads/2026/2/27/49853134-17721868655569086_origin.png?io=w240 240w\" sizes=\"(max-width: 767px) calc(100vw - 36px), (max-width: 1023px) calc(100vw - 180px), 552px\"></a></span><figcaption><p class=\"item-caption\"><span>Earnings Q4 2025</span></p></figcaption></figure></p> <p class=\"paywall-full-content\">In any other growth story, these two numbers would settle any debate. Yet the stock went down, and I understand why. When a company commits to at least <a href=\"https://seekingalpha.com/article/4875914-coreweave-inc-crwv-q4-2025-earnings-call-transcript\">$30-$35 billion</a> of Capex spending in 2026 while also posting a $452 million GAAP net loss in one quarter, the conversation stops being about the demand curve and starts becoming about the financing curve.</p> <p class=\"paywall-full-content\">My view is quite simple, uncomfortable but very investable if one accepts it. CoreWeave is not being valued on the size of the AI industry. It is being valued on whether it can keep its hypergrowth synchronized with the cost of capital. And today, the market is implying a non-trivial probability that the former will not be synchronized with the latter.</p> <p class=\"paywall-full-content\"><figure class=\"regular-img-figure paywall-full-content\" contenteditable=\"false\"><span><a href=\"https://static.seekingalpha.com/uploads/2026/2/27/49853134-1772186865628448_origin.png\" rel=\"lightbox\" data-width=\"2048\" data-height=\"1106\" data-og-image-twitter_small_card=\"true\" data-og-image-twitter_large_card=\"true\" data-og-image-twitter_image_post=\"true\" data-og-image-msn=\"true\" data-og-image-facebook=\"true\" data-og-image-google_news=\"true\" data-og-image-google_plus=\"true\" data-og-image-linkedin=\"true\" role=\"button\" aria-label=\"Expand image into lightbox view\"><img src=\"https://static.seekingalpha.com/uploads/2026/2/27/49853134-1772186865628448_origin.png?io=w640\" alt=\"CRWV\" width=\"640\" height=\"346\" contenteditable=\"false\" loading=\"lazy\" srcset=\"https://static.seekingalpha.com/uploads/2026/2/27/49853134-1772186865628448_origin.png?io=w640 640w,https://static.seekingalpha.com/uploads/2026/2/27/49853134-1772186865628448_origin.png?io=w480 480w,https://static.seekingalpha.com/uploads/2026/2/27/49853134-1772186865628448_origin.png?io=w320 320w,https://static.seekingalpha.com/uploads/2026/2/27/49853134-1772186865628448_origin.png?io=w240 240w\" sizes=\"(max-width: 767px) calc(100vw - 36px), (max-width: 1023px) calc(100vw - 180px), 552px\"></a></span><figcaption><p class=\"item-caption\"><span>Earnings Q4 2025</span></p></figcaption></figure></p> <p class=\"paywall-full-content\">With regard to operating, the company is continuing to operate as a company that found a rare pocket of structural scarcity. The revenue growth came in at $5.13 billion, growing 168% year-over-year, which is one of the faster growth stories we've seen for infrastructure growth in the public markets.</p> <p class=\"paywall-full-content\">The revenue guide for Q1 of $1.9-$2.0 billion and for FY26 of $12-$13 billion indicates that the flywheel is continuing to go, although slightly softer than investors might have wanted at mid-point. This is not a demand story. In fact, the demand story that came out of the call yesterday was almost ridiculously confident. Virtually sold out for 2026 capacity, stable prices, and selling old-generation GPUs into inference ahead of the arrival of the newer generation.</p> <p class=\"paywall-full-content\">The not-so-understood factor is the way that CoreWeave is going about growing that number. In Q4 alone, the company added around 260MW of active power, bringing the total to <a href=\"https://static.seekingalpha.com/uploads/sa_presentations/248/123248/original.pdf\">over 850MW</a> active, with over 3.1 GW contracted. This isn’t a growth rate; it’s a sprint where the company is continuously adding capacity, then correctly pointing out that revenue monetization takes a little longer as the work ramps up and contract revenue recognition comes online. In other words, the operational win of Q4 is the seed of the guided trough of Q1.</p> <p class=\"paywall-full-content\"><figure class=\"regular-img-figure paywall-full-content\" contenteditable=\"false\"><span><a href=\"https://static.seekingalpha.com/uploads/2026/2/27/49853134-17721868658756926_origin.png\" rel=\"lightbox\" data-width=\"2048\" data-height=\"1137\" data-og-image-twitter_small_card=\"true\" data-og-image-twitter_large_card=\"true\" data-og-image-twitter_image_post=\"true\" data-og-image-msn=\"true\" data-og-image-facebook=\"true\" data-og-image-google_news=\"true\" data-og-image-google_plus=\"true\" data-og-image-linkedin=\"true\" role=\"button\" aria-label=\"Expand image into lightbox view\"><img src=\"https://static.seekingalpha.com/uploads/2026/2/27/49853134-17721868658756926_origin.png?io=w640\" alt=\"CRWV\" width=\"640\" height=\"355\" contenteditable=\"false\" loading=\"lazy\" srcset=\"https://static.seekingalpha.com/uploads/2026/2/27/49853134-17721868658756926_origin.png?io=w640 640w,https://static.seekingalpha.com/uploads/2026/2/27/49853134-17721868658756926_origin.png?io=w480 480w,https://static.seekingalpha.com/uploads/2026/2/27/49853134-17721868658756926_origin.png?io=w320 320w,https://static.seekingalpha.com/uploads/2026/2/27/49853134-17721868658756926_origin.png?io=w240 240w\" sizes=\"(max-width: 767px) calc(100vw - 36px), (max-width: 1023px) calc(100vw - 180px), 552px\"></a></span><figcaption><p class=\"item-caption\"><span>Earnings Q4 2025</span></p></figcaption></figure></p> <p class=\"paywall-full-content\">This isn’t a mistake; it’s the business model. I think the lazy assumption that investors make is that backlog equals safety. Backlog is good; it’s not the same as liquidity or certainty of timing. A $66.8 billion backlog with a significant percentage of that backlog extending beyond 24 months is a phenomenal position, but it also creates a subtle pitfall where the market assumes that a long-dated demand asset is, in fact, a short-dated cash asset.</p> <p class=\"paywall-full-content\">This isn’t something that CoreWeave’s equity can afford to misunderstand, as the cost structure is up-front and heavily weighted, reflected in a balance sheet that now tops $49.3 billion in total assets, driven by $30.6 billion of property and equipment.</p> <h2 class=\"paywall-full-content\">The Interest Meter Is Now the Real Earnings Story</h2> <p class=\"paywall-full-content\">CoreWeave’s soft quarter wasn’t driven by demand but rather by how the company is choosing to finance it. Revenue grew 110% year over year, while adjusted EBITDA came in at $898 million, affirming the strength of the economics of core compute. However, the real news is hiding below the operating line, where interest expense grew to $388 million in Q4 and $1.23 billion for the year, while the Q1 guide implies an even higher growth rate.</p> <p class=\"paywall-full-content\">The way I approach the stock is now different. The issue is that the company is funding its growth with a rising debt stack at an increasing rate. The company now has greater than $18 billion in total debt, and the leverage is now impacting the timing risk. Their view is Q1 is the margin trough, and the ramp in new capacity and the ramp in revenue are post-Q1. That’s a reasonable view. The question is, as an investor, is the execution speed keeping pace with the financing speed?</p> <p class=\"paywall-full-content\"><figure class=\"sa-widget sa-ycharts paywall-full-content\"><img src=\"https://static.seekingalpha.com/uploads/2026/2/27/saupload_29baece6b9fa7333e7aa8d3b5febd055.png?io=w640\" alt=\"Chart\" width=\"635\" height=\"366\" class=\"sa-ycharts-img\" data-width=\"635\" data-height=\"366\" loading=\"lazy\" srcset=\"https://static.seekingalpha.com/uploads/2026/2/27/saupload_29baece6b9fa7333e7aa8d3b5febd055.png?io=w480 480w,https://static.seekingalpha.com/uploads/2026/2/27/saupload_29baece6b9fa7333e7aa8d3b5febd055.png?io=w320 320w,https://static.seekingalpha.com/uploads/2026/2/27/saupload_29baece6b9fa7333e7aa8d3b5febd055.png?io=w240 240w\" sizes=\"(max-width: 767px) calc(100vw - 36px), (max-width: 1023px) calc(100vw - 180px), 552px\"><figcaption>Data by <a href=\"https://ycharts.com\" rel=\"nofollow\">YCharts</a></figcaption></figure></p> <h2 class=\"paywall-full-content\">Valuation: The Market Is Pricing in Execution, Not Perfection</h2> <p class=\"paywall-full-content\">Consensus revenue estimates have now projected revenue of $12.05 billion in 2026 and <a href=\"https://seekingalpha.com/symbol/CRWV/earnings/estimates\">$19.86 billion</a> in 2027, suggesting forward multiples of 4x sales in 2026 but compressing to 2.6x sales in 2027 and less than 2x sales in 2028. At a high level, the forward multiples appear relatively cheap for a company growing its revenue at triple digits in the near future.</p> <p class=\"paywall-full-content\">The problem is valuation multiples can't be analyzed in isolation. EV is highly levered due to over $18 billion in debt, which means EV to revenue is actually looking more like infrastructure multiples rather than cloud multiples. If they're able to execute and drive 25-30% operating margins from this backlog over time, then these types of multiples could actually prove to be pretty conservative.</p> <p class=\"paywall-full-content\"><figure class=\"sa-widget sa-ycharts paywall-full-content\"><img src=\"https://static.seekingalpha.com/uploads/2026/2/27/saupload_0f44388a295db1d190a3d547bda74453.png?io=w640\" alt=\"Chart\" width=\"635\" height=\"366\" class=\"sa-ycharts-img\" data-width=\"635\" data-height=\"366\" loading=\"lazy\" srcset=\"https://static.seekingalpha.com/uploads/2026/2/27/saupload_0f44388a295db1d190a3d547bda74453.png?io=w480 480w,https://static.seekingalpha.com/uploads/2026/2/27/saupload_0f44388a295db1d190a3d547bda74453.png?io=w320 320w,https://static.seekingalpha.com/uploads/2026/2/27/saupload_0f44388a295db1d190a3d547bda74453.png?io=w240 240w\" sizes=\"(max-width: 767px) calc(100vw - 36px), (max-width: 1023px) calc(100vw - 180px), 552px\"><figcaption>Data by <a href=\"https://ycharts.com\" rel=\"nofollow\">YCharts</a></figcaption></figure></p> <h2 class=\"paywall-full-content\">The Capital Structure Is the Single Point of Failure</h2> <p class=\"paywall-full-content\">The main risk is not related to demand, competition, or customer concentration but rather to financial leverage and timing. CoreWeave closed 2025 with more than $18 billion of debt on its balance sheet, FY interest expense of $1.23 billion, and Q1 2026 interest guidance towards a $2 billion+ annualized run rate (guidance <a href=\"https://seekingalpha.com/article/4875914-coreweave-inc-crwv-q4-2025-earnings-call-transcript\">$510-$590 million</a>). At the same time, 2026 Capex is projected to be $30-$35 billion.</p> <p class=\"paywall-full-content\">Depreciation and power costs are incurred immediately, while revenue growth is a function of time. As a result, there is a built-in margin compression during growth phases. This is a balance sheet-based model, and execution needs to be perfect for leverage to work for shareholders rather than against them.</p> <h2 class=\"paywall-full-content\">Takeaway</h2> <div class=\"before_last_paragraph-piano-placeholder paywall-full-content\"></div> <p class=\"paywall-full-content\">CoreWeave isn’t being evaluated based on the demand for AI anymore; it’s being evaluated based on capital discipline. If the management team is successful in turning the backlog into cash flow, with leverage management, the potential upside is large. This is a conviction story, but the position size depends upon the sensitivity of the balance sheet.</p>",
            "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2254337477/image_2254337477.jpg",
            "link": "https://seekingalpha.com/article/4876510-coreweave-from-growth-story-to-capital-story",
            "pub_date": "2026-02-28 04:11:43",
            "source": "seekalpha_articles",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "4876499",
            "title": "LeMaitre Vascular: The Compounder Keeps Compounding",
            "description": "<figure class=\"getty-figure\" data-type=\"getty-image\"><picture> <img src=\"https://media.gettyimages.com/id/2194227950/photo/red-heart-and-stethoscope-lying-on-euro-banknotes-illustrating-expensive-healthcare-or.jpg?b=1&amp;s=612x612&amp;w=0&amp;k=20&amp;c=CCi9-oDsnyaDgs2604xYctYgsAmCAUEt_ihHrCBJV9s=\" alt=\"Red heart and stethoscope lying on euro banknotes illustrating expensive healthcare or healthy investment\" data-id=\"2194227950\" data-type=\"getty-image\" fetchpriority=\"high\"> </picture><figcaption><p class=\"item-caption\"> </p> <p class=\"item-credits\">Alberto Marrupe Gutierrez/iStock via Getty Images</p></figcaption></figure><div class=\"inline_ad_placeholder\"></div> <p data-eci=\"true\">I last covered LeMaitre Vascular (<span class=\"ticker-hover-wrapper\">NASDAQ:<a href=\"https://seekingalpha.com/symbol/LMAT\" title=\"LeMaitre Vascular, Inc.\">LMAT</a></span>) at $81 <a href=\"mailto:https://seekingalpha.com/article/4795377-lemaitre-vascular-scaling-nicely-as-global-demand-builds\" rel=\"nofollow\" title=\"mailto:https://seekingalpha.com/article/4795377-lemaitre-vascular-scaling-nicely-as-global-demand-builds\" target=\"_blank\">in June 2025</a>, reiterating my Buy rating. Eight months later, shares are up about 35%, more than double that of the broader market. The stock jumped ~20% alone on the recent Q4 beat and raise, with 2026<span class=\"paywall-full-content\"> guidance coming in 13% above Wall Street’s consensus. Pricing power, operating leverage, and international growth were all contributors.</span></p> <p class=\"paywall-full-content\">LMAT has been one of the top performers in my own portfolio over this period. Is it time to trim? Is there still near-term upside for those looking to add shares?</p> <p class=\"paywall-full-content\">Having digested the 2025 results, my short answer is that the business has earned its high valuation multiples. A key catalyst is Artegraft – the international rollout is changing the math. But a more important takeaway is that LMAT’s overall earnings power appears to have stepped higher. This is structural rather than cyclical.</p> <h2 class=\"paywall-full-content\">Q4 and Full-Year 2025: Another Clean Sheet</h2> <p class=\"paywall-full-content\">The <a href=\"mailto:https://seekingalpha.com/pr/20414156-lemaitre-q4-2025-financial-results\" rel=\"nofollow\" title=\"mailto:https://seekingalpha.com/pr/20414156-lemaitre-q4-2025-financial-results\" target=\"_blank\">latest quarterly report</a> exceeded expectations in almost every way. Sales were up 16% YoY with organic growth at 15%. All segments gained, led by grafts (27%), valvulotomes (20%), and carotid shunts (18%). Growth was also broad-based geographically, with EMEA up 29%, APAC 20%, and the Americas 10%. Profitability metrics were also outstanding across the board. Organic growth in Q4 broke down to about 9% price and 6% unit growth, meaning the recent margin expansion isn’t just due to volume.</p> <p class=\"paywall-full-content\">Most important is that this has been a pattern. For several years LMAT has been growing sales by double digits while managing gross margins of 60-70%.</p> <figure class=\"regular-img-figure paywall-full-content\" contenteditable=\"false\"><picture> <span><a href=\"https://static.seekingalpha.com/uploads/2026/2/27/58879822-1772216013010596_origin.png\" rel=\"lightbox\" data-width=\"1432\" data-height=\"427\" data-og-image-twitter_small_card=\"false\" data-og-image-twitter_large_card=\"false\" data-og-image-twitter_image_post=\"false\" data-og-image-msn=\"false\" data-og-image-facebook=\"false\" data-og-image-google_news=\"false\" data-og-image-google_plus=\"false\" data-og-image-linkedin=\"false\" role=\"button\" aria-label=\"Expand image into lightbox view\"><img src=\"https://static.seekingalpha.com/uploads/2026/2/27/58879822-1772216013010596_origin.png?io=w640\" alt=\"Bar graph showing gross profit growth for LMAT over the past decade.\" contenteditable=\"false\" width=\"640\" height=\"191\" loading=\"lazy\" srcset=\"https://static.seekingalpha.com/uploads/2026/2/27/58879822-1772216013010596_origin.png?io=w640 640w,https://static.seekingalpha.com/uploads/2026/2/27/58879822-1772216013010596_origin.png?io=w480 480w,https://static.seekingalpha.com/uploads/2026/2/27/58879822-1772216013010596_origin.png?io=w320 320w,https://static.seekingalpha.com/uploads/2026/2/27/58879822-1772216013010596_origin.png?io=w240 240w\" sizes=\"(max-width: 767px) calc(100vw - 36px), (max-width: 1023px) calc(100vw - 180px), 552px\"></a></span> </picture><figcaption><p class=\"item-caption\"><span>Seeking Alpha (LMAT Financials - Gross Profit)</span></p></figcaption></figure><p class=\"paywall-full-content\">The FY 2025 results included beats on revenue and EPS. The $2.91 (midpoint) guidance for 2026 represents an 11.5% increase.</p> <h2 class=\"paywall-full-content\">The Artegraft Surprise</h2> <p class=\"paywall-full-content\">For me, the most important news in this report wasn’t the headline figures. It was buried <a href=\"mailto:https://seekingalpha.com/article/4875065-lemaitre-vascular-inc-lmat-q4-2025-earnings-call-transcript\" rel=\"nofollow\" title=\"mailto:https://seekingalpha.com/article/4875065-lemaitre-vascular-inc-lmat-q4-2025-earnings-call-transcript\" target=\"_blank\">in the earnings call Q&amp;A</a>.</p> <p class=\"paywall-full-content\">Management said the addressable market for Artegraft outside the U.S. may be much larger than previously understood. LMAT originally sold Artegraft in the U.S. for dialysis access procedures. The procedure is handled differently in Europe: patients skip the implanted graft step entirely and go straight to catheters. That creates an opportunity to develop new demand rather than simply substitute for existing procedures. As adoption has progressed, Artegraft is also being used in leg bypass procedures in addition to dialysis access.</p> <p class=\"paywall-full-content\">From a profitability standpoint, this fits well with LMAT’s “mix shift” toward biologic implants, which now account for more than half of total sales. These products tend to have higher average selling prices and attractive margins. As a result, Artegraft should disproportionately help earnings growth even if the impact on the top line is modest.</p> <p class=\"paywall-full-content\">2025 international sales of Artegraft came in at $4M versus guidance of $2M, and that’s expected to grow to $10M in 2026. Approvals are in place for 52 countries, with traction gaining in Germany, Austria, Switzerland, and the Netherlands. The U.K. and parts of southern Europe are just getting started.</p> <p class=\"paywall-full-content\">In short, this product is performing much better than management previously modeled. The markets are larger than anticipated, and there appears to be a long runway ahead. It’s a meaningful development for long-term LMAT investors and one I’ll watch closely this year.</p> <h2 class=\"paywall-full-content\">Balance Sheet and Capital Allocation for LMAT</h2> <p class=\"paywall-full-content\">LMAT ended 2025 with a net cash position of about $190M, accounting for its $168M in convertible notes. This is a significant war chest for a company with a ~$2.5B market cap. M&amp;A, as always, is on the table for LMAT. Management has identified a number of potential targets in both vascular and cardiac surgery.</p> <p class=\"paywall-full-content\">The board approved a <a href=\"mailto:https://seekingalpha.com/news/4557368-lemaitre-vascular-raises-dividend-by-25-to-025\" rel=\"nofollow\" title=\"mailto:https://seekingalpha.com/news/4557368-lemaitre-vascular-raises-dividend-by-25-to-025\" target=\"_blank\">25% dividend increase</a> for Q1 2026, making it fifteen consecutive years of increases. A new $100M share repurchase authorization was also approved. Neither makes LMAT an “income” play, but they do add to total return.</p> <figure class=\"regular-img-figure paywall-full-content\" contenteditable=\"false\"><picture> <span><a href=\"https://static.seekingalpha.com/uploads/2026/2/27/58879822-1772216013065088_origin.png\" rel=\"lightbox\" data-width=\"1431\" data-height=\"355\" data-og-image-twitter_small_card=\"false\" data-og-image-twitter_large_card=\"false\" data-og-image-twitter_image_post=\"false\" data-og-image-msn=\"false\" data-og-image-facebook=\"false\" data-og-image-google_news=\"false\" data-og-image-google_plus=\"false\" data-og-image-linkedin=\"false\" role=\"button\" aria-label=\"Expand image into lightbox view\"><img src=\"https://static.seekingalpha.com/uploads/2026/2/27/58879822-1772216013065088_origin.png?io=w640\" alt=\"Table showing dividend data for LeMaitre Vascular\" contenteditable=\"false\" width=\"640\" height=\"159\" loading=\"lazy\" srcset=\"https://static.seekingalpha.com/uploads/2026/2/27/58879822-1772216013065088_origin.png?io=w640 640w,https://static.seekingalpha.com/uploads/2026/2/27/58879822-1772216013065088_origin.png?io=w480 480w,https://static.seekingalpha.com/uploads/2026/2/27/58879822-1772216013065088_origin.png?io=w320 320w,https://static.seekingalpha.com/uploads/2026/2/27/58879822-1772216013065088_origin.png?io=w240 240w\" sizes=\"(max-width: 767px) calc(100vw - 36px), (max-width: 1023px) calc(100vw - 180px), 552px\"></a></span> </picture><figcaption><p class=\"item-caption\"><span>Seeking Alpha (February 27, 2026)</span></p></figcaption></figure><h2 class=\"paywall-full-content\">LMAT: Valuation and Updated Price Target</h2> <p class=\"paywall-full-content\">Here’s the tension: the stock has appreciated by ~35% since last summer, and Wall Street’s consensus price target shows no near-term upside. The market appears to have priced in a lot of good news.</p> <p class=\"paywall-full-content\">My preferred method of assessing valuation is to compare companies to their recent historical averages. Given LMAT’s niche direct-to-hospital model and biologics-heavy mix, its own history is more informative than comparing it to the much larger, diversified medtech conglomerates. (Broad sector comparisons are even less helpful – particularly in Health Care where the business models of insurers, drug makers, and equipment manufacturers are vastly different.)</p> <p class=\"paywall-full-content\">By those measures, LMAT is trading in line <a href=\"mailto:https://seekingalpha.com/symbol/LMAT/valuation/metrics\" rel=\"nofollow\" title=\"mailto:https://seekingalpha.com/symbol/LMAT/valuation/metrics\" target=\"_blank\">with its own norms</a>: slightly lower in P/E, about even in EV/EBITDA, and slightly higher in EV/sales.</p> <figure class=\"regular-img-figure paywall-full-content\" contenteditable=\"false\"><picture> <span><a href=\"https://static.seekingalpha.com/uploads/2026/2/27/58879822-17722160132261205_origin.png\" rel=\"lightbox\" data-width=\"1431\" data-height=\"552\" data-og-image-twitter_small_card=\"true\" data-og-image-twitter_large_card=\"true\" data-og-image-twitter_image_post=\"true\" data-og-image-msn=\"true\" data-og-image-facebook=\"true\" data-og-image-google_news=\"true\" data-og-image-google_plus=\"true\" data-og-image-linkedin=\"true\" role=\"button\" aria-label=\"Expand image into lightbox view\"><img src=\"https://static.seekingalpha.com/uploads/2026/2/27/58879822-17722160132261205_origin.png?io=w640\" alt=\"Table comparing current valuation data for LMAT against historical averages.\" contenteditable=\"false\" width=\"640\" height=\"247\" loading=\"lazy\" srcset=\"https://static.seekingalpha.com/uploads/2026/2/27/58879822-17722160132261205_origin.png?io=w640 640w,https://static.seekingalpha.com/uploads/2026/2/27/58879822-17722160132261205_origin.png?io=w480 480w,https://static.seekingalpha.com/uploads/2026/2/27/58879822-17722160132261205_origin.png?io=w320 320w,https://static.seekingalpha.com/uploads/2026/2/27/58879822-17722160132261205_origin.png?io=w240 240w\" sizes=\"(max-width: 767px) calc(100vw - 36px), (max-width: 1023px) calc(100vw - 180px), 552px\"></a></span> </picture><figcaption><p class=\"item-caption\"><span>Seeking Alpha (data compiled by the author on February 27, 2026)</span></p></figcaption></figure><p class=\"paywall-full-content\">Assuming the current P/E of 40x holds for the next couple of years, we’re looking at price targets of roughly $116 for 2026, $124 for 2027, and $134 for 2028. This is a CAGR of ~7.5%, or just over 8% annually including the dividend.</p> <p class=\"paywall-full-content\">I find this conservative given the growth rates outlined above, particularly with the potential bottom-line impact of Artegraft adoption in Europe. Positive reversion to the 45x multiple would add another ~12% upside.</p> <figure class=\"regular-img-figure paywall-full-content\" contenteditable=\"false\"><picture> <span><a href=\"https://static.seekingalpha.com/uploads/2026/2/27/58879822-17722160131071455_origin.png\" rel=\"lightbox\" data-width=\"1431\" data-height=\"263\" data-og-image-twitter_small_card=\"false\" data-og-image-twitter_large_card=\"false\" data-og-image-twitter_image_post=\"false\" data-og-image-msn=\"false\" data-og-image-facebook=\"false\" data-og-image-google_news=\"false\" data-og-image-google_plus=\"false\" data-og-image-linkedin=\"false\" role=\"button\" aria-label=\"Expand image into lightbox view\"><img src=\"https://static.seekingalpha.com/uploads/2026/2/27/58879822-17722160131071455_origin.png?io=w640\" alt=\"Table providing EPS estimates for LMAT through 2028.\" contenteditable=\"false\" width=\"640\" height=\"118\" loading=\"lazy\" srcset=\"https://static.seekingalpha.com/uploads/2026/2/27/58879822-17722160131071455_origin.png?io=w640 640w,https://static.seekingalpha.com/uploads/2026/2/27/58879822-17722160131071455_origin.png?io=w480 480w,https://static.seekingalpha.com/uploads/2026/2/27/58879822-17722160131071455_origin.png?io=w320 320w,https://static.seekingalpha.com/uploads/2026/2/27/58879822-17722160131071455_origin.png?io=w240 240w\" sizes=\"(max-width: 767px) calc(100vw - 36px), (max-width: 1023px) calc(100vw - 180px), 552px\"></a></span> </picture><figcaption><p class=\"item-caption\"><span>Seeking Alpha (data compiled by the author on February 27, 2026)</span></p></figcaption></figure><p class=\"paywall-full-content\">My current view: for those already holding LMAT, there’s no reason to sell. The intrinsic value is moving higher, and its operating leverage is among the industry leaders. But clearly for new investors, the entry point is less attractive than it was this time last year (based on what we knew then). The premium relative to peers like Boston Scientific (<a href=\"https://seekingalpha.com/symbol/BSX\" title=\"Boston Scientific Corporation\">BSX</a>), Stryker (<a href=\"https://seekingalpha.com/symbol/SYK\" title=\"Stryker Corporation\">SYK</a>), and Medtronic (<a href=\"https://seekingalpha.com/symbol/MDT\" title=\"Medtronic plc\">MDT</a>) stands out, though I believe it’s justified given LMAT’s niche focus. A pullback below $100 would improve the overall risk-reward dynamic.</p> <h2 class=\"paywall-full-content\">Bottom Line: Buy Rating Reiterated</h2> <p class=\"paywall-full-content\">LeMaitre Vascular is doing what it’s been doing for years: growing sales while maintaining pricing power and expanding internationally. The Artegraft surprise is the latest reason to believe earnings have room to grow beyond the base case.</p> <p class=\"paywall-full-content\">I’m raising my price target for year-end 2026 to $116-$130 based on a forward PE of 40-45x. I maintain a <em>Buy</em> rating for long-term investors. The potential upside (at present) may be less attractive than a year ago, but LMAT remains an excellent candidate for a dividend growth portfolio. The main questions remain: (1) Can LMAT continue to raise prices without softening demand? (2) Can management sustain gross margins in the low-70% range? (3) Can the company continue expanding its direct sales model internationally given the upfront costs and regulatory challenges?</p> <p class=\"paywall-full-content\">On all three counts, 2025 was certainly encouraging.</p> <div class=\"before_last_paragraph-piano-placeholder paywall-full-content\"></div> <p class=\"paywall-full-content\">Author’s Note: This analysis reflects data and information available as of February 27, 2026.</p>",
            "image": null,
            "link": "https://seekingalpha.com/article/4876499-lemaitre-vascular-the-compounder-keeps-compounding",
            "pub_date": "2026-02-28 04:01:27",
            "source": "seekalpha_articles",
            "kind": 1,
            "language": "en"
        }
    ]
}